[{"content": "Type 2 Diabetes Management Guidelines:\n        - First-line therapy: Metformin is recommended as initial pharmacologic therapy for type 2 diabetes.\n        - Target HbA1c: Generally less than 7% for most adults, individualized based on patient factors.\n        - Lifestyle modifications: Medical nutrition therapy and physical activity (150 min/week moderate intensity).\n        - Monitoring: HbA1c testing at least twice yearly if stable, quarterly if therapy changed.\n        - Complications screening: Annual dilated eye exam, annual foot exam, annual urine albumin-to-creatinine ratio.", "metadata": {"source": "ADA Standards of Care", "category": "endocrinology", "condition": "diabetes"}}, {"content": "Metformin Prescribing Information:\n        - Starting dose: 500mg once or twice daily with meals\n        - Maximum dose: 2550mg daily in divided doses\n        - Contraindications: eGFR <30 mL/min, acute/chronic metabolic acidosis\n        - Hold before contrast: Discontinue at time of or before iodinated contrast procedures\n        - Common side effects: GI upset, diarrhea, nausea (usually transient)\n        - Rare but serious: Lactic acidosis (risk factors: renal impairment, hepatic disease, hypoxia)", "metadata": {"source": "FDA Drug Label", "category": "pharmacology", "drug": "metformin"}}, {"content": "Hypertension Management Guidelines:\n        - Stage 1 HTN: BP 130-139/80-89 mmHg - lifestyle modification, consider medication if high ASCVD risk\n        - Stage 2 HTN: BP >=140/90 mmHg - medication recommended in addition to lifestyle changes\n        - First-line agents: ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics\n        - Target BP: <130/80 mmHg for most adults with confirmed hypertension\n        - Lifestyle: DASH diet, sodium restriction (<2300mg/day), regular exercise, weight management", "metadata": {"source": "ACC/AHA Hypertension Guidelines", "category": "cardiology", "condition": "hypertension"}}, {"content": "ACE Inhibitor Considerations:\n        - Common ACE inhibitors: Lisinopril, Enalapril, Ramipril, Benazepril\n        - Contraindications: Pregnancy, history of angioedema, bilateral renal artery stenosis\n        - Monitor: Potassium levels, renal function (especially first few weeks)\n        - Drug interactions: NSAIDs may reduce efficacy, potassium-sparing diuretics increase hyperkalemia risk\n        - Common side effects: Dry cough (10-15%), hyperkalemia, acute kidney injury\n        - Serious adverse effects: Angioedema (0.1-0.2%), especially higher risk in Black patients", "metadata": {"source": "Clinical Pharmacology", "category": "pharmacology", "drug_class": "ACE inhibitors"}}, {"content": "Chest Pain Evaluation - Acute Coronary Syndrome:\n        - STEMI: ST elevation >=1mm in 2 contiguous leads, activate cath lab immediately\n        - NSTEMI: Elevated troponin without ST elevation, risk stratify with TIMI/GRACE score\n        - Unstable Angina: Negative troponin, concerning symptoms (rest pain, new/worsening)\n        - Initial management: Aspirin 325mg, anticoagulation, consider P2Y12 inhibitor\n        - High-risk features: Ongoing chest pain, hemodynamic instability, arrhythmias, heart failure\n        - Time-sensitive: Door-to-balloon time <90 minutes for STEMI", "metadata": {"source": "ACC/AHA STEMI/NSTEMI Guidelines", "category": "cardiology", "condition": "ACS"}}, {"content": "Heart Failure Management:\n        - HFrEF (EF <=40%): Guideline-directed medical therapy (GDMT) includes ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2i\n        - HFpEF (EF >=50%): SGLT2 inhibitors, diuretics for congestion, treat underlying conditions\n        - Monitoring: Daily weights, sodium restriction (<2g/day), fluid restriction if severe\n        - Warning signs: Weight gain >3 lbs in 1 day or >5 lbs in 1 week, worsening dyspnea, edema\n        - Avoid: NSAIDs, non-dihydropyridine CCBs (HFrEF), excessive fluid intake", "metadata": {"source": "ACC/AHA Heart Failure Guidelines", "category": "cardiology", "condition": "heart failure"}}, {"content": "COPD Management Guidelines:\n        - GOLD Classification: Based on FEV1% predicted and symptoms (CAT/mMRC scores)\n        - Initial therapy: LAMA or LABA monotherapy for most patients\n        - Escalation: LAMA + LABA if persistent symptoms, add ICS if eosinophils >=300\n        - Acute exacerbation: Short-acting bronchodilators, systemic corticosteroids (5-7 days), antibiotics if purulent sputum\n        - Prevention: Smoking cessation (most important), influenza and pneumococcal vaccines\n        - Oxygen therapy: If PaO2 <=55 mmHg or SpO2 <=88% at rest", "metadata": {"source": "GOLD COPD Guidelines", "category": "pulmonology", "condition": "COPD"}}, {"content": "Asthma Management:\n        - Step 1: SABA as needed (mild intermittent)\n        - Step 2: Low-dose ICS (mild persistent)\n        - Step 3: Low-dose ICS + LABA or medium-dose ICS\n        - Step 4: Medium-dose ICS + LABA\n        - Step 5: High-dose ICS + LABA, consider add-on therapy (tiotropium, biologics)\n        - Control assessment: Daytime symptoms, nighttime awakening, SABA use, activity limitation\n        - Exacerbation management: Systemic corticosteroids, frequent SABA, consider hospitalization if severe", "metadata": {"source": "GINA Asthma Guidelines", "category": "pulmonology", "condition": "asthma"}}, {"content": "Chronic Kidney Disease Management:\n        - Staging: Based on GFR (G1-G5) and albuminuria (A1-A3)\n        - Blood pressure target: <130/80 mmHg, ACEi/ARB preferred if proteinuria\n        - Diabetes in CKD: SGLT2 inhibitors (if eGFR >20), GLP-1 RA as second-line\n        - Anemia: Target Hgb 10-11.5 g/dL, iron supplementation first, then ESA if needed\n        - Mineral bone disease: Phosphorus restriction, phosphate binders, vitamin D\n        - Nephrology referral: eGFR <30, rapid decline (>5 mL/min/year), significant proteinuria", "metadata": {"source": "KDIGO CKD Guidelines", "category": "nephrology", "condition": "CKD"}}, {"content": "Common Critical Drug Interactions:\n        - Warfarin + NSAIDs: Increased bleeding risk, avoid combination\n        - ACEi + Potassium supplements: Hyperkalemia risk, monitor closely\n        - Statins + Macrolides: Increased statin levels, myopathy risk\n        - Metformin + Contrast dye: Hold metformin, risk of lactic acidosis\n        - SSRIs + MAOIs: Serotonin syndrome, contraindicated\n        - Digoxin + Amiodarone: Increased digoxin levels, reduce dose by 50%\n        - Fluoroquinolones + QT-prolonging drugs: Risk of torsades de pointes", "metadata": {"source": "Clinical Drug Interactions Database", "category": "pharmacology", "topic": "drug interactions"}}, {"content": "Sepsis Recognition and Management (Sepsis-3):\n        - Definition: Life-threatening organ dysfunction caused by dysregulated response to infection\n        - qSOFA (quick screen): RR >=22, altered mentation, SBP <=100 mmHg (>=2 suggests sepsis)\n        - SOFA score: For ICU patients, assesses 6 organ systems\n        - Hour-1 Bundle: Measure lactate, blood cultures before antibiotics, broad-spectrum antibiotics, 30 mL/kg crystalloid if hypotensive/lactate >=4, vasopressors if MAP <65 after fluids\n        - Target: MAP >=65 mmHg, lactate normalization, urine output >0.5 mL/kg/hr", "metadata": {"source": "Surviving Sepsis Campaign", "category": "critical care", "condition": "sepsis"}}, {"content": "Stroke Recognition and Management:\n        - FAST screening: Face drooping, Arm weakness, Speech difficulty, Time to call 911\n        - tPA window: Within 4.5 hours of symptom onset for eligible patients\n        - Thrombectomy: Within 24 hours for large vessel occlusion (with imaging selection)\n        - Blood pressure: Permissive hypertension if not receiving tPA (up to 220/120)\n        - If receiving tPA: Maintain BP <180/105 mmHg\n        - Acute workup: CT head (rule out hemorrhage), CTA/MRA, labs, ECG", "metadata": {"source": "AHA/ASA Stroke Guidelines", "category": "neurology", "condition": "stroke"}}, {"content": "Insulin Management for Inpatient Hyperglycemia:\n        - Target glucose: 140-180 mg/dL for most hospitalized patients\n        - Basal-bolus insulin preferred over sliding scale alone\n        - Basal insulin: Glargine or detemir; calculate 0.2-0.4 units/kg/day\n        - Bolus insulin: Rapid-acting (lispro, aspart) before meals\n        - Correction factor: 1 unit per 50 mg/dL above target (adjust based on insulin sensitivity)\n        - Hold oral hypoglycemics in acute illness; transition back before discharge\n        - Hypoglycemia protocol: <70 mg/dL - give 15-20g fast-acting carbohydrate, recheck in 15 min", "metadata": {"source": "ADA Inpatient Guidelines", "category": "endocrinology", "condition": "inpatient diabetes"}}, {"content": "# Non-ST Elevation ACS (NSTEMI / Unstable Angina) Management\n\n## Diagnosis\n- **NSTEMI**: Elevated troponin with ischemic symptoms and/or ECG changes (ST depression, T-wave inversion)\n- **Unstable Angina**: Negative troponin with concerning symptoms (rest pain, crescendo angina, new-onset severe angina)\n- ECG: ST depression \u22650.5mm, T-wave inversion \u22651mm, or transient ST elevation\n\n## Risk Stratification\n- **TIMI Score** (0-7): Age \u226565, \u22653 CAD risk factors, known CAD (\u226550% stenosis), ASA use in last 7 days, \u22652 anginal events in 24hr, ST deviation \u22650.5mm, elevated troponin\n  - Low risk (0-2): Conservative strategy may be appropriate\n  - Intermediate (3-4): Early invasive strategy preferred\n  - High risk (5-7): Early invasive strategy recommended\n- **GRACE Score**: More comprehensive, predicts in-hospital and 6-month mortality", "metadata": {"source": "acs_nstemi.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391600", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/acs_nstemi.md", "chunk_index": 0, "total_chunks": 2}}, {"content": "## Initial Medical Management\n- **Aspirin** 325mg loading, then 81mg daily\n- **P2Y12 inhibitor**: Ticagrelor 180mg load \u2192 90mg BID, or Clopidogrel 300-600mg load \u2192 75mg daily\n- **Anticoagulation**: Enoxaparin 1mg/kg BID, UFH, fondaparinux, or bivalirudin\n- **Beta-blocker**: Metoprolol if no contraindications\n- **Nitroglycerin**: Sublingual or IV for ongoing ischemia\n- **Statin**: High-intensity statin therapy\n\n## Invasive Strategy\n- **Early invasive** (within 24 hours): High-risk features \u2014 recurrent angina, hemodynamic instability, sustained VT/VF, elevated troponin, GRACE >140\n- **Delayed invasive** (within 25-72 hours): Intermediate risk without high-risk features\n- **Ischemia-guided** (conservative): Low-risk, patient preference, comorbidities\n\n## Discharge and Follow-Up\n- DAPT: 12 months (may shorten to 6 months or extend to 36 months based on bleeding/ischemic risk)\n- Cardiac rehabilitation\n- Echocardiogram if new HF suspected\n- Follow-up within 2 weeks", "metadata": {"source": "acs_nstemi.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391600", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/acs_nstemi.md", "chunk_index": 1, "total_chunks": 2}}, {"content": "# ST-Elevation Myocardial Infarction (STEMI) Management\n\n## Diagnosis\n- ECG: ST elevation \u22651mm in 2 contiguous leads, or new LBBB\n- Biomarkers: Troponin elevation (may be normal early)\n- Symptoms: Chest pain/pressure, diaphoresis, dyspnea, nausea\n\n## Immediate Management (Door-to-Balloon <90 min)\n- **Aspirin** 325mg chewed immediately\n- **P2Y12 inhibitor**: Ticagrelor 180mg or Clopidogrel 600mg loading\n- **Anticoagulation**: Unfractionated heparin bolus + infusion\n- **Primary PCI** is preferred reperfusion strategy if available within 120 min of first medical contact\n- **Fibrinolysis** if PCI not available within 120 min: tenecteplase (weight-based), alteplase, or reteplase; door-to-needle <30 min", "metadata": {"source": "acs_stemi.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391760", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/acs_stemi.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "## Contraindications to Fibrinolysis\n- Active internal bleeding (excluding menses)\n- Prior hemorrhagic stroke at any time\n- Ischemic stroke within 3 months\n- Intracranial neoplasm, AVM, or aneurysm\n- Known active bleeding or bleeding diathesis\n- Significant head/facial trauma within 3 months\n- Suspected aortic dissection\n\n## Adjunctive Therapy\n- **Beta-blocker**: Metoprolol \u2014 start within 24 hours if no contraindications (avoid in cardiogenic shock, decompensated HF, heart block)\n- **ACE inhibitor/ARB**: Start within 24 hours if anterior MI, HF, or EF \u226440%\n- **Statin**: High-intensity (Atorvastatin 80mg or Rosuvastatin 20mg)\n- **Nitrates**: For ongoing ischemia (avoid if RV infarct, hypotension, PDE5 inhibitor use)\n- **Morphine**: Only if pain uncontrolled with nitrates", "metadata": {"source": "acs_stemi.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391760", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/acs_stemi.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Post-MI Care\n- Dual antiplatelet therapy (DAPT): 12 months minimum after stent\n- Cardiac rehabilitation referral\n- Echocardiogram to assess LV function\n- Risk factor modification: smoking cessation, lipid management, BP control, diabetes management\n- Follow-up: 2-6 weeks post-discharge\n\n## Complications to Monitor\n- Cardiogenic shock, mechanical complications (free wall rupture, VSD, papillary muscle rupture)\n- Arrhythmias (VT/VF, heart block), pericarditis, LV thrombus", "metadata": {"source": "acs_stemi.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391760", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/acs_stemi.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Adrenal Insufficiency and Adrenal Crisis\n\n## Classification\n\n### Primary Adrenal Insufficiency (Addison Disease)\n- Destruction of adrenal cortex; deficiency of cortisol AND aldosterone\n- Causes: Autoimmune adrenalitis (most common in developed countries), infections (TB, CMV, HIV), hemorrhage (Waterhouse-Friderichsen syndrome), metastatic disease, medications (ketoconazole, etomidate, mitotane)\n- Distinguishing features: Hyperpigmentation, salt craving, hyperkalemia, hyponatremia\n\n### Secondary Adrenal Insufficiency\n- Deficient ACTH from pituitary pathology; cortisol deficient but aldosterone preserved\n- Causes: Pituitary tumor, surgery, radiation, Sheehan syndrome, infiltrative disease\n- No hyperpigmentation; no hyperkalemia (aldosterone intact)", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "### Tertiary Adrenal Insufficiency\n- Most common form; due to chronic exogenous glucocorticoid use causing HPA axis suppression\n- Risk: Any patient on >= 20 mg prednisone daily (or equivalent) for >= 3 weeks, or any dose of systemic corticosteroid for >= 4 weeks\n- HPA axis recovery may take 6-12 months after discontinuation\n\n## Diagnosis\n\n### Biochemical Testing\n- **Morning cortisol** (8 AM): <3 mcg/dL confirms adrenal insufficiency; >18 mcg/dL excludes it; 3-18 mcg/dL requires dynamic testing\n- **ACTH stimulation test (Cosyntropin test)**: Administer cosyntropin 250 mcg IV/IM; measure cortisol at 0 and 30-60 minutes. Peak cortisol <18 mcg/dL confirms adrenal insufficiency\n- **ACTH level**: Elevated in primary AI, low or inappropriately normal in secondary/tertiary AI\n- **Renin and aldosterone**: Elevated renin with low aldosterone in primary AI\n\n## Recognition of Adrenal Crisis", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "### Clinical Presentation\n- **Hypotension/shock** refractory to IV fluids and vasopressors (hallmark)\n- Severe fatigue, weakness, altered mental status\n- Nausea, vomiting, abdominal pain (may mimic acute abdomen)\n- Fever (may be from crisis itself or underlying infection)\n- Hyponatremia, hyperkalemia (primary AI), hypoglycemia\n- Hypercalcemia (rare but described)\n\n### Common Precipitants\n- Acute infection or illness (most common trigger)\n- Surgery, trauma, or significant physiologic stress\n- Abrupt discontinuation of chronic glucocorticoids\n- Adrenal hemorrhage (anticoagulation, sepsis, coagulopathy)\n- Missed replacement doses\n\n## Hydrocortisone Protocol for Adrenal Crisis", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "### Emergency Treatment (Do Not Delay for Diagnostic Testing)\n1. **Hydrocortisone 100 mg IV bolus** immediately\n2. **IV normal saline** with dextrose: Bolus 1-2 liters rapidly, then continue aggressive fluid resuscitation\n3. **Hydrocortisone 50 mg IV every 6-8 hours** for the first 24 hours (total 200 mg/day)\n4. Once hemodynamically stable: Taper by 50% per day until reaching physiologic replacement\n5. **Physiologic replacement**: Hydrocortisone 15-25 mg/day in divided doses (typically 10-15 mg morning, 5-10 mg afternoon)\n6. **Fludrocortisone** (primary AI only): 0.05-0.2 mg daily for mineralocorticoid replacement; not needed during crisis (hydrocortisone at stress doses provides adequate mineralocorticoid activity)\n7. Monitor electrolytes, glucose, and hemodynamics closely", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "### Key Principles\n- Treat empirically if clinical suspicion is high; draw cortisol and ACTH before treatment if possible, but DO NOT delay hydrocortisone\n- Vasopressor-dependent hypotension unresponsive to fluids should always prompt consideration of adrenal crisis\n- Dexamethasone 4 mg IV can be used instead of hydrocortisone if cosyntropin test is planned (does not interfere with cortisol assay)\n\n## Stress Dosing Guidelines\n\n### Sick Day Rules for Patients on Chronic Replacement\n- **Minor illness** (cold, mild gastroenteritis): Double oral hydrocortisone dose for 2-3 days\n- **Moderate illness** (fever >38C, flu with vomiting): Triple oral dose; consider IM hydrocortisone if unable to take oral\n- **Severe illness/major stress** (surgery, trauma, sepsis, critical illness): Hydrocortisone 100 mg IV bolus then 50 mg IV every 6-8 hours\n- **Vomiting/unable to take oral medications**: IM hydrocortisone 100 mg; present to emergency department immediately\n\n### Surgical Stress Dosing", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "| Procedure | Hydrocortisone Dose |\n|---|---|\n| Minor (dental, local anesthesia) | Take usual morning dose; no additional needed |\n| Moderate (orthopedic, abdominal) | 50 mg IV before induction, then 25 mg IV q8h for 24-48 hours |\n| Major (cardiac, major abdominal) | 100 mg IV before induction, then 50 mg IV q8h for 48-72 hours |\n| Critical illness / septic shock | 50 mg IV q6h (200 mg/day) continuous until stable |\n\n## Patient Education and Safety Measures\n\n### Medical Alert\n- All patients with adrenal insufficiency MUST wear a medical alert bracelet or necklace\n- Carry an emergency card detailing diagnosis, medication doses, and emergency instructions\n\n### Emergency Injection Kit\n- Patients should carry and be trained to self-administer IM hydrocortisone 100 mg\n- Family members and close contacts should also be trained\n- Kit contents: Hydrocortisone sodium succinate 100 mg vial, syringe, needle, instructions\n- Replace kit before expiration date", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Follow-Up\n- Endocrinology follow-up every 6-12 months\n- Monitor for over- or under-replacement (weight gain, hyperglycemia vs. fatigue, hypotension)\n- Annual screening for associated autoimmune conditions in primary AI (thyroid disease, type 1 diabetes, celiac disease)", "metadata": {"source": "adrenal_crisis.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.391919", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/adrenal_crisis.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Acute Kidney Injury (AKI) Management\n\n## KDIGO Staging\n- **Stage 1**: Creatinine 1.5-1.9x baseline OR increase \u22650.3 mg/dL within 48 hours OR UOP <0.5 mL/kg/hr \u00d7 6-12 hours\n- **Stage 2**: Creatinine 2.0-2.9x baseline OR UOP <0.5 mL/kg/hr \u00d7 \u226512 hours\n- **Stage 3**: Creatinine \u22653.0x baseline OR increase to \u22654.0 mg/dL OR initiation of RRT OR UOP <0.3 mL/kg/hr \u00d7 \u226524 hours OR anuria \u226512 hours\n\n## Etiology \u2014 Prerenal (60-70%)\n- Volume depletion: Hemorrhage, GI losses, burns, diuresis\n- Decreased effective circulating volume: Heart failure, cirrhosis, sepsis\n- Hemodynamic: NSAIDs (afferent arteriole), ACEi/ARBs (efferent arteriole)\n- Diagnostic clues: BUN/Cr ratio >20:1, FENa <1%, FEUrea <35%, bland sediment", "metadata": {"source": "aki_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392028", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/aki_management.md", "chunk_index": 0, "total_chunks": 4}}, {"content": "## Etiology \u2014 Intrinsic Renal (25-30%)\n- **Acute tubular necrosis (ATN)**: Ischemia or nephrotoxins (contrast, aminoglycosides, cisplatin)\n- **Acute interstitial nephritis (AIN)**: Drug-induced (NSAIDs, antibiotics, PPIs), autoimmune\n- **Glomerulonephritis**: Rapidly progressive GN \u2014 urgent evaluation (ANCA, anti-GBM, complement levels)\n- Diagnostic clues: FENa >2%, muddy brown casts (ATN), WBC casts (AIN), RBC casts (GN)\n\n## Etiology \u2014 Postrenal (5-10%)\n- Obstruction: BPH, nephrolithiasis, malignancy, blood clots\n- Diagnosis: Renal ultrasound showing hydronephrosis\n- Treatment: Urgent decompression (Foley catheter, ureteral stent, nephrostomy tube)", "metadata": {"source": "aki_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392028", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/aki_management.md", "chunk_index": 1, "total_chunks": 4}}, {"content": "## Management Principles\n- **Volume assessment**: JVP, lung exam, edema, orthostatics; use point-of-care ultrasound\n- **Prerenal**: IV fluid resuscitation (isotonic crystalloid); discontinue offending agents\n- **Avoid nephrotoxins**: Stop NSAIDs, aminoglycosides, contrast; hold ACEi/ARB temporarily\n- **Monitor**: Creatinine and electrolytes at least daily; strict I&O; daily weights\n- **Medication dose adjustments**: Renally cleared drugs require adjustment\n\n## Indications for Dialysis (AEIOU)\n- **A**cidosis: Severe metabolic acidosis (pH <7.1) refractory to bicarbonate\n- **E**lectrolytes: Hyperkalemia refractory to medical management\n- **I**ntoxication: Toxic alcohols, lithium, salicylates\n- **O**verload: Volume overload refractory to diuretics\n- **U**remia: Uremic encephalopathy, pericarditis, bleeding", "metadata": {"source": "aki_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392028", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/aki_management.md", "chunk_index": 2, "total_chunks": 4}}, {"content": "## Prevention\n- Adequate hydration before contrast procedures\n- Avoid nephrotoxic drug combinations\n- Monitor renal function with high-risk medications\n- Volume resuscitation in sepsis per Surviving Sepsis guidelines", "metadata": {"source": "aki_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392028", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/aki_management.md", "chunk_index": 3, "total_chunks": 4}}, {"content": "# Anaphylaxis Management\n\n## Recognition\nAnaphylaxis is likely when ANY ONE of the following criteria is met:\n1. Acute onset (minutes to hours) with skin/mucosal involvement (urticaria, angioedema, flushing) PLUS respiratory compromise OR hypotension\n2. Two or more of the following after exposure to likely allergen: skin/mucosal involvement, respiratory compromise, hypotension, persistent GI symptoms\n3. Hypotension after exposure to known allergen (SBP <90 or >30% decrease from baseline)\n\n## Immediate Management\n### Epinephrine \u2014 FIRST-LINE (do not delay)\n- **IM epinephrine 1:1000 (1mg/mL)**: 0.3-0.5mg IM in anterolateral thigh\n- Pediatric: 0.01mg/kg (max 0.3mg for <30kg)\n- **Repeat every 5-15 minutes** if symptoms persist\n- Auto-injectors: EpiPen 0.3mg (>30kg) or EpiPen Jr 0.15mg (<30kg)\n- If refractory: Consider IV epinephrine infusion (1-10 mcg/min) in monitored setting", "metadata": {"source": "anaphylaxis_management.md", "category": "emergency_medicine", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392136", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/anaphylaxis_management.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "### Positioning\n- Supine with legs elevated (if tolerated)\n- Sitting upright if respiratory distress\n- Do NOT sit or stand patient upright suddenly (risk of cardiovascular collapse)\n\n### Adjunctive Therapies\n- **IV fluids**: 1-2L normal saline bolus (20 mL/kg in children); may need large volumes\n- **Supplemental oxygen**: High-flow, target SpO2 >94%\n- **Albuterol** nebulized: For bronchospasm not responsive to epinephrine\n- **H1 antihistamine**: Diphenhydramine 25-50mg IV/IM (symptom relief, NOT first-line)\n- **H2 antihistamine**: Famotidine 20mg IV (adjunctive)\n- **Corticosteroids**: Methylprednisolone 125mg IV or dexamethasone 10mg IV \u2014 may help prevent biphasic reaction (limited evidence)\n- **Glucagon**: 1-5mg IV for patients on beta-blockers with refractory hypotension", "metadata": {"source": "anaphylaxis_management.md", "category": "emergency_medicine", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392136", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/anaphylaxis_management.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Biphasic Reactions\n- Occur in 5-20% of cases, typically within 8-12 hours (up to 72 hours)\n- Risk factors: Severe initial presentation, delayed epinephrine administration, wide trigger\n- **Observation period**: Minimum 4-6 hours after symptom resolution; 12-24 hours for severe reactions\n\n## Discharge Planning\n- Prescribe epinephrine auto-injector (2 doses)\n- Written anaphylaxis action plan\n- Allergy/immunology referral for trigger identification and desensitization\n- Medical alert identification\n- Educate: Avoid known triggers, early epinephrine use, seek emergency care even if symptoms resolve\n\n## Common Triggers\n- Foods: Peanuts, tree nuts, shellfish, milk, eggs, wheat, soy\n- Medications: Penicillins, cephalosporins, NSAIDs, neuromuscular blocking agents\n- Insect stings: Hymenoptera (bees, wasps, hornets, fire ants)\n- Latex, exercise, idiopathic", "metadata": {"source": "anaphylaxis_management.md", "category": "emergency_medicine", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392136", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/anaphylaxis_management.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Anticoagulation Therapy Management\n\n## Direct Oral Anticoagulants (DOACs)\n\n### Apixaban (Eliquis)\n- Dose: 5mg BID (reduce to 2.5mg BID if \u22652 of: age \u226580, weight \u226460kg, Cr \u22651.5)\n- Renal: No dose adjustment for renal impairment; use with caution if CrCl <25\n- No routine monitoring needed; Anti-Xa level if needed\n- Reversal: Andexanet alfa (Andexxa)\n\n### Rivaroxaban (Xarelto)\n- AF dose: 20mg daily with evening meal (15mg daily if CrCl 15-50)\n- VTE treatment: 15mg BID \u00d7 21 days, then 20mg daily\n- Avoid if CrCl <15; take with food for optimal absorption\n- Reversal: Andexanet alfa\n\n### Dabigatran (Pradaxa)\n- Dose: 150mg BID (110mg BID if CrCl 30-50 in some guidelines)\n- Renal: Avoid if CrCl <30; highly renal-cleared\n- Reversal: Idarucizumab (Praxbind) \u2014 specific reversal agent\n- GI side effects common; take with food", "metadata": {"source": "anticoagulation_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392237", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/anticoagulation_management.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "### Edoxaban (Savaysa)\n- Dose: 60mg daily (30mg daily if CrCl 15-50, weight \u226460kg, or P-gp inhibitors)\n- Requires \u22655 days parenteral anticoagulation lead-in for VTE\n- Avoid if CrCl >95 (reduced efficacy) or <15\n\n## Warfarin Management\n- **Target INR**: 2.0-3.0 for most indications (AF, VTE); 2.5-3.5 for mechanical mitral valve\n- **Loading**: 5mg daily \u00d7 2-3 days, then adjust based on INR (avoid 10mg loading in elderly)\n- **Monitoring**: INR 2-3x/week initially, then weekly, then every 4 weeks when stable\n- **Drug interactions**: CYP2C9/VKORC1 substrates \u2014 amiodarone (decrease dose 30-50%), fluconazole, metronidazole, TMP-SMX increase INR; rifampin, carbamazepine, phenytoin decrease INR\n- **Diet**: Consistent vitamin K intake; counsel on green leafy vegetables\n- **Reversal**: Vitamin K (IV for urgent, PO for non-urgent), 4-factor PCC for life-threatening bleeding, FFP", "metadata": {"source": "anticoagulation_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392237", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/anticoagulation_management.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Bridging Therapy\n- **High risk** (mechanical mitral valve, recent stroke <3 months, CHA2DS2-VASc \u22657): Bridge with LMWH\n- **Low risk** (AF without recent stroke, CHA2DS2-VASc \u22644): No bridging (BRIDGE trial)\n- **Moderate risk**: Individualize based on bleeding and thrombotic risk\n\n## Perioperative Management\n- **DOACs**: Hold 1-2 days for low bleeding risk procedures, 2-4 days for high bleeding risk; no bridging needed\n- **Warfarin**: Stop 5 days before surgery; check INR day before; restart 12-24 hours post-op if hemostasis adequate\n\n## Reversal Agents Summary\n| Agent | Reversal |\n|-------|----------|\n| Warfarin | Vitamin K, 4-factor PCC, FFP |\n| Dabigatran | Idarucizumab (Praxbind) |\n| Apixaban/Rivaroxaban | Andexanet alfa; 4-factor PCC if unavailable |\n| Heparin (UFH) | Protamine sulfate |\n| Enoxaparin (LMWH) | Protamine (partial reversal ~60%) |", "metadata": {"source": "anticoagulation_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392237", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/anticoagulation_management.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Asthma Stepwise Management (Adults and Adolescents \u226512 years)\n\n## Diagnosis\n- Variable respiratory symptoms: Wheeze, shortness of breath, chest tightness, cough\n- Variable expiratory airflow limitation: FEV1/FVC reduced, positive bronchodilator reversibility (\u226512% and \u2265200mL increase in FEV1)\n- Supportive: Peak flow variability >10%, positive methacholine challenge, FeNO \u226525 ppb\n\n## Stepwise Therapy (GINA 2024)\n### Step 1 \u2014 Mild Intermittent\n- **Preferred**: As-needed low-dose ICS-formoterol (budesonide-formoterol)\n- **Alternative**: As-needed SABA + ICS taken together\n\n### Step 2 \u2014 Mild Persistent\n- **Preferred**: Low-dose ICS daily OR as-needed low-dose ICS-formoterol\n- **Alternative**: LTRA (montelukast) \u2014 less effective than ICS\n\n### Step 3 \u2014 Moderate Persistent\n- **Preferred**: Low-dose ICS-LABA maintenance (with as-needed ICS-formoterol)\n- **Alternative**: Medium-dose ICS, or low-dose ICS + LTRA", "metadata": {"source": "asthma_management.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392514", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/asthma_management.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "### Step 4 \u2014 Moderate-Severe\n- **Preferred**: Medium-dose ICS-LABA (with as-needed ICS-formoterol as reliever)\n- **Alternative**: Add tiotropium (Spiriva Respimat), or high-dose ICS-LABA\n\n### Step 5 \u2014 Severe\n- **Preferred**: High-dose ICS-LABA + LAMA (tiotropium)\n- **Add-on**: Anti-IgE (omalizumab), anti-IL5/IL5R (mepolizumab, benralizumab), anti-IL4R (dupilumab), anti-TSLP (tezepelumab)\n- Low-dose oral corticosteroids as last resort\n- Phenotype-guided biologic selection based on eosinophils, IgE, FeNO\n\n## Asthma Control Assessment\nAssess over last 4 weeks:\n- Daytime symptoms >2/week\n- Any night waking due to asthma\n- Reliever needed >2/week\n- Any activity limitation\n- **Well controlled**: None of the above; **Partly**: 1-2; **Uncontrolled**: 3-4", "metadata": {"source": "asthma_management.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392514", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/asthma_management.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Acute Exacerbation Management\n- **Mild-Moderate**: SABA 4-10 puffs via MDI + spacer every 20 min \u00d7 1 hour; prednis(ol)one 40-50mg \u00d7 5-7 days\n- **Severe**: Continuous nebulized SABA, ipratropium bromide, systemic corticosteroids, supplemental O2 (target 93-95%)\n- **Life-threatening**: IV magnesium sulfate 2g over 20 min, consider IV salbutamol, ICU admission, intubation if needed\n\n## Asthma Action Plan\n- Green zone (well): Continue maintenance medications\n- Yellow zone (worsening): Increase ICS dose or start ICS-formoterol reliever, add OCS if not improving\n- Red zone (emergency): Seek immediate medical care, use SABA, start OCS", "metadata": {"source": "asthma_management.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392514", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/asthma_management.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Atrial Fibrillation Management\n\n## Diagnosis\n- Irregularly irregular rhythm on ECG\n- Absence of distinct P waves, fibrillatory baseline\n- Classification: Paroxysmal (<7 days), Persistent (>7 days), Long-standing persistent (>12 months), Permanent\n\n## Stroke Risk Assessment \u2014 CHA2DS2-VASc Score\n- **C** Congestive heart failure (1 point)\n- **H** Hypertension (1 point)\n- **A2** Age \u226575 (2 points)\n- **D** Diabetes mellitus (1 point)\n- **S2** Stroke/TIA/thromboembolism (2 points)\n- **V** Vascular disease (1 point)\n- **A** Age 65-74 (1 point)\n- **Sc** Sex category \u2014 female (1 point)\n- Score \u22652 (men) or \u22653 (women): Anticoagulation recommended\n- Score 1 (men) or 2 (women): Consider anticoagulation\n- Score 0 (men) or 1 (women): No anticoagulation needed", "metadata": {"source": "atrial_fibrillation.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392619", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/atrial_fibrillation.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "## Bleeding Risk \u2014 HAS-BLED Score\n- Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly (>65), Drugs/alcohol\n- Score \u22653: High bleeding risk \u2014 does NOT contraindicate anticoagulation but warrants closer monitoring\n\n## Anticoagulation\n- **DOACs preferred** over warfarin for non-valvular AF: Apixaban 5mg BID (preferred), Rivaroxaban 20mg daily, Dabigatran 150mg BID, Edoxaban 60mg daily\n- **Warfarin**: For mechanical valve, moderate-severe mitral stenosis; target INR 2.0-3.0\n- Dose adjustments: Renal function (CrCl), age, weight, drug interactions\n\n## Rate Control\n- **Target**: Resting HR <110 bpm (lenient) or <80 bpm (strict if symptomatic)\n- **First-line**: Beta-blockers (metoprolol, atenolol) or non-dihydropyridine CCBs (diltiazem, verapamil)\n- **Second-line**: Digoxin (adjunct, not monotherapy), amiodarone (if HFrEF)\n- Avoid CCBs in HFrEF", "metadata": {"source": "atrial_fibrillation.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392619", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/atrial_fibrillation.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Rhythm Control\n- Consider if symptomatic despite rate control, younger patients, first episode\n- **Cardioversion**: Electrical or pharmacologic; requires \u22653 weeks anticoagulation before OR TEE to exclude LAA thrombus\n- **Antiarrhythmics**: Flecainide/propafenone (no structural heart disease), amiodarone/dofetilide/sotalol (structural heart disease)\n- **Catheter ablation**: Pulmonary vein isolation \u2014 for drug-refractory symptomatic AF, increasingly first-line for paroxysmal AF\n- Continue anticoagulation \u22654 weeks post-cardioversion regardless of method", "metadata": {"source": "atrial_fibrillation.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392619", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/atrial_fibrillation.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Blood Product Transfusion Guidelines\n\n## Packed Red Blood Cells (pRBCs)\n\n### Restrictive vs. Liberal Transfusion Strategy\n- **Restrictive strategy (Hb <7 g/dL)**: Recommended for most hemodynamically stable hospitalized patients (TRICC, TRISS, FOCUS trials)\n- **Liberal strategy (Hb <8 g/dL)**: Consider for acute coronary syndrome, symptomatic cardiovascular disease, and postoperative cardiac surgery patients\n- **Hb <8 g/dL**: Also reasonable threshold for patients with chronic cardiovascular disease or symptoms attributable to anemia (dyspnea, tachycardia, chest pain, presyncope)", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "### Special Situations\n- **Active hemorrhage/hemorrhagic shock**: Transfuse based on clinical status, not specific Hb threshold; activate massive transfusion protocol if indicated\n- **Chronic anemia**: Patients often well-compensated at very low Hb; transfuse for symptoms rather than number\n- **Sickle cell disease**: Maintain Hb 10 g/dL for acute chest syndrome and stroke; simple transfusion or exchange transfusion depending on clinical scenario\n- **Pre-operative**: Optimize Hb; transfuse to >7-8 g/dL before surgery based on patient comorbidities and expected blood loss\n\n### Administration\n- Each unit of pRBCs raises Hb approximately 1 g/dL and Hct by 3%\n- Infuse over 1-2 hours per unit (maximum 4 hours); slower rate for patients at risk of volume overload\n- Single-unit transfusion strategy: Transfuse one unit, reassess clinically, and recheck Hb before ordering additional units\n\n## Platelet Transfusion\n\n### Indications and Thresholds", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "| Clinical Scenario | Platelet Threshold |\n|---|---|\n| Prophylactic (stable, non-bleeding) | <10,000/mcL |\n| Active non-surgical bleeding | <50,000/mcL |\n| Major surgery or invasive procedure | <50,000/mcL |\n| Neurosurgery or ophthalmic surgery | <100,000/mcL |\n| Lumbar puncture | <50,000/mcL (some guidelines suggest <40,000) |\n| Epidural placement | <80,000/mcL |\n| Massive transfusion | <50,000/mcL |\n\n### Special Considerations\n- **Immune thrombocytopenia (ITP)**: Transfuse only for life-threatening bleeding; platelets are rapidly consumed\n- **Thrombotic thrombocytopenic purpura (TTP)**: Platelet transfusion is relatively CONTRAINDICATED (may worsen thrombosis); treat with plasma exchange\n- **Heparin-induced thrombocytopenia (HIT)**: Avoid platelet transfusion unless life-threatening bleeding\n- Each apheresis unit raises platelet count by approximately 30,000-50,000/mcL\n- Refractory to transfusion: Consider HLA-matched platelets for patients with HLA antibodies", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "## Fresh Frozen Plasma (FFP)\n\n### Indications\n- Active bleeding with INR >1.5-2.0\n- Reversal of warfarin in urgent/emergent situations when 4-factor PCC unavailable\n- DIC with active bleeding\n- Massive transfusion protocol\n- TTP (plasma exchange with FFP replacement)\n- Liver disease with coagulopathy and active bleeding or prior to invasive procedure\n\n### Dosing\n- 10-15 mL/kg (typical: 3-4 units for average adult)\n- Reassess INR after transfusion to guide additional dosing\n- Must be ABO-compatible\n\n## Cryoprecipitate\n\n### Contents\n- Concentrated source of fibrinogen, factor VIII, factor XIII, von Willebrand factor, and fibronectin\n\n### Indications\n- **Fibrinogen <100-150 mg/dL** with active bleeding or DIC\n- Massive transfusion with hypofibrinogenemia\n- Uremic bleeding (DDAVP preferred first-line)\n- Factor XIII deficiency\n\n### Dosing\n- 1 pooled unit (5 individual donor units) raises fibrinogen by approximately 50-75 mg/dL\n- Goal fibrinogen: >150-200 mg/dL in active bleeding", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "## Massive Transfusion Protocol (MTP)\n\n### Definition\n- Transfusion of >= 10 units pRBCs within 24 hours, OR >= 4 units in 1 hour with anticipated ongoing need\n\n### Protocol (1:1:1 Ratio)\n- 6 units pRBCs : 6 units FFP : 1 apheresis platelet (or 6 pooled platelet concentrates)\n- Based on PROPPR trial showing improved hemostasis with balanced resuscitation\n- Supplement with cryoprecipitate if fibrinogen <150 mg/dL\n- **Tranexamic acid (TXA)**: 1g IV over 10 minutes followed by 1g over 8 hours (administer within 3 hours of injury per CRASH-2 trial)\n\n### Monitoring During MTP\n- Check CBC, INR, PTT, fibrinogen, ionized calcium, ABG/lactate every 30-60 minutes\n- Correct hypocalcemia (citrate toxicity): Calcium gluconate 1g IV per 4 units blood products\n- Correct hypothermia: Use blood warmers; target temperature >36C\n- Monitor for hyperkalemia (stored blood products have elevated potassium)\n\n## Transfusion Reactions\n\n### Acute Reactions", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "| Reaction | Onset | Signs/Symptoms | Management | |---|---|---|---| | Febrile non-hemolytic | During or within 4 hours | Fever, rigors, no hemolysis | Stop transfusion, acetaminophen; usually benign; rule out hemolytic reaction | | Allergic (mild) | During transfusion | Urticaria, pruritus, no hypotension | Pause transfusion, diphenhydramine 25-50mg IV; may resume if symptoms resolve | | Anaphylactic | Minutes of starting | Hypotension, bronchospasm, angioedema | STOP transfusion, epinephrine 0.3-0.5mg IM, IV fluids, airway management | | Acute hemolytic | Minutes to hours | Fever, flank pain, dark urine, hypotension, DIC | STOP transfusion immediately, aggressive NS resuscitation, send direct Coombs, repeat type and screen, maintain urine output >1 mL/kg/hr | | TRALI | Within 6 hours | Acute respiratory distress, bilateral infiltrates, hypoxemia, no volume overload | STOP transfusion, supportive care with oxygen and mechanical ventilation if needed; usually resolves in 48-96 hours |", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "| TACO | During or within 6 hours | Dyspnea, hypertension, pulmonary edema, elevated BNP | STOP transfusion, upright positioning, diuretics (furosemide 20-40mg IV), supplemental oxygen |\n\n### Delayed Reactions\n- **Delayed hemolytic**: 2-14 days post-transfusion; positive DAT, falling Hb, jaundice; usually self-limited\n- **Transfusion-associated GVHD**: Rare, often fatal; prevented with irradiated blood products in immunocompromised patients\n- **Iron overload**: Chronic transfusion patients; monitor ferritin; chelation with deferasirox when ferritin >1000 ng/mL\n\n### Universal Precautions\n- Verify patient identity and blood product compatibility at bedside (two-person verification)\n- Observe patient for first 15 minutes of transfusion (most severe reactions occur early)\n- Document transfusion volume, duration, and any adverse events", "metadata": {"source": "blood_transfusion.md", "category": "hematology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392717", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/blood_transfusion.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Coronary Artery Disease (CAD) - Chronic Management Guideline\n\n## Definition\n\nCoronary artery disease encompasses the spectrum of myocardial ischemia caused by atherosclerotic plaque in the epicardial coronary arteries, ranging from stable angina to acute coronary syndromes. This guideline addresses chronic coronary disease (stable ischemic heart disease).\n\n## Diagnosis of Stable Angina\n\n### Clinical Features\n- Substernal chest discomfort provoked by exertion or emotional stress\n- Typically lasts 3-5 minutes; relieved by rest or sublingual nitroglycerin within 5 minutes\n- May radiate to left arm, jaw, neck, back, or epigastrium\n- Associated with dyspnea, diaphoresis, or nausea\n- **Typical angina**: 3/3 features (substernal, provoked by exertion/stress, relieved by rest/NTG)\n- **Atypical angina**: 2/3 features\n- **Non-cardiac chest pain**: 0-1/3 features", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 0, "total_chunks": 8}}, {"content": "### Diagnostic Testing (Based on Pretest Probability)\n- **Low pretest probability (< 15%)**: No further testing; consider alternative diagnoses\n- **Intermediate pretest probability (15-85%)**:\n  - Exercise ECG stress test (if able to exercise and baseline ECG interpretable)\n  - Stress imaging (nuclear perfusion, stress echocardiography, stress CMR) if unable to exercise, abnormal baseline ECG, or intermediate exercise ECG result\n  - Coronary CT angiography (CCTA): Preferred in lower-intermediate risk; high negative predictive value\n- **High pretest probability (> 85%)**: Consider direct referral for invasive coronary angiography\n\n## Risk Factor Modification", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 1, "total_chunks": 8}}, {"content": "### Lipid Management\n- **High-intensity statin therapy** for ALL patients with established CAD:\n  - Atorvastatin 40-80 mg or rosuvastatin 20-40 mg\n  - Target: LDL-C < 70 mg/dL (< 55 mg/dL per ESC for very high risk)\n- If LDL not at target on maximally tolerated statin:\n  - Add ezetimibe 10 mg (reduces LDL by additional 15-20%)\n  - If still not at target: add PCSK9 inhibitor (evolocumab 140 mg SC q2 weeks or alirocumab 75-150 mg SC q2 weeks)\n- Monitor lipid panel 4-12 weeks after initiation or dose change\n- Statin-associated muscle symptoms: trial of alternative statin, lower dose, or every-other-day dosing\n\n### Blood Pressure Control\n- Target < 130/80 mmHg\n- Beta-blocker preferred if concurrent angina; ACEi/ARB if concurrent LV dysfunction, diabetes, or CKD\n- See hypertension management guideline\n\n### Glycemic Control\n- HbA1c < 7% for most patients with diabetes\n- SGLT2 inhibitors and GLP-1 RAs have demonstrated cardiovascular benefit in patients with CAD and T2DM", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 2, "total_chunks": 8}}, {"content": "### Smoking Cessation\n- Counsel at every visit; offer pharmacotherapy (varenicline, bupropion, NRT)\n- Reduces cardiovascular mortality by 36% within 3-5 years\n\n### Weight and Exercise\n- Cardiac rehabilitation referral for all patients with established CAD\n- 150 minutes/week moderate-intensity aerobic exercise; prescribe based on stress test results\n- Target BMI < 25 kg/m2; waist circumference < 40 inches (men), < 35 inches (women)\n\n## Antiplatelet Therapy", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 3, "total_chunks": 8}}, {"content": "- **Aspirin 75-100 mg daily**: Lifelong for all patients with established CAD\n- **Dual antiplatelet therapy (DAPT)**: Aspirin + clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg BID\n  - After PCI with drug-eluting stent (DES): minimum 6 months DAPT; 12 months if post-ACS\n  - Short-duration DAPT (1-3 months) followed by P2Y12 monotherapy may be considered in high bleeding risk patients\n- **In patients who cannot take aspirin**: Clopidogrel 75 mg daily as monotherapy\n- **Rivaroxaban 2.5 mg BID + aspirin** (COMPASS regimen): Consider in stable CAD with high ischemic risk and low bleeding risk\n\n## Anti-Anginal Therapy", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 4, "total_chunks": 8}}, {"content": "### First-Line\n- **Beta-blockers**: Metoprolol succinate 25-200 mg daily, bisoprolol 2.5-10 mg daily, atenolol 25-100 mg daily\n  - Target resting heart rate 55-60 bpm\n  - Preferred in patients with prior MI (mortality benefit) or HFrEF\n- **Calcium channel blockers**: Amlodipine 5-10 mg, diltiazem ER 180-360 mg\n  - Use when beta-blockers contraindicated (vasospastic angina, severe reactive airway disease)\n  - Non-DHP CCBs provide rate control; avoid with beta-blockers\n\n### Second-Line\n- **Long-acting nitrates**: Isosorbide mononitrate ER 30-120 mg daily\n  - Provide 10-14 hour nitrate-free interval to prevent tolerance\n- **Ranolazine**: 500-1000 mg BID; inhibits late sodium current; no effect on HR or BP\n  - Add when symptoms persist on beta-blocker/CCB; particularly useful in diabetes", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 5, "total_chunks": 8}}, {"content": "### Sublingual Nitroglycerin\n- 0.4 mg sublingual PRN for acute anginal episodes\n- Instruct: sit down, place tablet under tongue; repeat every 5 minutes up to 3 times; call 911 if no relief after first dose\n- Replace supply every 6 months\n\n## Revascularization Indications\n\n### Percutaneous Coronary Intervention (PCI)\n- Significant stenosis (> 70% by angiography or FFR <= 0.80) with refractory angina despite optimal medical therapy\n- Left main disease > 50% (select cases depending on SYNTAX score)\n- Improve quality of life in symptomatic patients\n\n### Coronary Artery Bypass Grafting (CABG)\n- **Preferred over PCI when**:\n  - Left main disease with high SYNTAX score (> 32)\n  - Three-vessel disease, especially with diabetes or LV dysfunction\n  - Two-vessel disease with proximal LAD involvement and diabetes\n- **Survival benefit demonstrated in**: Left main stenosis, three-vessel disease with depressed LVEF", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 6, "total_chunks": 8}}, {"content": "### Heart Team Approach\n- Complex multivessel or left main disease should be discussed by a multidisciplinary heart team (interventional cardiology, cardiac surgery, clinical cardiology)\n\n## Follow-Up\n\n- Clinical assessment every 4-6 months in the first year, then annually if stable\n- Annual stress testing NOT recommended in stable, asymptomatic patients\n- Reassess if change in symptoms: stress imaging or angiography as indicated\n- Influenza vaccination annually; pneumococcal vaccination per guidelines", "metadata": {"source": "cad_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.392882", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cad_management.md", "chunk_index": 7, "total_chunks": 8}}, {"content": "# Cancer Screening Guidelines\n\n## Breast Cancer Screening\n\n### Mammography (USPSTF 2024)\n- **Age 40-49**: Biennial screening mammography recommended (B recommendation)\n- **Age 50-74**: Biennial screening mammography (B recommendation)\n- **Age 75+**: Insufficient evidence; individualize based on life expectancy and comorbidities\n- **High-risk patients** (BRCA carriers, prior chest radiation, >20% lifetime risk): Annual mammography starting at age 30 plus breast MRI\n\n### Supplemental Screening\n- Women with dense breasts (BI-RADS C or D) may benefit from breast ultrasound or MRI\n- Risk assessment tools: Tyrer-Cuzick model preferred for determining high-risk status\n\n## Cervical Cancer Screening", "metadata": {"source": "cancer_screening.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393036", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cancer_screening.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "### Recommended Approaches\n- **Age 21-29**: Cervical cytology (Pap smear) alone every 3 years\n- **Age 30-65**: Three acceptable strategies:\n  - HPV primary testing alone every 5 years (preferred)\n  - Co-testing (Pap + HPV) every 5 years\n  - Cytology alone every 3 years\n- **Age >65**: Discontinue screening if adequate prior negative results (three consecutive negative cytologies or two negative co-tests within 10 years, with most recent within 5 years)\n- **Post-hysterectomy**: No screening needed if cervix removed for benign indication and no history of CIN2+\n\n### Special Populations\n- HIV-positive women: Screen at diagnosis, repeat at 12 months, then every 3 years if normal\n- Immunosuppressed patients: More frequent screening per specialist guidance\n\n## Colorectal Cancer Screening", "metadata": {"source": "cancer_screening.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393036", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cancer_screening.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "### Average Risk (Age 45-75)\n- **Colonoscopy**: Every 10 years (gold standard)\n- **FIT (fecal immunochemical test)**: Annually\n- **FIT-DNA (Cologuard)**: Every 1-3 years\n- **Flexible sigmoidoscopy**: Every 5 years (or every 10 years if combined with annual FIT)\n- **CT colonography**: Every 5 years\n\n### Age Considerations\n- **Age 45-49**: Screening recommended (updated from prior age 50 start)\n- **Age 76-85**: Individualize decision based on health status, prior screening history, and patient preference\n- **Age >85**: Do not screen\n\n### High-Risk Patients\n- Family history of CRC in first-degree relative <60 years: Colonoscopy starting at age 40 or 10 years before youngest affected relative, every 5 years\n- Lynch syndrome: Colonoscopy every 1-2 years starting at age 20-25\n- Inflammatory bowel disease: Colonoscopy with biopsies 8-10 years after diagnosis, then every 1-3 years\n\n## Lung Cancer Screening", "metadata": {"source": "cancer_screening.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393036", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cancer_screening.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "### Low-Dose CT (LDCT) Criteria (USPSTF)\n- Age 50-80 years\n- 20 pack-year smoking history AND currently smoking or quit within past 15 years\n- Annual LDCT screening\n- Discontinue when patient has not smoked for 15 years or develops a condition substantially limiting life expectancy\n\n### Lung-RADS Reporting\n- Category 1-2: Benign or probably benign; continue annual screening\n- Category 3: Probably benign; 6-month follow-up LDCT\n- Category 4A/4B: Suspicious; short-interval follow-up or tissue sampling\n\n## Prostate Cancer Screening", "metadata": {"source": "cancer_screening.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393036", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cancer_screening.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "### PSA-Based Screening (Shared Decision Making)\n- **Age 55-69**: Offer shared decision-making conversation about PSA screening; discuss potential benefits (small mortality reduction) and harms (false positives, overdiagnosis, overtreatment)\n- **Age 40-54 with high risk**: Consider earlier discussion for African American men and those with first-degree relative with prostate cancer\n- **Age >70**: Do not routinely screen\n- If PSA elevated (>4.0 ng/mL or age-adjusted threshold), consider repeat PSA, free PSA ratio, or MRI before biopsy", "metadata": {"source": "cancer_screening.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393036", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/cancer_screening.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Chronic Kidney Disease (CKD) Management\n\n## Staging by GFR\n- **G1**: GFR \u226590 (normal/high) \u2014 with evidence of kidney damage\n- **G2**: GFR 60-89 (mildly decreased)\n- **G3a**: GFR 45-59 (mild-moderate decrease)\n- **G3b**: GFR 30-44 (moderate-severe decrease)\n- **G4**: GFR 15-29 (severely decreased)\n- **G5**: GFR <15 (kidney failure)\n\n## Albuminuria Categories\n- **A1**: <30 mg/g (normal to mildly increased)\n- **A2**: 30-300 mg/g (moderately increased \u2014 \"microalbuminuria\")\n- **A3**: >300 mg/g (severely increased \u2014 \"macroalbuminuria\")\n\n## Blood Pressure Management\n- Target: <130/80 mmHg (for all CKD patients)\n- **First-line**: ACEi or ARB if albuminuria (A2-A3) \u2014 reduce proteinuria and slow progression\n- Do NOT combine ACEi + ARB (increased adverse events without benefit)\n- Monitor K+ and creatinine 1-2 weeks after initiation or dose change (up to 30% rise in Cr acceptable)", "metadata": {"source": "ckd_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393116", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/ckd_management.md", "chunk_index": 0, "total_chunks": 4}}, {"content": "## Kidney-Protective Therapies\n- **SGLT2 inhibitors**: Dapagliflozin or empagliflozin \u2014 slow CKD progression, reduce proteinuria (indicated if eGFR \u226520)\n- **Finerenone** (non-steroidal MRA): For T2DM with CKD \u2014 reduces kidney and cardiovascular events\n- **GLP-1 receptor agonists**: Semaglutide, liraglutide \u2014 cardiovascular and possible renal benefit in T2DM\n\n## Anemia of CKD\n- Screen when eGFR <60: CBC, reticulocyte count, iron studies, B12/folate\n- **Iron supplementation first**: Target TSAT >20%, ferritin >100 ng/mL (>200 for dialysis patients)\n- **Erythropoiesis-stimulating agents (ESA)**: Epoetin alfa, darbepoetin \u2014 target Hgb 10-11.5 g/dL\n- Avoid Hgb >13 g/dL (increased cardiovascular events)", "metadata": {"source": "ckd_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393116", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/ckd_management.md", "chunk_index": 1, "total_chunks": 4}}, {"content": "## CKD-Mineral and Bone Disorder\n- **Phosphorus**: Restrict dietary phosphorus, phosphate binders (sevelamer, calcium acetate, lanthanum) if serum phos elevated\n- **Calcium**: Avoid calcium-based binders if hypercalcemia; monitor total and ionized calcium\n- **Vitamin D**: Check 25-OH vitamin D; supplement if deficient; active vitamin D (calcitriol) for secondary hyperparathyroidism\n- **PTH management**: Target varies by CKD stage; calcimimetics (cinacalcet) for dialysis patients with elevated PTH\n\n## Metabolic Acidosis\n- Maintain serum bicarbonate \u226522 mEq/L\n- Oral sodium bicarbonate supplementation (may slow CKD progression)\n\n## Nephrology Referral\n- eGFR <30 (plan for dialysis access at eGFR 15-20)\n- Rapid decline (>5 mL/min/1.73m\u00b2/year)\n- Significant proteinuria (ACR >300)\n- Uncertain etiology, refractory hypertension, refractory electrolyte abnormalities", "metadata": {"source": "ckd_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393116", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/ckd_management.md", "chunk_index": 2, "total_chunks": 4}}, {"content": "## Dialysis Preparation (eGFR 15-20)\n- Modality education: Hemodialysis vs peritoneal dialysis vs kidney transplant\n- Vascular access creation: AV fistula preferred (6 months before anticipated start)\n- Hepatitis B vaccination series\n- Transplant evaluation if candidate", "metadata": {"source": "ckd_management.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393116", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/ckd_management.md", "chunk_index": 3, "total_chunks": 4}}, {"content": "# Chronic Obstructive Pulmonary Disease (COPD) Management\n\n## Diagnosis\n- Post-bronchodilator FEV1/FVC <0.70 confirms airflow obstruction\n- Symptoms: Dyspnea, chronic cough, sputum production\n- Risk factors: Smoking (>10 pack-years), occupational exposures, alpha-1 antitrypsin deficiency\n\n## GOLD Severity Classification (by FEV1 % predicted)\n- **GOLD 1 (Mild)**: FEV1 \u226580%\n- **GOLD 2 (Moderate)**: 50% \u2264 FEV1 < 80%\n- **GOLD 3 (Severe)**: 30% \u2264 FEV1 < 50%\n- **GOLD 4 (Very Severe)**: FEV1 <30%\n\n## GOLD ABE Assessment (symptom burden + exacerbation history)\n- **Group A**: Low symptoms (mMRC 0-1 or CAT <10), 0-1 moderate exacerbations\n- **Group B**: High symptoms (mMRC \u22652 or CAT \u226510), 0-1 moderate exacerbations\n- **Group E**: \u22652 moderate exacerbations or \u22651 hospitalization regardless of symptoms\n\n## Pharmacotherapy\n### Group A\n- Bronchodilator (SABA or SAMA as needed, or LABA or LAMA)\n\n### Group B\n- LABA + LAMA combination preferred", "metadata": {"source": "copd_management.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393245", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/copd_management.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "### Group E\n- LABA + LAMA preferred initial therapy\n- If eosinophils \u2265300: LABA + LAMA + ICS (triple therapy)\n- If eosinophils 100-300: Consider ICS addition\n- If eosinophils <100: Avoid ICS\n\n## Key Medications\n- **LAMA**: Tiotropium, umeclidinium, glycopyrrolate\n- **LABA**: Salmeterol, formoterol, indacaterol, olodaterol, vilanterol\n- **ICS**: Fluticasone, budesonide, beclomethasone (only with LABA in COPD)\n- **PDE4 inhibitor**: Roflumilast \u2014 for FEV1 <50%, chronic bronchitis phenotype, frequent exacerbations\n\n## Acute Exacerbation Management (AECOPD)\n- **Bronchodilators**: Increase frequency of SABA \u00b1 SAMA\n- **Systemic corticosteroids**: Prednisone 40mg \u00d7 5 days\n- **Antibiotics**: If increased sputum purulence + either increased dyspnea or sputum volume; amoxicillin-clavulanate, azithromycin, or doxycycline\n- **Oxygen**: Target SpO2 88-92% (avoid over-oxygenation)\n- **NIV (BiPAP)**: For respiratory acidosis (pH <7.35), severe dyspnea", "metadata": {"source": "copd_management.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393245", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/copd_management.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Non-Pharmacologic\n- **Smoking cessation**: Single most effective intervention\n- **Vaccination**: Influenza (annual), pneumococcal (PCV20), COVID-19, Tdap, Zoster\n- **Pulmonary rehabilitation**: Reduces dyspnea, improves exercise tolerance and quality of life\n- **Long-term oxygen**: If PaO2 \u226455 mmHg or SpO2 \u226488% at rest\n\n## Surgical Options\n- Lung volume reduction surgery (LVRS) for upper-lobe predominant emphysema\n- Lung transplantation for advanced disease", "metadata": {"source": "copd_management.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393245", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/copd_management.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Depression Screening and Management\n\n## Screening\n- **PHQ-2** (initial screen): \"Over the past 2 weeks, how often have you been bothered by: 1) Little interest or pleasure in doing things? 2) Feeling down, depressed, or hopeless?\"\n- Score \u22653: Proceed to PHQ-9\n\n## PHQ-9 Severity\n- **0-4**: Minimal/none\n- **5-9**: Mild depression \u2014 watchful waiting, supportive counseling\n- **10-14**: Moderate \u2014 consider pharmacotherapy and/or psychotherapy\n- **15-19**: Moderately severe \u2014 pharmacotherapy + psychotherapy recommended\n- **20-27**: Severe \u2014 pharmacotherapy + psychotherapy, consider psychiatry referral\n\n## Question 9 \u2014 Suicidality Screening\n- \"Thoughts that you would be better off dead or of hurting yourself\"\n- Any positive response requires further safety assessment (Columbia Suicide Severity Rating Scale)\n- Document risk assessment, safety plan, and follow-up plan", "metadata": {"source": "depression_screening.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393348", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/depression_screening.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "## First-Line Pharmacotherapy \u2014 SSRIs\n- **Sertraline** (Zoloft): 50mg daily \u2192 max 200mg; good safety profile, evidence in cardiac patients\n- **Escitalopram** (Lexapro): 10mg daily \u2192 max 20mg; fewest drug interactions\n- **Fluoxetine** (Prozac): 20mg daily \u2192 max 80mg; long half-life; CYP2D6 inhibitor\n- **Paroxetine** (Paxil): 20mg daily \u2192 max 50mg; most anticholinergic SSRI; discontinuation syndrome\n- **Citalopram** (Celexa): 20mg daily \u2192 max 40mg (20mg if >60yo); QT prolongation risk at high doses\n\n## Alternative First-Line\n- **SNRIs**: Duloxetine 60mg daily (also for neuropathic pain, fibromyalgia); Venlafaxine XR 75-225mg daily (monitor BP)\n- **Bupropion** XL 150-300mg daily: No sexual side effects, no weight gain; avoid if seizure risk; good for smoking cessation co-treatment", "metadata": {"source": "depression_screening.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393348", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/depression_screening.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "## SSRI Monitoring and Management\n- **Onset**: 2-4 weeks for initial response; 6-8 weeks for full effect\n- **Common side effects**: Nausea (transient), sexual dysfunction, weight gain, insomnia or somnolence\n- **Serotonin syndrome risk**: Avoid with MAOIs, use caution with tramadol, triptans\n- **Discontinuation syndrome**: Taper gradually over 2-4 weeks (especially paroxetine, venlafaxine)\n- **Monitoring**: Follow up 1-2 weeks after starting, then 4 weeks, then monthly until stable; repeat PHQ-9", "metadata": {"source": "depression_screening.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393348", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/depression_screening.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "## Treatment-Resistant Depression (inadequate response to \u22652 adequate trials)\n- Optimization: Ensure adequate dose and duration (6-8 weeks at therapeutic dose)\n- Augmentation: Add lithium, atypical antipsychotic (aripiprazole, quetiapine), or thyroid hormone (T3)\n- Switch: To different class (SSRI \u2192 SNRI \u2192 bupropion)\n- **Esketamine** (Spravato): Intranasal, for treatment-resistant depression; REMS program required\n- ECT: Gold standard for severe/refractory depression; particularly effective for psychotic features, catatonia\n- TMS (transcranial magnetic stimulation): Non-invasive, FDA-approved for treatment-resistant MDD\n\n## Psychotherapy\n- **CBT** (Cognitive Behavioral Therapy): Strong evidence, comparable to medication for mild-moderate depression\n- **IPT** (Interpersonal Therapy): Focuses on relationship patterns\n- **Behavioral Activation**: Especially useful when motivation is severely impaired\n- Combination of pharmacotherapy + psychotherapy is more effective than either alone", "metadata": {"source": "depression_screening.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393348", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/depression_screening.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "## Duration of Treatment\n- First episode: Continue 6-12 months after remission, then consider tapering\n- Recurrent episodes (\u22653): Consider indefinite maintenance therapy\n- Chronic depression (>2 years): Long-term treatment recommended", "metadata": {"source": "depression_screening.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393348", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/depression_screening.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Diabetic Ketoacidosis (DKA) - Emergency Management Guideline\n\n## Definition and Diagnosis\n\nDiabetic ketoacidosis is an acute, life-threatening complication of diabetes characterized by the triad of hyperglycemia, metabolic acidosis, and ketosis.\n\n### Diagnostic Criteria\n\n| Parameter | Mild DKA | Moderate DKA | Severe DKA |\n|-----------|----------|--------------|------------|\n| Blood glucose | > 250 mg/dL | > 250 mg/dL | > 250 mg/dL |\n| Arterial pH | 7.25-7.30 | 7.00-7.24 | < 7.00 |\n| Serum bicarbonate | 15-18 mEq/L | 10-14.9 mEq/L | < 10 mEq/L |\n| Anion gap | > 10 | > 12 | > 12 |\n| Serum ketones | Positive | Positive | Positive |\n| Mental status | Alert | Alert/drowsy | Stupor/coma |\n\n**Note**: Euglycemic DKA (glucose < 250 mg/dL) may occur with SGLT2 inhibitor use, pregnancy, or reduced oral intake. Maintain high clinical suspicion.\n\n## Common Precipitants", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "- Infection (most common cause, 30-40% of cases)\n- Non-adherence with insulin therapy\n- New-onset type 1 diabetes\n- Myocardial infarction, stroke, or acute illness\n- Medications (corticosteroids, SGLT2 inhibitors, atypical antipsychotics)\n- Substance use (cocaine, alcohol)\n\n## Initial Assessment\n\n- **ABCs**: Secure airway if altered mental status; intubate if GCS < 8\n- **Labs**: BMP (glucose, electrolytes, BUN, creatinine), venous or arterial blood gas, serum ketones (beta-hydroxybutyrate preferred), CBC, urinalysis, blood cultures if infection suspected\n- **Calculate**: Anion gap = Na - (Cl + HCO3); corrected sodium = measured Na + 1.6 x ((glucose - 100) / 100); effective osmolality\n- **ECG**: Assess for hyperkalemia/hypokalemia changes, ischemia\n- **Identify precipitant**: Chest X-ray, urine culture, lipase as indicated\n\n## Fluid Resuscitation", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "### Initial Resuscitation\n- **0.9% NaCl**: 1-1.5 L/hour for the first 1-2 hours (15-20 mL/kg/hour)\n- Assess corrected sodium after initial bolus\n\n### Subsequent Fluids\n- **If corrected Na is normal or elevated**: Switch to 0.45% NaCl at 250-500 mL/hour\n- **If corrected Na is low**: Continue 0.9% NaCl at 250-500 mL/hour\n- **When glucose reaches 200-250 mg/dL**: Add dextrose (D5W with 0.45% NaCl) to allow continued insulin infusion while avoiding hypoglycemia\n- Typical fluid deficit: 5-7 liters; replace over 24-48 hours\n\n## Insulin Protocol", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "### Continuous IV Insulin Infusion (Preferred for Moderate-Severe DKA)\n- **Bolus**: Regular insulin 0.1 units/kg IV push (optional per protocol)\n- **Infusion**: Regular insulin 0.1 units/kg/hour (or 0.14 units/kg/hour if no bolus)\n- **Target glucose decline**: 50-75 mg/dL per hour\n- If glucose does not decrease by 10% in the first hour, give 0.14 units/kg IV bolus and reassess\n- **When glucose reaches 200-250 mg/dL**: Reduce insulin infusion to 0.02-0.05 units/kg/hour; add dextrose to IV fluids\n- Maintain glucose 150-200 mg/dL until DKA resolves\n\n### Subcutaneous Insulin (Mild DKA Only)\n- Rapid-acting insulin 0.2 units/kg SC initially, then 0.1 units/kg every hour\n- Or rapid-acting insulin 0.3 units/kg initially, then 0.2 units/kg every 2 hours\n\n**Critical**: Do NOT stop insulin infusion until DKA has resolved. Hyperglycemia resolves before ketoacidosis.\n\n## Potassium Management\n\nPotassium replacement is critical due to total body depletion despite initial serum levels.", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "- **K+ < 3.3 mEq/L**: Hold insulin; replace potassium aggressively (20-40 mEq/hour IV) until K+ > 3.3 mEq/L\n- **K+ 3.3-5.3 mEq/L**: Add 20-30 mEq KCl to each liter of IV fluid; target K+ 4.0-5.0 mEq/L\n- **K+ > 5.3 mEq/L**: Do not supplement; recheck every 2 hours\n- Monitor serum potassium every 1-2 hours during initial management\n\n## Bicarbonate Therapy\n\n- **Not routinely recommended**\n- Consider only if pH < 6.9: 100 mEq NaHCO3 in 400 mL sterile water with 20 mEq KCl over 2 hours\n- Repeat ABG 2 hours after infusion; repeat bicarbonate if pH remains < 6.9\n\n## Phosphate Replacement\n\n- Routine replacement not recommended\n- Replace if serum phosphate < 1.0 mg/dL or if cardiac dysfunction, respiratory depression, or hemolytic anemia present\n- Administer 20-30 mEq potassium phosphate in IV fluids\n\n## Monitoring During Treatment", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "- **Glucose**: Every 1 hour\n- **Electrolytes (Na, K, Cl, HCO3)**: Every 2-4 hours\n- **Venous blood gas**: Every 2-4 hours until pH > 7.3\n- **Beta-hydroxybutyrate**: Every 2-4 hours if available\n- **Anion gap**: Calculate with each electrolyte panel\n- **Fluid balance**: Strict intake/output; Foley catheter if altered mental status\n- **Neurologic checks**: Assess for cerebral edema (especially in pediatric patients)\n\n## Resolution Criteria\n\nDKA is considered resolved when ALL of the following are met:\n- Blood glucose < 200 mg/dL\n- Serum bicarbonate >= 15 mEq/L\n- Venous pH > 7.3\n- Anion gap <= 12 mEq/L\n\n## Transition to Subcutaneous Insulin", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "- Administer subcutaneous basal insulin (glargine or detemir) at least 2 hours BEFORE discontinuing IV insulin infusion\n- If patient was previously on insulin, resume home regimen (with dose adjustment as needed)\n- If newly diagnosed, initiate basal-bolus regimen at 0.5-0.8 units/kg/day\n- Ensure patient can tolerate oral intake before transitioning\n- Overlap IV and SC insulin for at least 1-2 hours to prevent rebound hyperglycemia/ketosis", "metadata": {"source": "diabetes_dka.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393410", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_dka.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Gestational Diabetes Mellitus (GDM) - Clinical Guideline\n\n## Definition\n\nGestational diabetes mellitus is glucose intolerance with onset or first recognition during pregnancy, typically diagnosed in the second or third trimester, in patients without preexisting type 1 or type 2 diabetes.\n\n## Screening and Diagnosis\n\n### Timing\n- **Universal screening** at 24-28 weeks gestation is recommended for all pregnant individuals not previously diagnosed with diabetes\n- **Early screening** (at first prenatal visit) for patients with risk factors: BMI >= 25, prior GDM, first-degree relative with diabetes, high-risk ethnicity, PCOS, prior macrosomic infant, HbA1c >= 5.7%\n\n### Two-Step Approach (Preferred in US - Carpenter-Coustan Criteria)\n\n**Step 1: 50g Glucose Challenge Test (GCT)** - non-fasting\n- Positive screen: 1-hour glucose >= 130-140 mg/dL (threshold varies by institution)\n- If >= 200 mg/dL, may diagnose GDM without OGTT", "metadata": {"source": "diabetes_gestational.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393466", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_gestational.md", "chunk_index": 0, "total_chunks": 6}}, {"content": "**Step 2: 100g 3-Hour Oral Glucose Tolerance Test (OGTT)**\n- Diagnosis requires 2 or more values meeting or exceeding thresholds:\n  - Fasting: >= 95 mg/dL\n  - 1-hour: >= 180 mg/dL\n  - 2-hour: >= 155 mg/dL\n  - 3-hour: >= 140 mg/dL\n\n### One-Step Approach (IADPSG / WHO Criteria)\n\n**75g 2-Hour OGTT** - fasting\n- Diagnosis requires 1 or more values meeting or exceeding thresholds:\n  - Fasting: >= 92 mg/dL\n  - 1-hour: >= 180 mg/dL\n  - 2-hour: >= 153 mg/dL\n\n## Glycemic Targets During Pregnancy\n\n- **Fasting glucose**: < 95 mg/dL (< 5.3 mmol/L)\n- **1-hour postprandial**: < 140 mg/dL (< 7.8 mmol/L)\n- **2-hour postprandial**: < 120 mg/dL (< 6.7 mmol/L)\n- **HbA1c**: < 6.0% if achievable without significant hypoglycemia\n\n## Management\n\n### Non-Pharmacologic (First-Line)", "metadata": {"source": "diabetes_gestational.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393466", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_gestational.md", "chunk_index": 1, "total_chunks": 6}}, {"content": "- **Medical nutrition therapy (MNT)**: Individualized meal plan by registered dietitian; carbohydrate-controlled diet with 3 meals and 2-3 snacks daily\n- **Carbohydrate distribution**: 33-40% of total calories from carbohydrates; complex carbohydrates preferred\n- **Physical activity**: 30 minutes/day moderate exercise (e.g., walking) unless obstetric contraindication\n- **Self-monitoring of blood glucose (SMBG)**: Fasting and 1-hour or 2-hour postprandial after each meal (4 times/day minimum)\n\n### Pharmacologic Therapy\n\nInitiate if glycemic targets are not achieved after 1-2 weeks of lifestyle modification.", "metadata": {"source": "diabetes_gestational.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393466", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_gestational.md", "chunk_index": 2, "total_chunks": 6}}, {"content": "**Insulin (Preferred)**\n- No significant placental transfer; considered safest pharmacologic option\n- **Basal insulin**: NPH insulin, typically at bedtime for fasting hyperglycemia\n- **Prandial insulin**: Rapid-acting analogs (lispro or aspart) for postprandial hyperglycemia\n- Starting dose: 0.7-1.0 units/kg/day, adjusted based on glucose patterns\n- Dose requirements typically increase throughout pregnancy\n\n**Metformin (Alternative)**\n- May be considered when insulin is refused or not accessible\n- Starting dose: 500 mg daily, titrate to 500 mg twice or three times daily\n- Crosses the placenta; long-term offspring safety data still accumulating\n- Contraindicated in preeclampsia, renal insufficiency, or fetal growth restriction\n\n**Glyburide**\n- Previously used as alternative; current evidence shows inferior outcomes compared to insulin and metformin\n- Higher rates of neonatal hypoglycemia and macrosomia\n- Generally not recommended as first-line alternative\n\n## Antepartum Surveillance", "metadata": {"source": "diabetes_gestational.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393466", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_gestational.md", "chunk_index": 3, "total_chunks": 6}}, {"content": "- **Fetal growth ultrasound**: Every 4 weeks starting at 28-32 weeks to assess for macrosomia or growth restriction\n- **Non-stress testing (NST)**: Begin at 32-36 weeks depending on severity; weekly or twice weekly\n- **Kick counts**: Daily starting at 28 weeks\n\n## Delivery Timing\n\n- **Diet-controlled GDM**: Delivery by 39-40 weeks; avoid expectant management beyond 41 weeks\n- **Medication-requiring GDM**: Delivery at 37-39 weeks depending on glycemic control and comorbidities\n- Cesarean delivery should be discussed if estimated fetal weight > 4500g\n\n## Intrapartum Glucose Management\n\n- Target glucose 70-110 mg/dL during labor\n- Monitor glucose every 1-2 hours during active labor\n- Insulin infusion or dextrose infusion as needed; discontinue long-acting insulin at onset of labor\n\n## Postpartum Follow-Up", "metadata": {"source": "diabetes_gestational.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393466", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_gestational.md", "chunk_index": 4, "total_chunks": 6}}, {"content": "- Discontinue all diabetes medications immediately postpartum\n- **OGTT (75g, 2-hour)**: Perform at 4-12 weeks postpartum to screen for persistent diabetes or prediabetes\n- Classify results using standard non-pregnant diagnostic criteria\n- If postpartum OGTT is normal, screen for diabetes every 1-3 years lifelong (50% lifetime risk of T2DM)\n- Encourage breastfeeding (associated with reduced future diabetes risk for mother and offspring)\n- Preconception counseling before subsequent pregnancies", "metadata": {"source": "diabetes_gestational.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393466", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_gestational.md", "chunk_index": 5, "total_chunks": 6}}, {"content": "# Type 1 Diabetes Mellitus (T1DM) - Management Guideline\n\n## Overview\n\nType 1 diabetes mellitus results from autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Lifelong exogenous insulin therapy is required. Diagnosis is supported by positive autoantibodies (GAD65, IA-2, ZnT8, IAA) and low or undetectable C-peptide levels.\n\n## Glycemic Targets\n\n- **HbA1c**: < 7.0% for most adults; < 7.5% for pediatric/adolescent patients\n- **Fasting/pre-meal glucose**: 80-130 mg/dL\n- **Postprandial glucose (1-2 hours)**: < 180 mg/dL\n- **Time in range (CGM)**: > 70% between 70-180 mg/dL\n- **Time below range**: < 4% below 70 mg/dL; < 1% below 54 mg/dL\n\n## Insulin Regimens\n\n### Basal-Bolus (Multiple Daily Injections - MDI)", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "- **Basal insulin**: Insulin glargine (U-100 or U-300), insulin detemir, or insulin degludec administered once or twice daily\n- **Bolus (prandial) insulin**: Rapid-acting analogs (lispro, aspart, glulisine, or ultra-rapid lispro/aspart) before meals\n- **Starting total daily dose (TDD)**: 0.4-0.5 units/kg/day; 50% basal, 50% bolus divided across meals\n- **Insulin-to-carbohydrate ratio (ICR)**: Typically start with 1 unit per 10-15g carbohydrate; individualize based on response\n- **Correction factor (ISF)**: Use 1800 rule (1800 / TDD = mg/dL drop per 1 unit rapid-acting)\n\n### Insulin Pump Therapy (CSII)", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "- Delivers rapid-acting insulin continuously as basal rate with patient-initiated boluses\n- Candidates: Motivated patients with frequent SMBG/CGM use, recurrent hypoglycemia, dawn phenomenon, desire for flexible lifestyle\n- Basal rate: Typically 40-60% of TDD; multiple rates programmed across 24 hours\n- Advantages: Reduced glycemic variability, reduced severe hypoglycemia, improved quality of life\n- Requires comprehensive diabetes education and follow-up\n\n### Automated Insulin Delivery (AID) / Closed-Loop Systems\n\n- Hybrid closed-loop systems adjust basal insulin delivery based on CGM readings\n- User still boluses for meals\n- Associated with improved time in range and reduced hypoglycemia\n\n## Continuous Glucose Monitoring (CGM)", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "- Recommended for all adults with T1DM on intensive insulin regimens\n- Real-time CGM (rtCGM): Provides continuous glucose display with trend arrows and alerts\n- Intermittently scanned CGM (isCGM): Requires scanning for current glucose value\n- Key metrics to review: Time in range, glucose management indicator (GMI), coefficient of variation (< 36% target)\n- Calibration requirements vary by device; factory-calibrated systems preferred\n\n## Hypoglycemia Management\n\n### Classification\n- **Level 1 (Alert)**: Glucose 54-70 mg/dL\n- **Level 2 (Clinically significant)**: Glucose < 54 mg/dL\n- **Level 3 (Severe)**: Altered mental status, requires third-party assistance", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "### Treatment\n- **Conscious patient**: 15-20g fast-acting carbohydrate (glucose tablets, juice); recheck in 15 minutes; repeat if still < 70 mg/dL (Rule of 15)\n- **Unconscious/unable to swallow**: Glucagon 1 mg IM/SC or nasal glucagon 3 mg; IV dextrose 25g (D50W 50 mL) if IV access available\n- All patients should have glucagon prescribed and household members trained\n\n### Prevention\n- Review insulin doses, timing, physical activity, alcohol intake\n- Set CGM low glucose alerts at 70-80 mg/dL\n- Pre-exercise carbohydrate intake or basal rate reduction (pump)\n\n## Diabetic Ketoacidosis (DKA) Prevention", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "- Never discontinue basal insulin, even when not eating\n- Sick day management rules: Check blood glucose every 2-4 hours; check ketones if glucose > 250 mg/dL\n- Increase fluid intake; supplement with rapid-acting insulin for correction\n- Seek emergency care if persistent vomiting, ketones > 1.5 mmol/L (blood), or inability to maintain hydration\n- Patients on SGLT2 inhibitors (off-label in T1DM) are at risk for euglycemic DKA\n\n## Screening for Complications\n\n- Follow T2DM screening protocols starting 5 years after diagnosis (or at puberty)\n- Annual dilated eye exam, foot exam, renal function, lipid panel\n- Screen for thyroid disease (TSH annually) and celiac disease at diagnosis and if symptomatic\n- Assess for diabetes distress and depression at routine visits\n\n## Adjunctive Therapies", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "- Pramlintide (amylin analog): May reduce postprandial glucose excursions and weight; requires meal-dose insulin reduction\n- SGLT2 inhibitors: Not FDA-approved for T1DM; if used, monitor closely for euglycemic DKA", "metadata": {"source": "diabetes_type1_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393527", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type1_management.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Type 2 Diabetes Mellitus (T2DM) - Comprehensive Management Guideline\n\n## Diagnosis\n\n- Fasting plasma glucose >= 126 mg/dL (7.0 mmol/L)\n- 2-hour plasma glucose >= 200 mg/dL (11.1 mmol/L) during 75g OGTT\n- HbA1c >= 6.5% (48 mmol/mol)\n- Random plasma glucose >= 200 mg/dL with classic symptoms\n\nTwo abnormal results from the same or separate samples are required for confirmation in asymptomatic patients.\n\n## Glycemic Targets\n\n- **General adult population**: HbA1c < 7.0% (53 mmol/mol)\n- **Younger patients with short disease duration, no cardiovascular disease**: HbA1c < 6.5%\n- **Older adults, limited life expectancy, extensive comorbidities**: HbA1c < 8.0%\n- **Fasting glucose target**: 80-130 mg/dL\n- **Postprandial glucose target (1-2 hours after meal)**: < 180 mg/dL\n\n## First-Line Pharmacotherapy\n\n**Metformin** remains the preferred initial agent in combination with lifestyle modification.", "metadata": {"source": "diabetes_type2_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393666", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type2_management.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "- Starting dose: 500 mg once or twice daily with meals\n- Titrate over 1-2 weeks to target dose of 1000 mg twice daily\n- Maximum dose: 2550 mg/day\n- Contraindicated when eGFR < 30 mL/min/1.73m2; dose reduction when eGFR 30-45\n- Monitor vitamin B12 levels annually with long-term use\n- Hold before and 48 hours after iodinated contrast procedures if eGFR < 60\n\n## Second-Line Agents (Add to Metformin When HbA1c Not at Target)\n\n**Patients with established ASCVD or high cardiovascular risk:**\n- GLP-1 receptor agonists with proven CV benefit (liraglutide, semaglutide, dulaglutide)\n- SGLT2 inhibitors with proven CV benefit (empagliflozin, canagliflozin, dapagliflozin)\n\n**Patients with heart failure (especially HFrEF):**\n- SGLT2 inhibitors (empagliflozin, dapagliflozin) - Class I recommendation\n\n**Patients with CKD (eGFR 20-60 or albuminuria):**\n- SGLT2 inhibitors for renal protection (dapagliflozin, empagliflozin)\n- GLP-1 RA as alternative or adjunct", "metadata": {"source": "diabetes_type2_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393666", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type2_management.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "**When weight loss is a priority:**\n- GLP-1 receptor agonists (especially semaglutide) or dual GIP/GLP-1 RA (tirzepatide)\n- SGLT2 inhibitors\n\n**When cost is a major barrier:**\n- Sulfonylureas (glimepiride, glipizide) - use with hypoglycemia counseling\n- Thiazolidinediones (pioglitazone) - avoid in heart failure\n\n## Lifestyle Modifications\n\n- **Medical nutrition therapy**: Individualized meal plan; Mediterranean or DASH dietary patterns recommended\n- **Physical activity**: 150 minutes/week moderate-intensity aerobic exercise; resistance training 2-3 sessions/week\n- **Weight management**: Target 5-10% body weight loss for overweight/obese patients\n- **Smoking cessation**: Mandatory counseling and pharmacotherapy as needed\n- **Alcohol**: Limit to 1 drink/day (women), 2 drinks/day (men)\n\n## Monitoring Schedule", "metadata": {"source": "diabetes_type2_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393666", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type2_management.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "- **HbA1c**: Every 3 months if not at target; every 6 months if stable\n- **Self-monitoring of blood glucose (SMBG)**: Individualized; more frequent if on insulin or sulfonylureas\n- **Renal function (eGFR, urine albumin-to-creatinine ratio)**: Annually\n- **Lipid panel**: Annually or 4-12 weeks after initiation/dose change of statin\n- **Hepatic function**: At baseline and as clinically indicated\n\n## Complication Screening\n\n- **Retinopathy**: Dilated eye exam at diagnosis, then annually (every 2 years if no retinopathy on 2 consecutive exams)\n- **Nephropathy**: Annual eGFR and urine albumin-to-creatinine ratio (UACR)\n- **Neuropathy**: Annual comprehensive foot exam; monofilament testing and vibration assessment\n- **Cardiovascular risk**: Annual assessment; initiate statin therapy per risk profile (moderate-intensity for ages 40-75; high-intensity if ASCVD present)\n- **Blood pressure**: Target < 130/80 mmHg; ACEi or ARB preferred if albuminuria present\n\n## When to Refer to Endocrinology", "metadata": {"source": "diabetes_type2_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393666", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type2_management.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "- HbA1c persistently > 9% despite dual or triple therapy\n- Suspected secondary diabetes or atypical presentation\n- Complex insulin regimen management\n- Recurrent severe hypoglycemia", "metadata": {"source": "diabetes_type2_management.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.393666", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/diabetes_type2_management.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Critical Drug Interactions\n\n## QT Prolongation Risk\nDrugs that prolong QT interval \u2014 combining \u22652 increases risk of Torsades de Pointes:\n- **Antiarrhythmics**: Amiodarone, sotalol, dofetilide, procainamide\n- **Antibiotics**: Fluoroquinolones (moxifloxacin > levofloxacin), macrolides (azithromycin, erythromycin)\n- **Antipsychotics**: Haloperidol, ziprasidone, quetiapine\n- **Antidepressants**: Citalopram/escitalopram (dose-dependent), TCAs\n- **Antiemetics**: Ondansetron (IV high dose), droperidol\n- **Antifungals**: Fluconazole\n- **Risk factors**: Hypokalemia, hypomagnesemia, bradycardia, female sex, structural heart disease\n- **Monitoring**: Baseline ECG, correct electrolytes before starting, periodic ECG monitoring", "metadata": {"source": "drug_interactions_critical.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394010", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/drug_interactions_critical.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "## Serotonin Syndrome\nPotentially fatal \u2014 caused by excess serotonergic activity:\n- **High risk combinations**: MAOI + SSRI/SNRI (contraindicated, 14-day washout required)\n- **Moderate risk**: SSRI + tramadol, SSRI + triptans, SSRI + linezolid, SSRI + methylene blue\n- **Symptoms triad**: Mental status changes (agitation, confusion), autonomic instability (tachycardia, hyperthermia, diaphoresis), neuromuscular hyperactivity (clonus, hyperreflexia, tremor)\n- **Treatment**: Discontinue offending agents, cyproheptadine, supportive care, benzodiazepines\n\n## CYP450 Interactions\n### CYP3A4 Inhibitors (increase levels of CYP3A4 substrates)\n- Strong: Ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice\n- Substrates affected: Statins (simvastatin, lovastatin \u2014 avoid combination), calcium channel blockers, calcineurin inhibitors, DOACs", "metadata": {"source": "drug_interactions_critical.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394010", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/drug_interactions_critical.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "### CYP3A4 Inducers (decrease levels of CYP3A4 substrates)\n- Strong: Rifampin, carbamazepine, phenytoin, St. John's Wort\n- Can reduce efficacy of: Oral contraceptives, DOACs, immunosuppressants, HIV medications\n\n### CYP2D6 Inhibitors\n- Strong: Fluoxetine, paroxetine, bupropion, quinidine\n- Affect: Codeine (block conversion to morphine \u2014 reduced analgesia), tamoxifen (block conversion to endoxifen \u2014 reduced efficacy)", "metadata": {"source": "drug_interactions_critical.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394010", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/drug_interactions_critical.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "## Narrow Therapeutic Index Drugs \u2014 Require Careful Monitoring\n- **Warfarin**: INR monitoring; numerous food/drug interactions\n- **Digoxin**: Target 0.5-0.9 ng/mL; toxicity with hypokalemia, renal impairment; amiodarone increases levels 70-100%\n- **Lithium**: Target 0.6-1.2 mEq/L; NSAIDs, ACEi, diuretics increase levels\n- **Phenytoin**: Target 10-20 mcg/mL; zero-order kinetics \u2014 small dose changes cause large level changes\n- **Theophylline**: Target 5-15 mcg/mL; CYP1A2 substrate (ciprofloxacin increases levels)\n- **Aminoglycosides**: Nephrotoxicity and ototoxicity; monitor peaks and troughs", "metadata": {"source": "drug_interactions_critical.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394010", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/drug_interactions_critical.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "## Other Critical Interactions\n- **Methotrexate + TMP-SMX**: Both antifolates \u2014 increased bone marrow suppression and toxicity\n- **Potassium + ACEi + spironolactone**: Triple threat for hyperkalemia \u2014 monitor K+ closely\n- **Clonidine + beta-blocker withdrawal**: Rebound hypertensive crisis\n- **Sildenafil + nitrates**: Severe hypotension \u2014 contraindicated\n- **Allopurinol + azathioprine/6-MP**: Allopurinol inhibits xanthine oxidase \u2014 reduce azathioprine dose by 75%", "metadata": {"source": "drug_interactions_critical.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394010", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/drug_interactions_critical.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Management\n\n## DVT Diagnosis\n- **Wells Score for DVT**: Active cancer, paralysis/immobilization, bedridden >3 days/surgery within 12 weeks, tenderness along deep veins, entire leg swelling, calf swelling >3cm vs asymptomatic side, pitting edema, collateral veins, previous DVT\n- **Low probability** (Wells \u22641): D-dimer \u2192 if negative, DVT excluded; if positive, compression ultrasound\n- **High probability** (Wells \u22652): Compression ultrasound; if negative but high suspicion, repeat in 5-7 days", "metadata": {"source": "dvt_pe_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394240", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/dvt_pe_management.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "## PE Diagnosis\n- **Wells Score for PE**: Clinical signs of DVT (3), PE most likely diagnosis (3), HR >100 (1.5), immobilization/surgery within 4 weeks (1.5), previous DVT/PE (1.5), hemoptysis (1), malignancy (1)\n- **Low risk** (Wells \u22644): D-dimer (age-adjusted cutoff: age \u00d7 10 for >50yo); if negative, PE excluded\n- **High risk** (Wells >4): CT pulmonary angiography (CTPA)\n- **Massive PE**: Hemodynamic instability (SBP <90, shock) \u2014 consider systemic thrombolysis or catheter-directed therapy\n\n## Anticoagulation Treatment\n### First-Line: DOACs (preferred for non-cancer VTE)\n- **Apixaban**: 10mg BID \u00d7 7 days, then 5mg BID\n- **Rivaroxaban**: 15mg BID \u00d7 21 days, then 20mg daily\n- **Dabigatran/Edoxaban**: Require 5-10 days of parenteral anticoagulation lead-in\n\n### Alternative\n- **LMWH** (enoxaparin 1mg/kg BID): Preferred in cancer-associated VTE (or DOAC)\n- **Warfarin**: Target INR 2.0-3.0; requires LMWH bridge for \u22655 days and until INR \u22652.0 \u00d7 2 consecutive days", "metadata": {"source": "dvt_pe_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394240", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/dvt_pe_management.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Duration of Anticoagulation\n- **Provoked** (surgery, trauma, immobilization): 3 months\n- **Unprovoked**: At least 3-6 months, then assess risk-benefit for extended therapy\n- **Cancer-associated**: Continue indefinitely while cancer active or on treatment\n- **Recurrent VTE**: Indefinite anticoagulation\n\n## Massive PE \u2014 Hemodynamic Instability\n- **Systemic thrombolysis**: Alteplase 100mg IV over 2 hours (or tenecteplase weight-based)\n- **Catheter-directed therapy**: For contraindications to systemic lysis\n- **Surgical embolectomy**: Last resort\n- **Supportive**: IV fluids (cautious, 500mL bolus), vasopressors, supplemental oxygen\n\n## IVC Filter\n- Only if absolute contraindication to anticoagulation with acute proximal DVT or PE\n- Retrieve as soon as anticoagulation can resume", "metadata": {"source": "dvt_pe_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394240", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/dvt_pe_management.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Electrolyte Emergencies\n\n## Hyponatremia\n\n### Classification\n- **Mild**: 130-134 mEq/L\n- **Moderate**: 125-129 mEq/L\n- **Severe**: <125 mEq/L\n\n### Diagnostic Algorithm\n1. Confirm true hyponatremia (exclude pseudohyponatremia from hyperglycemia or hyperlipidemia). Corrected Na = Measured Na + 1.6 x [(glucose - 100) / 100]\n2. Assess serum osmolality: Hypotonic (<280), isotonic (280-295), hypertonic (>295)\n3. Assess volume status: Hypovolemic, euvolemic, or hypervolemic\n4. Check urine sodium and urine osmolality\n\n### Common Causes by Volume Status\n- **Hypovolemic**: GI losses, diuretics (thiazides most common), cerebral salt wasting, adrenal insufficiency\n- **Euvolemic**: SIADH (most common cause overall), hypothyroidism, psychogenic polydipsia, medications (SSRIs, carbamazepine, cyclophosphamide)\n- **Hypervolemic**: Heart failure, cirrhosis, nephrotic syndrome, advanced kidney disease\n\n### Treatment", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "**Acute Symptomatic Hyponatremia (seizures, obtundation)**:\n- 3% hypertonic saline 100-150 mL IV bolus over 10-20 minutes\n- May repeat once or twice if symptoms persist\n- Goal: Raise sodium 4-6 mEq/L in first 1-2 hours to improve symptoms\n\n**Correction Rate Limits (CRITICAL)**:\n- **Maximum correction: <8 mEq/L in any 24-hour period**\n- In patients at high risk for osmotic demyelination syndrome (ODS) -- chronic hyponatremia >48 hours, alcoholism, malnutrition, hypokalemia, liver disease -- limit to <6 mEq/L in 24 hours\n- Overcorrection management: Administer DDAVP 1-2 mcg IV every 6-8 hours and/or D5W infusion to lower sodium back down\n- Monitor serum sodium every 2-4 hours during active correction", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "**Chronic Asymptomatic Hyponatremia**:\n- Treat underlying cause\n- SIADH: Fluid restriction (800-1000 mL/day), salt tablets, loop diuretics; tolvaptan 15 mg daily for refractory cases (monitor Na closely, risk of overcorrection)\n- Hypovolemic: Normal saline (caution: rapid correction can occur as ADH suppresses with volume repletion)\n\n## Hyperkalemia\n\n### Classification\n- **Mild**: 5.0-5.9 mEq/L\n- **Moderate**: 6.0-6.4 mEq/L\n- **Severe**: >= 6.5 mEq/L or any level with ECG changes\n\n### ECG Changes (Progressive)\n1. Peaked T waves (earliest sign)\n2. PR prolongation\n3. QRS widening\n4. Loss of P waves\n5. Sine wave pattern (pre-arrest)\n6. Ventricular fibrillation or asystole\n\n### Treatment Protocol", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "**Step 1 - Cardiac Membrane Stabilization (if ECG changes present)**:\n- **Calcium gluconate** 10% 10 mL (1 ampule) IV over 2-3 minutes; may repeat in 5 minutes if persistent ECG changes\n- Or calcium chloride 10% 10 mL IV (via central line preferred; more calcium per volume but tissue necrosis risk peripherally)\n- Does NOT lower potassium; protects the heart\n\n**Step 2 - Intracellular Shift (Temporizing)**:\n- **Regular insulin 10 units IV + dextrose 50% 25g (1 ampule D50) IV**: Onset 15-30 minutes, duration 4-6 hours. Monitor glucose hourly for 4-6 hours; hypoglycemia occurs in 10-20% of patients.\n- **Sodium bicarbonate** 50 mEq IV over 5 minutes: Most effective in metabolic acidosis; limited benefit with normal pH\n- **Albuterol** 10-20 mg nebulized (4-8x standard dose): Onset 15-30 minutes; additive effect with insulin/dextrose; avoid in cardiac patients (tachycardia)", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "**Step 3 - Potassium Elimination**:\n- **Sodium polystyrene sulfonate (Kayexalate)**: 15-30g PO or 30-50g PR in sorbitol; onset 1-6 hours; each gram binds approximately 1 mEq K+. Risk of intestinal necrosis (rare); avoid in postoperative patients and bowel pathology.\n- **Patiromer (Veltassa)**: 8.4g PO daily; better tolerated; onset 7+ hours; not for acute emergencies\n- **Sodium zirconium cyclosilicate (Lokelma)**: 10g PO TID for 48 hours (acute), then 5-10g daily; faster onset than patiromer\n- **Loop diuretics**: Furosemide 40-80 mg IV if adequate renal function\n- **Hemodialysis**: Definitive treatment for severe, refractory hyperkalemia or in oliguric/anuric renal failure\n\n## Hypocalcemia", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Symptomatic Hypocalcemia (Corrected Ca <7.5 mg/dL or Ionized Ca <1.0 mmol/L)\n- Symptoms: Perioral numbness, paresthesias, carpopedal spasm, Chvostek sign, Trousseau sign, seizures, QT prolongation, laryngospasm\n- **Calcium gluconate** 10% 1-2 ampules (10-20 mL) IV over 10-20 minutes with cardiac monitoring\n- Follow with continuous infusion: Calcium gluconate 10% 100 mL (10 ampules) in 1L NS or D5W at 50 mL/hour; titrate to maintain ionized calcium >1.0 mmol/L\n- **Correct hypomagnesemia first**: Hypocalcemia is refractory to treatment if Mg is low; administer MgSO4 2g IV over 15 minutes\n\n### Chronic Management\n- Oral calcium carbonate 1000-2000 mg elemental calcium daily in divided doses\n- Calcitriol 0.25-0.5 mcg BID (active vitamin D)\n- Monitor calcium, phosphorus, and 25-OH vitamin D regularly\n\n## Hypomagnesemia", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Clinical Significance\n- Often coexists with hypokalemia and hypocalcemia; both are refractory to correction until magnesium is repleted\n- Symptoms: Tremor, muscle cramps, cardiac arrhythmias (torsades de pointes), seizures\n\n### Treatment\n- **Severe (<1.0 mg/dL) or symptomatic**: MgSO4 1-2g IV over 15-60 minutes, then 4-8g IV infusion over 24 hours\n- **Torsades de pointes**: MgSO4 2g IV push over 1-2 minutes\n- **Moderate (1.0-1.5 mg/dL)**: MgSO4 1-2g IV over 1 hour; repeat as needed based on levels\n- **Mild or chronic**: Magnesium oxide 400-800 mg PO daily (limited absorption); magnesium chloride or magnesium lactate better absorbed\n- **Monitoring**: Recheck levels every 6-12 hours during IV repletion; urine magnesium to assess renal wasting\n- **Caution**: Reduce dose in renal impairment; monitor patellar reflexes (loss indicates toxicity)", "metadata": {"source": "electrolyte_disorders.md", "category": "nephrology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394304", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/electrolyte_disorders.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Falls Risk Assessment in Elderly\n\n## Epidemiology\n- One in four adults aged >= 65 years falls each year\n- Falls are the leading cause of injury-related death in adults >= 65\n- Approximately 30% of falls result in moderate to severe injury\n- Annual healthcare cost exceeds $50 billion in the United States\n\n## Screening\n- **All adults >= 65**: Ask annually about falls, difficulty with walking or balance\n- **Positive screen**: Assess gait and balance; if abnormal, perform multifactorial risk assessment\n- **Single fall without injury**: Assess gait and balance\n- **Recurrent falls (>=2 in 12 months) or injurious fall**: Full multifactorial assessment\n\n## Timed Up and Go (TUG) Test\n\n### Procedure\n1. Patient sits in a standard armchair\n2. On \"go,\" patient stands, walks 3 meters at usual pace, turns, walks back, and sits down\n3. Time from standing to seated again", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "### Interpretation\n- **<10 seconds**: Normal mobility; low fall risk\n- **10-13.5 seconds**: Mildly impaired; moderate fall risk\n- **>13.5 seconds**: Significantly impaired; high fall risk\n- **>20 seconds**: Marked impairment; very high fall risk; may need assistive device\n\n### Additional Balance Assessments\n- **Berg Balance Scale**: 14-item assessment scored 0-56; score <45 predicts fall risk\n- **30-Second Chair Stand Test**: Measures lower extremity strength\n- **4-Stage Balance Test**: Assesses static balance (feet together, semi-tandem, tandem, single-leg)\n\n## Risk Factors", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "### Intrinsic Factors\n- Age >= 80 years\n- Female sex\n- History of previous falls (strongest predictor)\n- Gait and balance impairment\n- Lower extremity weakness\n- Visual impairment (acuity, depth perception, contrast sensitivity)\n- Cognitive impairment and dementia\n- Depression\n- Urinary incontinence (urgency leading to rushing)\n- Orthostatic hypotension\n- Peripheral neuropathy\n- Arthritis and foot disorders\n- Fear of falling (paradoxically increases risk through activity restriction)\n\n### Extrinsic Factors\n- Environmental hazards (loose rugs, poor lighting, clutter, uneven surfaces)\n- Inappropriate footwear (slippers, high heels, worn soles)\n- Lack of grab bars and handrails\n- Psychoactive medications (see medication review)\n\n## Medication Review", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "### High-Risk Medication Classes\n- Benzodiazepines and sedative-hypnotics (OR 1.4-1.8 for falls)\n- Opioids\n- Antidepressants (SSRIs and TCAs)\n- Antihypertensives (especially alpha-blockers, diuretics)\n- Anticholinergics\n- Antipsychotics\n- Anticonvulsants (gabapentin, pregabalin)\n\n### Actions\n- Reduce or eliminate psychoactive medications when possible\n- Review antihypertensives if orthostatic hypotension present\n- Check orthostatic vitals (lying, sitting, standing at 1 and 3 minutes)\n- Taper gradually; avoid abrupt discontinuation\n\n## Home Safety Assessment", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "### Recommended Modifications\n- **Lighting**: Adequate illumination in all rooms, hallways, and stairways; nightlights in bedroom and bathroom\n- **Flooring**: Remove throw rugs or secure with double-sided tape; repair uneven surfaces\n- **Bathroom**: Install grab bars near toilet and in shower/tub; use non-slip mats; raised toilet seat\n- **Stairs**: Handrails on both sides; contrast strips on edges; remove clutter\n- **Kitchen**: Store frequently used items at waist height; use step stools with handrails\n- **General**: Remove clutter from walkways; secure electrical cords; ensure adequate space for assistive devices\n\n### Referral\n- Occupational therapy home safety evaluation recommended for patients with recurrent falls or high-risk environments\n\n## Exercise Programs", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Evidence-Based Programs\n- **Otago Exercise Programme**: Individually prescribed home-based strength and balance exercises; demonstrated 35% reduction in falls\n- **Tai Chi**: Improves balance, proprioception, and lower extremity strength; 20-40% fall reduction\n- **Group balance and strength training**: Community-based classes 2-3 times per week\n- **Stepping On program**: 7-week group-based program combining exercise, home safety, medication review\n\n### Exercise Prescription\n- Balance training: >= 3 hours per week (moderate to high challenge level)\n- Progressive resistance training: 2-3 sessions per week targeting lower extremities (quadriceps, hip abductors, ankle dorsiflexors)\n- Walking programs alone are insufficient for fall prevention but improve overall fitness\n\n## Hip Fracture Prevention", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Osteoporosis Screening\n- DEXA scan recommended for all women >= 65 and men >= 70\n- Earlier screening if risk factors present (low body weight, smoking, prior fracture, glucocorticoid use)\n- FRAX tool to calculate 10-year fracture probability\n\n### Pharmacologic Prevention\n- Vitamin D supplementation: 800-1000 IU daily (maintain 25-OH vitamin D >= 30 ng/mL)\n- Calcium: 1000-1200 mg daily (preferably dietary)\n- Bisphosphonates (alendronate, risedronate, zoledronic acid) if osteoporosis confirmed\n- Denosumab for bisphosphonate-intolerant patients\n\n### Hip Protectors\n- External hip protectors may reduce hip fracture risk in nursing home residents\n- Adherence is a significant barrier to effectiveness", "metadata": {"source": "geriatric_falls.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394357", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_falls.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Geriatric Polypharmacy Management\n\n## Definition\n- **Polypharmacy**: Use of 5 or more concurrent medications\n- **Excessive polypharmacy**: Use of 10 or more concurrent medications\n- Prevalence: Approximately 40% of older adults (>65 years) take 5+ medications\n\n## Beers Criteria (AGS 2023 Update)\n\nThe American Geriatrics Society Beers Criteria identifies potentially inappropriate medications (PIMs) for older adults.\n\n### Medications to Avoid in Most Older Adults", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "| Drug Class | Examples | Rationale | |---|---|---| | First-generation antihistamines | Diphenhydramine, hydroxyzine, chlorpheniramine | Highly anticholinergic; confusion, urinary retention, constipation, sedation | | Benzodiazepines | Diazepam, lorazepam, alprazolam, clonazepam | Increased fall risk, cognitive impairment, delirium, fractures | | Non-benzodiazepine hypnotics | Zolpidem, zaleplon, eszopiclone | Falls, delirium, fractures; minimal improvement in sleep latency | | Tertiary TCAs | Amitriptyline, imipramine, doxepin (>6 mg) | Highly anticholinergic, orthostatic hypotension, cardiac conduction effects | | Antipsychotics (first and second gen) | Haloperidol, quetiapine, olanzapine | Increased stroke risk, mortality in dementia; avoid for behavioral symptoms of dementia unless non-pharmacologic measures failed | | Skeletal muscle relaxants | Cyclobenzaprine, methocarbamol, carisoprodol | Anticholinergic effects, sedation, questionable efficacy in elderly | | Proton pump", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "inhibitors (>8 weeks) | Omeprazole, pantoprazole | C. difficile risk, fractures, hypomagnesemia; use lowest dose for shortest duration | | NSAIDs (chronic use) | Ibuprofen, naproxen, meloxicam | GI bleeding, renal injury, cardiovascular events, HTN exacerbation | | Sulfonylureas (long-acting) | Glyburide, chlorpropamide | Higher risk of prolonged hypoglycemia | | Meperidine | -- | Neurotoxic metabolite accumulation, seizure risk |\n\n## Anticholinergic Burden\n\n### Anticholinergic Cognitive Burden (ACB) Scale\n- Score 1 (possible anticholinergic): Atenolol, metformin, furosemide, warfarin\n- Score 2 (definite anticholinergic): Amantadine, carbamazepine, cyclobenzaprine\n- Score 3 (definite, high potency): Oxybutynin, tolterodine, amitriptyline, diphenhydramine, paroxetine, olanzapine\n\n**Cumulative ACB score >= 3**: Associated with increased cognitive decline, delirium, falls, hospitalization, and mortality.", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "### Management of Anticholinergic Burden\n- Calculate total ACB score at each medication review\n- Prioritize discontinuation or substitution of highest-scoring agents\n- Common substitutions: Oxybutynin to mirabegron, amitriptyline to duloxetine or nortriptyline, diphenhydramine to melatonin\n\n## Fall Risk Medications", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "Medications associated with increased fall risk in elderly:\n- **Sedative-hypnotics**: Benzodiazepines, Z-drugs, barbiturates\n- **Opioids**: All opioids increase fall and fracture risk\n- **Antihypertensives**: Alpha-blockers (doxazosin), centrally-acting agents (clonidine); risk of orthostatic hypotension\n- **Diuretics**: Overdiuresis leading to dehydration and orthostatic hypotension\n- **Antidepressants**: SSRIs (hyponatremia, serotonin-mediated bone effects), TCAs (orthostasis, sedation)\n- **Antipsychotics**: Orthostatic hypotension, sedation, extrapyramidal effects\n- **Anticonvulsants**: Gabapentin, pregabalin (dizziness, ataxia)\n- **Anticholinergics**: Blurred vision, confusion, dizziness\n\n## Deprescribing Principles", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Systematic Approach\n1. **Ascertain**: List all current medications including OTC, supplements, and herbals\n2. **Identify**: Flag potentially inappropriate medications using Beers criteria, STOPP/START criteria, and anticholinergic burden tools\n3. **Determine**: Assess whether each medication has an ongoing indication\n4. **Prioritize**: Rank medications for discontinuation based on harm potential and patient preferences\n5. **Plan**: Taper gradually (avoid abrupt discontinuation of beta-blockers, benzodiazepines, antidepressants, corticosteroids, opioids, gabapentinoids)\n6. **Monitor**: Follow up within 1-4 weeks for withdrawal symptoms, rebound effects, and clinical status\n\n### Key Deprescribing Resources\n- deprescribing.org evidence-based algorithms for PPIs, benzodiazepines, antipsychotics, and antihyperglycemics\n- STOPP/START criteria (European-based complementary tool to Beers)\n- MedStopper tool for prioritizing medications to discontinue\n\n## Medication Reconciliation", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Best Practices\n- Perform at every transition of care (admission, transfer, discharge)\n- Use \"brown bag\" method: Ask patients to bring all medications to appointments\n- Verify against pharmacy records, primary care records, and specialist lists\n- Engage pharmacist for comprehensive medication therapy management (MTM)\n- Document intentional discrepancies with rationale\n- Communicate updated medication list to patient, caregivers, and all providers", "metadata": {"source": "geriatric_polypharmacy.md", "category": "geriatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394416", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/geriatric_polypharmacy.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Lower Gastrointestinal Bleeding\n\n## Definition\n- Bleeding originating distal to the ligament of Treitz (small bowel and colon)\n- Most commonly colonic in origin\n- Presentation: Hematochezia (bright red blood per rectum), maroon stools, or occult blood\n\n## Common Etiologies\n\n| Cause | Frequency | Typical Presentation |\n|---|---|---|\n| Diverticular bleeding | 30-40% | Painless, acute, large-volume hematochezia |\n| Angiodysplasia | 5-20% | Chronic or recurrent, often right-sided |\n| Colitis (ischemic, infectious, IBD) | 10-20% | Bloody diarrhea, cramping, fever |\n| Hemorrhoids/anal fissures | 5-10% | Bright red blood on toilet paper or coating stool |\n| Post-polypectomy bleeding | 5-10% | Delayed bleeding 1-14 days after procedure |\n| Colorectal neoplasia | 5-10% | Chronic occult blood loss, iron deficiency anemia |\n| Rectal ulcers | 2-5% | Rectal pain, tenesmus |\n\n## Evaluation Algorithm", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "### Step 1: Initial Assessment and Resuscitation\n- Assess hemodynamic stability (heart rate, blood pressure, orthostatic changes)\n- Two large-bore IV access, type and crossmatch\n- Labs: CBC, BMP, coagulation studies, lactate\n- Transfuse pRBCs for Hb <7 g/dL (or <8 g/dL with cardiovascular disease)\n- Correct coagulopathy if actively bleeding\n\n### Step 2: Exclude Upper GI Source\n- Brisk upper GI bleeding can present as hematochezia\n- Consider upper endoscopy first if: hemodynamic instability, BUN/creatinine ratio >30, nasogastric aspirate with blood (though routine NG tube placement is not recommended)\n- Clinical clues favoring upper source: melena, hematemesis, elevated BUN\n\n### Step 3: Anorectal Examination\n- Digital rectal examination and anoscopy to evaluate for hemorrhoids, fissures, rectal masses\n- If clear anorectal source identified in stable patient with minor bleeding, no further workup may be needed", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "### Step 4: Colonoscopy\n- **Timing**: Within 24 hours of presentation after adequate bowel preparation (urgent colonoscopy)\n- **Bowel preparation**: Rapid prep with 4-6 liters of polyethylene glycol solution over 3-4 hours (via NG tube if unable to drink)\n- Colonoscopy identifies bleeding source in 45-90% of cases\n- Therapeutic interventions: Epinephrine injection, bipolar cautery, hemoclipping, band ligation", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "### Step 5: Additional Diagnostic Studies (if colonoscopy non-diagnostic)\n- **CT angiography**: Detects bleeding rates >= 0.3-0.5 mL/min; useful when colonoscopy cannot be performed or is non-diagnostic\n- **Tagged RBC scan (nuclear scintigraphy)**: Detects bleeding rates >= 0.1-0.4 mL/min; high sensitivity but poor localization; useful to confirm active bleeding before angiography\n- **Mesenteric angiography**: Detects bleeding >= 0.5-1.0 mL/min; allows therapeutic embolization; obtain after positive CTA or RBC scan\n- **Capsule endoscopy**: For suspected small bowel bleeding after negative upper and lower endoscopy\n\n## Diverticular Bleeding\n\n### Characteristics\n- Most common cause of significant lower GI bleeding\n- Typically painless, acute-onset, large-volume hematochezia\n- 70-80% stops spontaneously\n- Right-sided diverticula bleed more frequently despite left-sided prevalence of diverticulosis\n- Recurrence rate: 20-30% after first episode, up to 50% after second episode", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "### Management\n- Resuscitation and colonoscopy with hemostasis when source identified\n- If recurrent bleeding: consider segmental colectomy after localization\n- Avoid NSAIDs and aspirin when possible (increase recurrence risk)\n\n## Angiodysplasia (Arteriovenous Malformations)\n\n### Characteristics\n- Degenerative vascular lesions; prevalence increases with age\n- Most common in cecum and right colon\n- Associated with aortic stenosis (Heyde syndrome), chronic kidney disease, von Willebrand disease\n- Typically causes chronic, intermittent, low-volume bleeding; can cause acute hemorrhage\n\n### Management\n- Endoscopic treatment: Argon plasma coagulation (APC) preferred, also bipolar cautery or hemoclipping\n- Refractory cases: Angiographic embolization or surgical resection\n- Medical therapy for recurrent bleeding: Consider octreotide or thalidomide (limited evidence)\n\n## Massive Lower GI Bleeding Management", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Definition\n- Hemodynamic instability (SBP <90, HR >100) requiring >= 2 units pRBCs\n- Ongoing brisk hematochezia with hemodynamic compromise\n\n### Protocol\n1. **Activate massive transfusion protocol** if indicated (1:1:1 pRBC:FFP:platelets)\n2. **Resuscitate aggressively**: Target MAP >= 65 mmHg; vasopressors if needed after volume resuscitation\n3. **Urgent CT angiography**: First-line imaging in hemodynamically unstable patients to localize bleeding\n4. **Interventional radiology**: Mesenteric angiography with embolization if CTA positive\n5. **Emergent colonoscopy**: After stabilization and rapid bowel prep if feasible\n6. **Surgical consultation**: Early involvement for massive or refractory bleeding\n7. **Emergent surgery**: Subtotal colectomy for life-threatening hemorrhage when source cannot be localized; segmental colectomy if source definitively identified", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Outcomes\n- Overall mortality for lower GI bleeding: 2-4%\n- Massive lower GI bleeding mortality: 10-20%\n- 80-85% of lower GI bleeding stops spontaneously", "metadata": {"source": "gi_bleeding_lower.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394480", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_lower.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Upper Gastrointestinal Bleeding\n\n## Definition\n- Bleeding originating proximal to the ligament of Treitz\n- Presentation: Hematemesis (bloody or coffee-ground emesis), melena, or hematochezia (if massive)\n- Common causes: Peptic ulcer disease (35-50%), esophageal/gastric varices (10-20%), Mallory-Weiss tears (5-10%), erosive gastritis/esophagitis, vascular malformations, malignancy\n\n## Glasgow-Blatchford Score (GBS)\n\nUsed for pre-endoscopy risk stratification to identify patients who may not require intervention.\n\n| Parameter | Value | Score |\n|---|---|---|\n| BUN (mg/dL) | 18.2-22.4 | 2 |\n| | 22.4-28.0 | 3 |\n| | 28.0-70.0 | 4 |\n| | >70.0 | 6 |\n| Hemoglobin (men, g/dL) | 12.0-12.9 | 1 |\n| | 10.0-11.9 | 3 |\n| | <10.0 | 6 |\n| Hemoglobin (women, g/dL) | 10.0-11.9 | 1 |\n| | <10.0 | 6 |\n| Systolic BP (mmHg) | 100-109 | 1 |\n| | 90-99 | 2 |\n| | <90 | 3 |\n| Heart rate >= 100 | | 1 |\n| Melena | | 1 |\n| Syncope | | 2 |\n| Hepatic disease | | 2 |\n| Heart failure | | 2 |", "metadata": {"source": "gi_bleeding_upper.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394540", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_upper.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "**Interpretation**: GBS = 0: Very low risk; may consider outpatient management and elective endoscopy. GBS >= 1: Inpatient management and endoscopy recommended.\n\n## Initial Resuscitation\n\n### Airway and Access\n- Consider endotracheal intubation for massive hematemesis, altered mental status, or high aspiration risk\n- Two large-bore (18G or larger) peripheral IVs\n- Type and crossmatch for minimum 2 units packed red blood cells\n\n### Fluid and Blood Product Resuscitation\n- Crystalloid resuscitation with normal saline or lactated Ringer's\n- **Transfusion threshold**: Hemoglobin <7 g/dL for most patients (restrictive strategy); <8 g/dL for patients with cardiovascular disease\n- **Massive transfusion protocol**: Activate if hemorrhagic shock, ongoing brisk bleeding, or anticipated need for >6 units pRBCs in 24 hours (1:1:1 ratio of pRBC:FFP:platelets)", "metadata": {"source": "gi_bleeding_upper.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394540", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_upper.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "### Medication Management\n- Hold anticoagulants and antiplatelet agents (consider reversal based on severity)\n- Correct coagulopathy: FFP for INR >1.5 in active bleeding; platelets if <50,000/mcL\n- Avoid nasogastric lavage (no longer recommended for diagnosis or management)\n\n## Proton Pump Inhibitor Therapy\n\n### Empiric PPI (Pre-Endoscopy)\n- **IV pantoprazole or esomeprazole**: 80 mg IV bolus, then 8 mg/hour continuous infusion for patients with suspected high-risk ulcer bleeding\n- Pre-endoscopy PPI does not reduce rebleeding or mortality but may downstage lesions at endoscopy\n\n### Post-Endoscopy PPI\n- **High-risk ulcer stigmata** (active bleeding, visible vessel, adherent clot): IV PPI infusion 8 mg/hour for 72 hours, then transition to oral PPI BID for 2 weeks, then daily\n- **Low-risk stigmata** (clean base, flat spot): Oral PPI once daily\n\n## Endoscopy Timing", "metadata": {"source": "gi_bleeding_upper.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394540", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_upper.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "- **Urgent (within 12 hours)**: Hemodynamic instability despite resuscitation, bloody NG aspirate or ongoing hematemesis, high clinical suspicion for variceal bleeding\n- **Early (within 24 hours)**: Recommended for all patients hospitalized with upper GI bleeding\n- **Elective**: GBS = 0 patients may undergo outpatient endoscopy within 72 hours\n\n## Variceal Bleeding\n\n### Pharmacologic Therapy (Start Before Endoscopy)\n- **Octreotide**: 50 mcg IV bolus, then 50 mcg/hour infusion for 3-5 days (reduces splanchnic blood flow)\n- **IV antibiotics**: Ceftriaxone 1g IV daily for 7 days (reduces infection and mortality in cirrhotic patients with GI bleeding)\n\n### Endoscopic Therapy\n- **Esophageal varices**: Endoscopic variceal ligation (banding) is first-line\n- **Gastric varices**: Cyanoacrylate glue injection or TIPS\n- **Balloon tamponade** (Blakemore or Minnesota tube): Temporizing measure only for uncontrolled bleeding as bridge to TIPS or repeat endoscopy (max 24 hours)", "metadata": {"source": "gi_bleeding_upper.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394540", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_upper.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "### Rescue Therapy\n- **TIPS (Transjugular Intrahepatic Portosystemic Shunt)**: For refractory variceal bleeding despite endoscopic and pharmacologic therapy; also consider early TIPS (within 72 hours) for high-risk patients (Child-Pugh C 10-13 or Child-Pugh B with active bleeding at endoscopy)\n\n## Rockall Score (Post-Endoscopy)\n\nPredicts rebleeding and mortality after endoscopy.\n\n| Parameter | 0 | 1 | 2 | 3 |\n|---|---|---|---|---|\n| Age | <60 | 60-79 | >=80 | -- |\n| Shock | None | Pulse >100, SBP >=100 | SBP <100 | -- |\n| Comorbidity | None | -- | CHF, IHD, major | Renal failure, liver failure, metastatic cancer |\n| Diagnosis | Mallory-Weiss, no lesion | All other | GI malignancy | -- |\n| Stigmata | Clean base | -- | Blood, adherent clot, visible vessel, spurting | -- |\n\n**Score <=2**: Low risk (<5% rebleeding, <1% mortality). **Score >=8**: High risk (>40% mortality).", "metadata": {"source": "gi_bleeding_upper.md", "category": "gastroenterology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394540", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/gi_bleeding_upper.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Heart Failure with Preserved Ejection Fraction (HFpEF) \u2014 EF \u226550%\n\n## Diagnosis\n- Signs/symptoms of heart failure with LVEF \u226550%\n- Elevated natriuretic peptides (BNP \u226535 pg/mL or NT-proBNP \u2265125 pg/mL)\n- Evidence of diastolic dysfunction on echocardiography (elevated E/e', LA enlargement, elevated PASP)\n- H2FPEF and HFA-PEFF scores aid in diagnosis\n\n## Pharmacotherapy\n### SGLT2 Inhibitors (Class I Recommendation)\n- **Empagliflozin** 10mg daily or **Dapagliflozin** 10mg daily\n- Demonstrated reduction in HF hospitalizations regardless of diabetes status\n- First drug class with strong evidence for HFpEF\n\n### Diuretics\n- Loop diuretics for congestion management\n- Titrate to relieve symptoms; avoid excessive diuresis\n- Monitor renal function and electrolytes\n\n### RAAS Inhibitors\n- ARBs (candesartan) and ARNI (sacubitril/valsartan) may provide modest benefit\n- Consider in patients with lower EF range (41-49% \u2014 HFmrEF)", "metadata": {"source": "heart_failure_hfpef.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394674", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/heart_failure_hfpef.md", "chunk_index": 0, "total_chunks": 2}}, {"content": "### MRA\n- Spironolactone may reduce hospitalizations in selected patients\n- Monitor potassium closely, especially with renal insufficiency\n\n## Treat Underlying Conditions\n- **Hypertension**: Aggressive BP control is critical; target <130/80\n- **Atrial fibrillation**: Rate or rhythm control\n- **Obesity**: Weight loss improves symptoms and exercise capacity\n- **Coronary artery disease**: Revascularization if ischemia contributes\n- **Diabetes**: SGLT2 inhibitors preferred\n\n## Non-Pharmacologic Management\n- **Exercise training**: Supervised cardiac rehabilitation improves functional capacity and quality of life\n- **Sodium restriction**: <2g/day\n- **Volume management**: Daily weights, fluid restriction if hyponatremic\n\n## Monitoring\n- Symptom assessment with NYHA class and KCCQ questionnaire\n- Echocardiography to monitor filling pressures and LVEF\n- Regular assessment of renal function and electrolytes", "metadata": {"source": "heart_failure_hfpef.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.394674", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/heart_failure_hfpef.md", "chunk_index": 1, "total_chunks": 2}}, {"content": "# Heart Failure with Reduced Ejection Fraction (HFrEF) \u2014 EF \u226440%\n\n## Guideline-Directed Medical Therapy (GDMT) \u2014 Four Pillars\nAll four drug classes should be initiated and titrated to target doses:\n\n### 1. RAAS Inhibition\n- **ACEi**: Enalapril 10-20mg BID, Lisinopril 20-40mg daily, Ramipril 10mg daily\n- **ARB** (if ACEi intolerant): Valsartan 160mg BID, Losartan 150mg daily\n- **ARNI** (preferred over ACEi/ARB): Sacubitril/valsartan 97/103mg BID \u2014 requires 36hr washout from ACEi\n\n### 2. Beta-Blockers\n- **Carvedilol** 25mg BID (50mg BID if >85kg), **Metoprolol succinate** 200mg daily, **Bisoprolol** 10mg daily\n- Start low, titrate every 2 weeks; do not initiate during acute decompensation\n\n### 3. Mineralocorticoid Receptor Antagonists (MRA)\n- **Spironolactone** 25-50mg daily or **Eplerenone** 50mg daily\n- Contraindicated if K+ >5.0 or eGFR <30; monitor potassium closely", "metadata": {"source": "heart_failure_hfref.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395090", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/heart_failure_hfref.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "### 4. SGLT2 Inhibitors\n- **Dapagliflozin** 10mg daily or **Empagliflozin** 10mg daily\n- Benefit regardless of diabetes status; can initiate early\n\n## Additional Therapies\n- **Hydralazine/isosorbide dinitrate**: For Black patients or if ACEi/ARB/ARNI intolerant\n- **Ivabradine**: If sinus rhythm with HR \u226570 despite maximized beta-blocker\n- **Diuretics**: Loop diuretics (furosemide, bumetanide, torsemide) for volume overload \u2014 titrate to euvolemia\n- **Digoxin**: May reduce HF hospitalizations; target level 0.5-0.9 ng/mL\n\n## Device Therapy\n- **ICD**: Primary prevention if EF \u226435% despite \u22653 months GDMT, NYHA II-III, expected survival >1 year\n- **CRT**: If EF \u226435%, LBBB with QRS \u2265150ms, NYHA II-IV despite GDMT\n\n## Monitoring\n- Daily weights, sodium restriction (<2g/day), fluid restriction if severe hyponatremia\n- Labs: BMP (K+, creatinine) 1-2 weeks after RAAS/MRA changes\n- Warning signs: Weight gain >3 lbs in 1 day or >5 lbs in 1 week", "metadata": {"source": "heart_failure_hfref.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395090", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/heart_failure_hfref.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Avoid\n- NSAIDs, non-dihydropyridine CCBs (verapamil, diltiazem), thiazolidinediones, most antiarrhythmics except amiodarone/dofetilide", "metadata": {"source": "heart_failure_hfref.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395090", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/heart_failure_hfref.md", "chunk_index": 2, "total_chunks": 3}}, {"content": "# Hypertensive Emergencies and Urgencies - Clinical Guideline\n\n## Definitions\n\n### Hypertensive Emergency\n- Severe blood pressure elevation (typically SBP > 180 and/or DBP > 120 mmHg) with **acute end-organ damage**\n- Requires immediate BP reduction with intravenous agents in an ICU setting\n- End-organ damage includes: hypertensive encephalopathy, acute intracranial hemorrhage, acute ischemic stroke, acute aortic dissection, acute coronary syndrome, acute decompensated heart failure/pulmonary edema, eclampsia, acute renal failure, microangiopathic hemolytic anemia\n\n### Hypertensive Urgency\n- Severe BP elevation (SBP > 180 and/or DBP > 120 mmHg) **without** evidence of acute end-organ damage\n- Can be managed with oral antihypertensives and outpatient follow-up within 24-48 hours\n- Avoid rapid BP reduction in urgency (risk of ischemic events)\n\n## Initial Assessment", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "- **Focused history**: Headache, visual changes, chest pain, dyspnea, neurologic deficits, medication non-adherence, substance use (cocaine, amphetamines), pregnancy status\n- **Physical exam**: Fundoscopy (papilledema, hemorrhages, exudates), neurologic exam, cardiopulmonary exam, peripheral pulses (aortic dissection screening)\n- **Urgent labs**: BMP (creatinine, potassium), CBC with peripheral smear, urinalysis, troponin, BNP/NT-proBNP\n- **Imaging**: ECG, chest X-ray; CT head if neurologic symptoms; CT angiography if aortic dissection suspected\n- **Urine drug screen**: If substance use suspected\n\n## Blood Pressure Reduction Targets\n\n### General Principle\n- Reduce mean arterial pressure (MAP) by **no more than 25%** in the first hour\n- Then reduce to approximately 160/100 mmHg over the next 2-6 hours\n- Gradual normalization to target BP over 24-48 hours\n- Excessively rapid reduction causes watershed ischemia (stroke, MI, renal failure)\n\n### Condition-Specific Targets", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "**Aortic Dissection**\n- Most aggressive target: SBP < 120 mmHg AND heart rate < 60 bpm within 20 minutes\n- IV esmolol (preferred) or labetalol first to reduce heart rate\n- Add IV nicardipine or nitroprusside if additional BP reduction needed AFTER rate control\n- Beta-blocker BEFORE vasodilator (prevent reflex tachycardia)\n\n**Acute Ischemic Stroke (Eligible for Thrombolysis)**\n- Reduce to < 185/110 mmHg before tPA administration\n- Maintain < 180/105 mmHg for 24 hours after tPA\n- IV labetalol or nicardipine preferred\n\n**Acute Ischemic Stroke (Not Eligible for Thrombolysis)**\n- Treat only if BP > 220/120 mmHg\n- Reduce by 15% over 24 hours\n\n**Intracerebral Hemorrhage**\n- If SBP 150-220 mmHg: Target SBP < 140 mmHg (INTERACT2/ATACH-2 evidence)\n- Rapid reduction (within 1 hour) is acceptable; IV nicardipine or clevidipine preferred", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "**Acute Pulmonary Edema/Decompensated Heart Failure**\n- IV nitroglycerin or nitroprusside (reduce preload and afterload)\n- IV loop diuretics concurrently\n- Avoid beta-blockers acutely in decompensated HF\n\n**Eclampsia/Severe Preeclampsia**\n- IV labetalol, IV hydralazine, or oral nifedipine\n- Target SBP < 160 and DBP < 110 mmHg\n- Magnesium sulfate for seizure prophylaxis (4-6g IV load, then 1-2g/hour)\n\n**Acute Coronary Syndrome**\n- IV nitroglycerin (preferred)\n- IV esmolol or labetalol\n- Avoid nitroprusside (coronary steal risk)\n\n**Pheochromocytoma Crisis**\n- IV phentolamine (alpha-blocker) first\n- Add beta-blocker ONLY after alpha-blockade established (prevent unopposed alpha stimulation)\n- Avoid beta-blockers alone\n\n## Intravenous Antihypertensive Agents", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "### Nicardipine\n- Dihydropyridine CCB; continuous infusion\n- Starting dose: 5 mg/hour IV; titrate by 2.5 mg/hour every 5-15 minutes; maximum 15 mg/hour\n- Predictable, titratable response; preferred in many scenarios\n- Avoid in decompensated HF with reduced EF\n\n### Labetalol\n- Combined alpha/beta-blocker\n- IV push: 20 mg over 2 minutes; repeat 20-80 mg every 10 minutes (max 300 mg total)\n- IV infusion: 0.5-2 mg/minute\n- Preferred in: aortic dissection (with rate control), eclampsia, acute stroke\n- Avoid in: decompensated HF, severe bradycardia, asthma, cocaine toxicity\n\n### Esmolol\n- Ultra-short-acting beta-1 selective blocker\n- Loading dose: 500 mcg/kg over 1 minute; infusion: 50-200 mcg/kg/minute\n- Preferred in aortic dissection (precise rate control)\n- Very short half-life (9 minutes); easily titratable", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Nitroglycerin\n- Venodilator (reduces preload); coronary vasodilator at higher doses\n- Infusion: 5-200 mcg/minute; titrate every 3-5 minutes\n- Preferred in ACS and acute pulmonary edema\n- Avoid in right ventricular infarction, PDE5 inhibitor use within 24-48 hours\n\n### Nitroprusside\n- Arterial and venous dilator; potent and rapid onset\n- Infusion: 0.25-10 mcg/kg/minute\n- Risk of cyanide toxicity with prolonged use (> 48 hours) or high doses; monitor thiocyanate levels\n- Avoid in hepatic/renal insufficiency, pregnancy, and increased ICP\n\n### Clevidipine\n- Ultra-short-acting dihydropyridine CCB\n- Infusion: 1-2 mg/hour initially; titrate by doubling every 90 seconds; max 32 mg/hour\n- Lipid emulsion formulation; avoid in soy/egg allergy, severe lipid disorders\n\n### Hydralazine\n- Direct arteriolar vasodilator\n- IV push: 5-10 mg every 20-30 minutes\n- Unpredictable response; reflex tachycardia\n- Primarily used in eclampsia/preeclampsia when labetalol is unavailable", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Phentolamine\n- Non-selective alpha-blocker\n- IV bolus: 5 mg every 10-15 minutes\n- Reserved for catecholamine-excess states (pheochromocytoma, cocaine, MAOi crisis)\n\n## Hypertensive Urgency Management\n\n- Reinstitute or uptitrate oral antihypertensives\n- Options: oral captopril 25 mg, oral labetalol 200 mg, oral clonidine 0.1-0.2 mg, oral amlodipine 5-10 mg\n- Observe for 2-6 hours to ensure BP trending down\n- Avoid sublingual nifedipine (unpredictable precipitous drops)\n- Discharge with close follow-up in 24-72 hours; optimize long-term regimen\n- Assess and address medication non-adherence", "metadata": {"source": "hypertension_emergencies.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395179", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_emergencies.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Hypertension (HTN) - Comprehensive Management Guideline\n\n## Classification (ACC/AHA 2017)\n\n| Category | Systolic (mmHg) | Diastolic (mmHg) |\n|----------|-----------------|-------------------|\n| Normal | < 120 | < 80 |\n| Elevated | 120-129 | < 80 |\n| Stage 1 HTN | 130-139 | 80-89 |\n| Stage 2 HTN | >= 140 | >= 90 |\n| Hypertensive Crisis | > 180 | > 120 |\n\n## Blood Pressure Measurement\n\n- Use validated, calibrated device with appropriately sized cuff\n- Patient seated quietly for 5 minutes, feet on floor, arm supported at heart level\n- Average of 2-3 readings on 2-3 separate occasions for diagnosis\n- Ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) recommended to confirm diagnosis and exclude white-coat hypertension\n- Rule out pseudohypertension in elderly (Osler maneuver)\n\n## Blood Pressure Targets", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "- **General population**: < 130/80 mmHg\n- **Patients >= 65 years**: SBP < 130 mmHg if tolerated (avoid < 120 in frail elderly)\n- **Diabetes mellitus**: < 130/80 mmHg\n- **Chronic kidney disease**: < 130/80 mmHg\n- **Post-stroke**: < 130/80 mmHg (after initial acute phase)\n- **Pregnancy**: See separate guideline; generally < 140/90; < 135/85 if on therapy\n\n## Lifestyle Modifications (All Stages)", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "- **DASH diet**: Rich in fruits, vegetables, whole grains, low-fat dairy; reduced saturated fat\n- **Sodium restriction**: < 1500 mg/day ideal; < 2300 mg/day minimum goal (approximately 5-6 mmHg SBP reduction)\n- **Physical activity**: 150 minutes/week moderate-intensity aerobic exercise (approximately 5-8 mmHg reduction)\n- **Weight loss**: Target BMI 18.5-24.9; each 1 kg loss reduces SBP by approximately 1 mmHg\n- **Alcohol moderation**: <= 2 drinks/day (men), <= 1 drink/day (women) (approximately 4 mmHg reduction)\n- **Smoking cessation**: Reduces overall cardiovascular risk; modest direct effect on BP\n- **Potassium intake**: 3500-5000 mg/day through diet (unless CKD with hyperkalemia risk)\n\n## When to Initiate Pharmacotherapy", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "- **Elevated BP (120-129/<80)**: Lifestyle modifications only\n- **Stage 1 HTN with 10-year ASCVD risk < 10%**: Lifestyle modifications; reassess in 3-6 months\n- **Stage 1 HTN with 10-year ASCVD risk >= 10%, or with diabetes, CKD, or known CVD**: Lifestyle + single antihypertensive agent\n- **Stage 2 HTN**: Lifestyle + two first-line agents from different classes\n\n## First-Line Antihypertensive Agents\n\n### ACE Inhibitors (ACEi)\n- Examples: lisinopril 10-40 mg, enalapril 5-40 mg, ramipril 2.5-20 mg\n- Preferred in: diabetes, CKD with proteinuria, post-MI, HFrEF\n- Side effects: dry cough (10-15%), hyperkalemia, angioedema (contraindication to rechallenge)\n- Contraindicated in pregnancy (all trimesters), bilateral renal artery stenosis\n\n### Angiotensin II Receptor Blockers (ARBs)\n- Examples: losartan 50-100 mg, valsartan 80-320 mg, irbesartan 150-300 mg\n- Use when ACEi not tolerated (cough)\n- Similar contraindications to ACEi; do NOT combine ACEi + ARB", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "### Calcium Channel Blockers (CCBs)\n- **Dihydropyridine**: amlodipine 2.5-10 mg, nifedipine ER 30-90 mg\n- **Non-dihydropyridine**: diltiazem ER 120-360 mg, verapamil ER 120-480 mg\n- Preferred in: African American patients, isolated systolic HTN in elderly\n- Avoid non-DHP CCBs with beta-blockers (risk of bradycardia/heart block)\n\n### Thiazide/Thiazide-like Diuretics\n- Chlorthalidone 12.5-25 mg (preferred; longer half-life), hydrochlorothiazide 12.5-50 mg, indapamide 1.25-2.5 mg\n- Preferred in: elderly, isolated systolic HTN, African American patients\n- Monitor: electrolytes (hypokalemia, hyponatremia), uric acid, glucose\n\n## Special Populations\n\n### Chronic Kidney Disease\n- ACEi or ARB first-line (especially with proteinuria; UACR > 300 mg/g)\n- Add dihydropyridine CCB or diuretic as second agent (loop diuretic if eGFR < 30)\n- Monitor potassium and creatinine within 2-4 weeks of ACEi/ARB initiation\n- Tolerate up to 30% rise in creatinine after ACEi/ARB initiation", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Diabetes Mellitus\n- ACEi or ARB preferred first-line (renoprotective)\n- CCB or thiazide diuretic as add-on\n- Avoid beta-blockers as first-line (mask hypoglycemia, metabolic effects) unless compelling indication\n\n### Pregnancy\n- **Safe agents**: labetalol, nifedipine ER, methyldopa\n- **Contraindicated**: ACEi, ARBs, direct renin inhibitors, nitroprusside\n- Target: < 140/90 mmHg (ACOG); some guidelines suggest < 135/85 mmHg\n\n### African American Patients\n- CCBs or thiazide diuretics preferred as initial therapy (stronger BP response)\n- ACEi/ARBs still indicated when compelling indications present (diabetes with proteinuria, HFrEF)\n\n## Resistant Hypertension\n\nDefined as BP above goal despite 3 optimally dosed antihypertensives (including a diuretic), or requiring 4 or more agents.", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "### Workup\n- Confirm adherence (pill counts, pharmacy records, directly observed therapy)\n- Exclude white-coat effect with ABPM or HBPM\n- Assess for secondary causes: primary aldosteronism (aldosterone/renin ratio), renal artery stenosis (renal duplex ultrasound), pheochromocytoma (plasma metanephrines), Cushing syndrome, OSA, thyroid disease, coarctation of aorta\n- Review medications that raise BP: NSAIDs, oral contraceptives, decongestants, stimulants, corticosteroids\n\n### Management\n- Optimize diuretic therapy: switch to chlorthalidone if on HCTZ; add loop diuretic if eGFR < 30\n- **Fourth-line agent**: spironolactone 25-50 mg/day (strongest evidence for resistant HTN)\n- Alternative fourth-line agents: eplerenone, amiloride, beta-blocker, alpha-blocker, clonidine, hydralazine, minoxidil", "metadata": {"source": "hypertension_management.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395241", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/hypertension_management.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Oncologic Emergencies\n\n## Tumor Lysis Syndrome (TLS)\n\n### Definition and Risk\nTLS results from rapid cell destruction releasing intracellular contents: potassium, phosphorus, uric acid, and nucleic acids.\n\n**High-risk malignancies**: Burkitt lymphoma, ALL with WBC >100K, DLBCL with bulky disease, AML with WBC >50K.\n\n### Cairo-Bishop Diagnostic Criteria\nLaboratory TLS (2 or more within 3 days before or 7 days after treatment):\n- Uric acid >= 8 mg/dL or 25% increase\n- Potassium >= 6.0 mEq/L or 25% increase\n- Phosphorus >= 4.5 mg/dL or 25% increase\n- Calcium <= 7.0 mg/dL or 25% decrease\n\nClinical TLS: Laboratory TLS plus one or more of: renal failure, seizure, cardiac arrhythmia, or death.", "metadata": {"source": "oncologic_emergencies.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395299", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/oncologic_emergencies.md", "chunk_index": 0, "total_chunks": 6}}, {"content": "### Management\n- **Prevention**: Aggressive IV hydration (2.5-3 L/m2/day), allopurinol 300-600 mg/day started 2-3 days before chemotherapy\n- **Rasburicase**: 0.2 mg/kg IV single dose for high-risk patients or established TLS. Contraindicated in G6PD deficiency (hemolytic anemia risk). Rapidly lowers uric acid within 4 hours.\n- **Hyperkalemia**: Treat per standard protocol (calcium gluconate, insulin/dextrose, kayexalate, dialysis if refractory)\n- **Hyperphosphatemia**: Phosphate binders (sevelamer, aluminum hydroxide); avoid calcium-based binders if calcium-phosphorus product >60\n- **Dialysis**: For refractory electrolyte disturbances, volume overload, or severe renal failure\n\n## Malignant Spinal Cord Compression\n\n### Clinical Presentation\n- Back pain (>90% of patients), often worse supine and at night\n- Neurologic deficits: weakness, sensory level, bowel/bladder dysfunction (late finding)\n- Thoracic spine most common location (60-70%)", "metadata": {"source": "oncologic_emergencies.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395299", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/oncologic_emergencies.md", "chunk_index": 1, "total_chunks": 6}}, {"content": "### Management (Time-Critical)\n1. **Dexamethasone**: 10 mg IV bolus immediately upon clinical suspicion, then 4 mg IV/PO every 6 hours\n2. **MRI of entire spine**: Obtain urgently (within 24 hours); CT myelography if MRI unavailable\n3. **Radiation therapy**: Standard treatment; begin within 24 hours of diagnosis\n4. **Surgical decompression**: Consider for single-level compression, radioresistant tumors (renal cell, melanoma), spinal instability, or neurologic deterioration during radiation\n5. **Prognosis**: Ambulatory status at diagnosis is strongest predictor of outcome; patients ambulatory at treatment have >80% chance of remaining ambulatory\n\n## Superior Vena Cava Syndrome\n\n### Etiology\nMalignant causes (>80%): Lung cancer (especially small cell), lymphoma, mediastinal tumors.", "metadata": {"source": "oncologic_emergencies.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395299", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/oncologic_emergencies.md", "chunk_index": 2, "total_chunks": 6}}, {"content": "### Management\n- **Severity assessment**: Mild (facial/neck swelling) vs. severe (stridor, cerebral edema, hemodynamic compromise)\n- **Tissue diagnosis**: Obtain before treatment when possible; do not delay treatment for life-threatening symptoms\n- **Treatment**: Radiation for NSCLC; chemotherapy for SCLC and lymphoma; endovascular stenting for severe symptoms or as bridge to definitive therapy\n- **Supportive care**: Elevate head of bed, supplemental oxygen, dexamethasone 4 mg IV q6h for airway edema\n\n## Febrile Neutropenia\n\n### Definition\n- Temperature >= 38.3C (101F) single reading or >= 38.0C (100.4F) sustained over 1 hour\n- ANC <500 cells/mcL or expected to decline to <500 within 48 hours", "metadata": {"source": "oncologic_emergencies.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395299", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/oncologic_emergencies.md", "chunk_index": 3, "total_chunks": 6}}, {"content": "### Empiric Antibiotic Therapy (Within 60 Minutes)\n- **Monotherapy**: Cefepime 2g IV q8h, meropenem 1g IV q8h, or piperacillin-tazobactam 4.5g IV q6h\n- **Add vancomycin** if: hemodynamic instability, skin/soft tissue infection, pneumonia, suspected catheter-related infection, or known MRSA colonization\n- **Antifungal coverage**: Add empirically if persistent fever after 4-7 days of broad-spectrum antibiotics (micafungin 100 mg IV daily or liposomal amphotericin B)\n\n### MASCC Risk Index\nScore >=21: Low risk; may consider outpatient oral antibiotics (ciprofloxacin + amoxicillin-clavulanate) in selected patients with close follow-up.\n\n## Hypercalcemia of Malignancy\n\n### Classification\n- Mild: 10.5-12.0 mg/dL (corrected)\n- Moderate: 12.1-14.0 mg/dL\n- Severe: >14.0 mg/dL", "metadata": {"source": "oncologic_emergencies.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395299", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/oncologic_emergencies.md", "chunk_index": 4, "total_chunks": 6}}, {"content": "### Management\n1. **IV normal saline**: 200-300 mL/hr initially; goal 2-4 L in first 24 hours\n2. **Zoledronic acid**: 4 mg IV over 15 minutes (onset 2-4 days, duration 2-4 weeks)\n3. **Calcitonin**: 4 IU/kg SC/IM every 12 hours for rapid but temporary effect (tachyphylaxis within 48 hours)\n4. **Denosumab**: 120 mg SC for bisphosphonate-refractory cases or renal insufficiency\n5. **Dialysis**: For severe, life-threatening hypercalcemia unresponsive to medical therapy\n6. **Treat underlying malignancy**: Definitive management requires tumor-directed therapy", "metadata": {"source": "oncologic_emergencies.md", "category": "oncology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395299", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/oncologic_emergencies.md", "chunk_index": 5, "total_chunks": 6}}, {"content": "# Pain Management\n\n## WHO Analgesic Ladder (Modified)\n### Step 1 \u2014 Mild Pain (1-3/10)\n- **Acetaminophen**: 500-1000mg every 6-8 hours; max 3g/day (2g/day if liver disease or alcohol use)\n- **NSAIDs**: Ibuprofen 400-600mg TID, naproxen 250-500mg BID, celecoxib 200mg daily\n- NSAID precautions: GI bleeding (use with PPI if risk factors), renal impairment, cardiovascular risk, avoid in CKD Stage 4-5\n\n### Step 2 \u2014 Moderate Pain (4-6/10)\n- **Tramadol**: 50-100mg every 4-6 hours; max 400mg/day; serotonin syndrome risk with SSRIs; seizure risk\n- **Combination therapy**: Acetaminophen + NSAID (different mechanisms, additive effect)\n- Consider adjuvants for specific pain types\n\n### Step 3 \u2014 Severe Pain (7-10/10)\n- **Strong opioids**: Morphine, hydromorphone, oxycodone, fentanyl\n- Start low, titrate slowly; equianalgesic dosing tables for conversions\n- Always prescribe laxatives (senna, docusate) with scheduled opioids\n- Consider naloxone co-prescription if \u226550 MME/day", "metadata": {"source": "pain_management.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395364", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pain_management.md", "chunk_index": 0, "total_chunks": 4}}, {"content": "## Neuropathic Pain\n- **First-line**: Gabapentin (start 300mg/day, titrate to 1800-3600mg/day in divided doses), pregabalin (75-300mg BID)\n- **First-line alternative**: Duloxetine (60-120mg daily), venlafaxine (150-225mg daily)\n- **Second-line**: TCAs (amitriptyline 25-75mg at bedtime \u2014 caution in elderly), topical lidocaine 5% patch\n- **Third-line**: Tramadol, tapentadol; combination therapy\n- For diabetic neuropathy: Duloxetine and pregabalin are FDA-approved\n\n## Multimodal Analgesia\n- Combine agents with different mechanisms to improve pain control and reduce opioid requirements\n- Regional anesthesia (nerve blocks, epidurals) when appropriate\n- Non-pharmacologic: Physical therapy, cognitive behavioral therapy, TENS, acupuncture, heat/cold therapy", "metadata": {"source": "pain_management.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395364", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pain_management.md", "chunk_index": 1, "total_chunks": 4}}, {"content": "## Opioid Prescribing Best Practices\n- Use lowest effective dose for shortest duration\n- Check prescription drug monitoring program (PDMP) before prescribing\n- Avoid concurrent benzodiazepines (FDA black box warning \u2014 increased risk of respiratory depression and death)\n- Risk assessment: Opioid Risk Tool (ORT), SOAPP-R\n- **Tapering**: Reduce by 10-25% every 2-4 weeks; slower for long-term use (>1 year)\n- Naloxone: Prescribe if \u226550 MME/day, concurrent benzodiazepines, or history of overdose/substance use\n\n## Opioid Equianalgesic Doses (Approximate, oral)\n| Opioid | Equianalgesic Dose |\n|--------|-------------------|\n| Morphine | 30mg |\n| Oxycodone | 20mg |\n| Hydromorphone | 6mg |\n| Hydrocodone | 30mg |\n| Fentanyl patch | 12.5 mcg/hr \u2248 30-44 MME/day |", "metadata": {"source": "pain_management.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395364", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pain_management.md", "chunk_index": 2, "total_chunks": 4}}, {"content": "## Chronic Pain Considerations\n- Emphasize function over pain scores\n- Set realistic expectations\n- Multimodal and multidisciplinary approach\n- Regular reassessment of risks and benefits\n- Consider interventional procedures for refractory pain", "metadata": {"source": "pain_management.md", "category": "pharmacology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395364", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pain_management.md", "chunk_index": 3, "total_chunks": 4}}, {"content": "# Palliative Care Principles\n\n## Overview\nPalliative care is specialized medical care focused on providing relief from symptoms, pain, and stress of serious illness, regardless of diagnosis or stage. It is appropriate at any point in illness and can be provided alongside curative treatment.\n\n## Symptom Management", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 0, "total_chunks": 8}}, {"content": "### Pain Management\n- **WHO Analgesic Ladder**: Step 1 (non-opioid: acetaminophen, NSAIDs) -> Step 2 (mild opioid: tramadol, codeine) -> Step 3 (strong opioid: morphine, hydromorphone, fentanyl)\n- **Opioid-naive starting doses**: Morphine 5-15 mg PO every 4 hours PRN or 2-5 mg IV every 2-4 hours PRN\n- **Titration**: Increase by 25-50% for moderate pain, 50-100% for severe pain\n- **Long-acting conversion**: Calculate 24-hour total opioid requirement; convert to extended-release formulation with 10-20% of total daily dose available as breakthrough\n- **Adjuvants**: Gabapentin/pregabalin for neuropathic pain, dexamethasone for bone pain and nerve compression, duloxetine for neuropathic pain, ketamine for refractory pain\n- **Opioid rotation**: Consider when side effects are intolerable or pain is refractory; use equianalgesic tables with 25-50% dose reduction for cross-tolerance", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 1, "total_chunks": 8}}, {"content": "### Dyspnea Management\n- Dyspnea is common in advanced heart failure, COPD, and cancer\n- **Opioids**: First-line pharmacologic therapy for refractory dyspnea; morphine 2.5-5 mg PO every 4 hours or 1-2 mg IV every 2-4 hours; opioid-tolerant patients: increase baseline dose by 25%\n- **Supplemental oxygen**: Benefit primarily in hypoxemic patients (SpO2 <90%); fan directed at face provides relief regardless of oxygen status\n- **Benzodiazepines**: Lorazepam 0.5-1 mg PO/SL/IV every 4-6 hours for anxiety-associated dyspnea; use as adjunct, not first-line\n- **Non-pharmacologic**: Positioning (upright, leaning forward), fan therapy, pursed-lip breathing, energy conservation techniques\n- **Corticosteroids**: Dexamethasone 4-8 mg daily for lymphangitic carcinomatosis, airway edema, or radiation pneumonitis\n\n### Nausea and Vomiting\nTreat based on underlying mechanism:", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 2, "total_chunks": 8}}, {"content": "| Mechanism | Medication | Dose |\n|---|---|---|\n| Chemoreceptor trigger zone | Ondansetron | 4-8 mg PO/IV every 8 hours |\n| | Haloperidol | 0.5-2 mg PO/IV every 6-8 hours |\n| | Prochlorperazine | 5-10 mg PO/IV every 6-8 hours |\n| Gastroparesis/GI dysmotility | Metoclopramide | 10 mg PO/IV every 6 hours (before meals) |\n| Bowel obstruction | Octreotide | 100-300 mcg SC every 8 hours |\n| | Dexamethasone | 8-16 mg IV daily |\n| Increased ICP/vestibular | Dexamethasone | 4-8 mg IV every 6-8 hours |\n| | Meclizine | 25 mg PO every 6 hours |\n| Anticipatory | Lorazepam | 0.5-1 mg PO/SL before trigger |\n| Multifactorial/refractory | Olanzapine | 2.5-5 mg PO daily |\n\n- **Constipation prevention**: All patients on opioids should receive a bowel regimen (senna 2 tabs BID + docusate 100 mg BID; add polyethylene glycol or lactulose if needed; methylnaltrexone 8-12 mg SC for opioid-induced constipation refractory to laxatives)\n\n## Advance Directives", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 3, "total_chunks": 8}}, {"content": "### Types\n- **Living will**: Written document specifying desired treatments in specific clinical scenarios\n- **Durable power of attorney for healthcare (healthcare proxy)**: Designates surrogate decision-maker for when patient lacks capacity\n- **POLST/MOLST (Physician/Medical Orders for Life-Sustaining Treatment)**: Actionable medical orders for seriously ill patients reflecting treatment preferences (CPR status, intubation, hospitalization, artificial nutrition)\n\n### Key Components to Address\n- Cardiopulmonary resuscitation preferences\n- Mechanical ventilation and intubation\n- Artificial nutrition and hydration\n- Dialysis\n- Hospitalization and ICU transfer\n- Antibiotic use for life-threatening infections\n- Blood transfusion\n\n## Goals of Care Conversations", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 4, "total_chunks": 8}}, {"content": "### SPIKES Framework for Serious Illness Communication\n1. **Setting**: Private space, sit down, adequate time, invite key family members\n2. **Perception**: Assess patient's understanding of their illness (\"What have your doctors told you about your condition?\")\n3. **Invitation**: Ask permission to share information (\"Would it be okay if I share what I'm seeing?\")\n4. **Knowledge**: Deliver information in clear, compassionate language; avoid jargon; use \"warning shot\" (\"I wish I had better news...\")\n5. **Emotions**: Respond to emotion with empathy before providing more information (NURSE: Name, Understand, Respect, Support, Explore)\n6. **Strategy/Summary**: Develop plan aligned with patient values; summarize decisions; document", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 5, "total_chunks": 8}}, {"content": "### Key Questions for Eliciting Values\n- \"What is most important to you as you think about your care?\"\n- \"What are you hoping for? What are you worried about?\"\n- \"If time is short, what matters most to you?\"\n- \"Are there things that would be worse than death for you?\"\n\n## Hospice Criteria\n\n### General Eligibility\n- Prognosis of 6 months or less if disease follows expected course\n- Patient elects comfort-focused care\n- Two physician certifications required\n\n### Disease-Specific Criteria\n\n**Heart Failure**: NYHA Class IV despite optimal therapy, EF <20%, refractory symptoms, recurrent hospitalizations, cardiac cachexia\n\n**COPD**: Disabling dyspnea at rest, FEV1 <30% predicted, oxygen-dependent, recurrent hospitalizations/exacerbations, cor pulmonale, unintentional weight loss >10%", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 6, "total_chunks": 8}}, {"content": "**Dementia**: FAST Stage 7 or beyond (unable to ambulate, dress, bathe independently; limited speech <6 words; urinary and fecal incontinence), plus comorbid conditions (aspiration pneumonia, pyelonephritis, decubitus ulcers, recurrent fever)\n\n**Cancer**: Metastatic or locally advanced disease; declining functional status (PPS <50%); not a candidate for or declining further disease-directed therapy; weight loss >10% in 6 months\n\n### Hospice Services Include\n- Nursing visits, aide services, social work, chaplaincy\n- Medications related to terminal diagnosis\n- Durable medical equipment (hospital bed, wheelchair, oxygen)\n- 24/7 on-call nursing support\n- Bereavement support for family for 13 months after death\n- Inpatient hospice for acute symptom management (respite and crisis care)", "metadata": {"source": "palliative_care.md", "category": "palliative_care", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395426", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/palliative_care.md", "chunk_index": 7, "total_chunks": 8}}, {"content": "# Pediatric Asthma Management\n\n## Diagnosis\n- Recurrent episodes of wheezing, cough, shortness of breath, and chest tightness\n- Reversible airflow obstruction (>12% improvement in FEV1 post-bronchodilator in children >= 5 years)\n- Spirometry recommended for children >= 5 years for diagnosis and monitoring\n\n## Stepwise Therapy: Ages 0-4 Years\n\n| Step | Preferred Controller | Alternative |\n|---|---|---|\n| Step 1 | SABA PRN only | -- |\n| Step 2 | Low-dose ICS daily | Montelukast |\n| Step 3 | Medium-dose ICS daily | Low-dose ICS + montelukast |\n| Step 4 | Medium-dose ICS + montelukast or referral | Specialist referral |\n\n## Stepwise Therapy: Ages 5-11 Years", "metadata": {"source": "pediatric_asthma.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395582", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_asthma.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "| Step | Preferred Controller | Alternative |\n|---|---|---|\n| Step 1 | SABA PRN only | -- |\n| Step 2 | Low-dose ICS daily | Montelukast, cromolyn |\n| Step 3 | Low-dose ICS + LABA OR medium-dose ICS | Low-dose ICS + montelukast |\n| Step 4 | Medium-dose ICS + LABA | Medium-dose ICS + montelukast |\n| Step 5 | High-dose ICS + LABA | Referral for biologic therapy |\n| Step 6 | High-dose ICS + LABA + oral corticosteroid | Omalizumab or other biologic |\n\n## Stepwise Therapy: Ages >= 12 Years\n- Follow adult NAEPP/GINA guidelines\n- Step 1: Low-dose ICS-formoterol PRN (preferred, GINA) or SABA PRN\n- Step 2: Low-dose ICS daily + SABA PRN or low-dose ICS-formoterol PRN\n- Steps 3-5: Escalate ICS dose and add LABA, LAMA, biologics as needed\n\n## ICS Dosing (Approximate Daily Doses - Fluticasone Propionate Equivalent)", "metadata": {"source": "pediatric_asthma.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395582", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_asthma.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "| Age Group | Low Dose | Medium Dose | High Dose |\n|---|---|---|---|\n| 0-4 years | 88 mcg | 176 mcg | >176 mcg |\n| 5-11 years | 88-176 mcg | 176-352 mcg | >352 mcg |\n| >= 12 years | 100-250 mcg | 250-500 mcg | >500 mcg |\n\n## Acute Exacerbation: PRAM Score (Preschool Respiratory Assessment Measure)\n\nValidated for ages 1-6 years. Scored 0-12.\n\n| Parameter | 0 | 1 | 2 | 3 |\n|---|---|---|---|---|\n| O2 saturation | >= 95% | 92-94% | <92% | -- |\n| Suprasternal retractions | Absent | Present | -- | -- |\n| Scalene retractions | Absent | Present | -- | -- |\n| Air entry | Normal | Decreased at bases | Widespread decrease | Absent/minimal |\n| Wheezing | Absent | Expiratory only | Inspiratory + expiratory | Audible without stethoscope or silent chest |\n\n**Interpretation**: Mild (0-3), Moderate (4-7), Severe (8-12)\n\n## Emergency Department Management", "metadata": {"source": "pediatric_asthma.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395582", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_asthma.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "### Mild Exacerbation (PRAM 0-3)\n- Salbutamol (albuterol) MDI 4-8 puffs via spacer every 20 minutes x 3 doses\n- Reassess after each treatment cycle\n- Consider oral prednisolone 1-2 mg/kg (max 40 mg) if incomplete response\n\n### Moderate Exacerbation (PRAM 4-7)\n- Salbutamol nebulization 2.5-5 mg every 20 minutes x 3 doses\n- Ipratropium bromide 250-500 mcg nebulized with first 3 salbutamol treatments\n- Oral prednisolone 1-2 mg/kg (max 40-60 mg) or dexamethasone 0.6 mg/kg (max 16 mg)\n- Reassess after each hour of treatment\n\n### Severe Exacerbation (PRAM 8-12)\n- Continuous albuterol nebulization 10-15 mg/hour\n- Ipratropium 500 mcg nebulized every 20 minutes x 3\n- IV methylprednisolone 2 mg/kg bolus (max 60 mg)\n- IV magnesium sulfate 50 mg/kg (max 2g) over 20 minutes for impending respiratory failure\n- Consider terbutaline IV infusion if refractory\n- Prepare for non-invasive ventilation or intubation if deteriorating", "metadata": {"source": "pediatric_asthma.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395582", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_asthma.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "### Adjunct Therapies\n- Supplemental oxygen to maintain SpO2 >= 92%\n- Heliox (70:30 helium-oxygen) may reduce work of breathing in severe cases\n- Epinephrine IM 0.01 mg/kg (max 0.5 mg) for anaphylaxis-triggered bronchospasm\n\n## Discharge Criteria\n- PRAM score <= 3 sustained for at least 1 hour after last bronchodilator\n- SpO2 >= 92% on room air\n- Adequate oral intake and able to ambulate (age-appropriate)\n- Caregiver demonstrates proper inhaler technique with spacer\n- Asthma action plan reviewed and provided\n\n### Discharge Prescriptions\n- Albuterol MDI with spacer: 2-4 puffs every 4-6 hours PRN\n- Prednisolone 1 mg/kg/day for 3-5 days OR dexamethasone 0.6 mg/kg daily for 2 days\n- Initiate or step up controller therapy as appropriate\n- Follow-up with primary care within 1-4 weeks", "metadata": {"source": "pediatric_asthma.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395582", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_asthma.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Pediatric Fever Management\n\n## Definition\n- Fever defined as rectal temperature >= 38.0C (100.4F)\n- Rectal temperature is the gold standard in infants <3 months\n\n## Age-Based Approach\n\n### Neonates (0-28 Days) - FULL SEPTIC WORKUP\n\nAll febrile neonates require emergent evaluation and empiric treatment.\n\n**Mandatory Workup**:\n- Complete blood count with differential\n- Blood culture\n- Urinalysis and urine culture (catheterized specimen)\n- Lumbar puncture with CSF studies (cell count, glucose, protein, Gram stain, culture)\n- Consider HSV PCR on CSF and surface cultures if risk factors present (maternal HSV, vesicular lesions, seizures, elevated LFTs)\n- Chest X-ray if respiratory symptoms present", "metadata": {"source": "pediatric_fever.md", "category": "pediatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395640", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_fever.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "**Empiric Treatment**:\n- **Ampicillin** 50 mg/kg IV q8h (covers Listeria, Group B Streptococcus, Enterococcus)\n- **Gentamicin** 4 mg/kg IV q24h OR **Cefotaxime** 50 mg/kg IV q8h (covers gram-negative organisms)\n- **Add acyclovir** 20 mg/kg IV q8h if any concern for HSV (vesicles, seizures, CSF pleocytosis, elevated AST/ALT, ill appearance)\n\n**Disposition**: Mandatory hospital admission pending culture results for minimum 48-72 hours.\n\n### Infants 29-60 Days\n\n**Risk Stratification Required**: Use validated criteria to determine need for LP and admission.\n\n**Rochester Criteria (Low Risk)**:\n- Previously healthy, term infant\n- Non-toxic appearance\n- No focal bacterial infection on exam (except otitis media)\n- WBC 5,000-15,000/mm3\n- Band count <1,500/mm3\n- Urinalysis <10 WBC/hpf\n- If diarrhea: stool <5 WBC/hpf", "metadata": {"source": "pediatric_fever.md", "category": "pediatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395640", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_fever.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "**If low-risk by Rochester criteria**: May consider outpatient management with close follow-up in 24 hours, provided blood and urine cultures obtained and empiric IM ceftriaxone (50 mg/kg) administered.\n\n**If high-risk or ill-appearing**: Full septic workup including LP, empiric IV antibiotics, and hospital admission.\n\n### Philadelphia Criteria (28-60 Days)\nLow-risk classification requires ALL of:\n- Well-appearing infant\n- No prior antibiotics\n- WBC <15,000/mm3\n- Band-to-neutrophil ratio <0.2\n- UA <10 WBC/hpf\n- CSF <8 WBC/mm3 and negative Gram stain\n- Normal chest X-ray if obtained\n\n### Infants 60-90 Days\n- Urinalysis and urine culture remain mandatory\n- Blood culture recommended\n- LP based on clinical assessment and inflammatory markers\n- Consider procalcitonin (<0.5 ng/mL supports low risk) and CRP as adjunct risk stratification tools\n- If well-appearing with negative urinalysis and low inflammatory markers, may manage as outpatient with reliable follow-up", "metadata": {"source": "pediatric_fever.md", "category": "pediatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395640", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_fever.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "### Children 3-36 Months\n- UTI evaluation: Obtain urinalysis/urine culture in all girls <24 months with fever, uncircumcised boys <12 months, circumcised boys <6 months\n- Blood work generally not required if well-appearing, immunized, and no focal source\n- Fever without source in a fully immunized child rarely requires extensive workup\n- Consider occult pneumonia if fever >39C for >48 hours without source; obtain CXR\n\n### Children >36 Months\n- Guided by clinical presentation and examination findings\n- Most febrile illnesses are viral and self-limited\n- Evaluate for specific source: pharyngitis (rapid strep), UTI, pneumonia, skin/soft tissue\n\n## Antipyretic Therapy\n\n| Medication | Dose | Frequency | Notes |\n|---|---|---|---|\n| Acetaminophen | 15 mg/kg/dose | Every 4-6 hours | Max 75 mg/kg/day; avoid in liver disease |\n| Ibuprofen | 10 mg/kg/dose | Every 6-8 hours | Age >= 6 months only; avoid in dehydration, renal disease |", "metadata": {"source": "pediatric_fever.md", "category": "pediatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395640", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_fever.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "- Alternating acetaminophen and ibuprofen is common but increases risk of dosing errors\n- Goal is comfort, not normothermia; fever itself is not harmful\n- Do NOT use aspirin in children (risk of Reye syndrome)\n\n## When to Admit\n- All febrile neonates <28 days\n- Ill or toxic appearance at any age\n- High-risk infants 29-60 days per stratification criteria\n- Signs of meningitis, sepsis, or serious bacterial infection\n- Immunocompromised patients with fever\n- Inability to maintain adequate oral hydration\n- Unreliable follow-up or caregiver concerns", "metadata": {"source": "pediatric_fever.md", "category": "pediatrics", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395640", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pediatric_fever.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Community-Acquired Pneumonia (CAP)\n\n## Definition\nPneumonia acquired outside of hospitals or long-term care facilities, presenting with acute respiratory symptoms and radiographic infiltrate in a patient not hospitalized in the prior 48 hours.\n\n## CURB-65 Severity Score\nAssign 1 point for each criterion:\n- **C**onfusion (AMT score <=8 or new disorientation)\n- **U**rea > 7 mmol/L (BUN > 20 mg/dL)\n- **R**espiratory rate >= 30 breaths/min\n- **B**lood pressure (SBP < 90 mmHg or DBP <= 60 mmHg)\n- Age **65** years or older\n\n### Disposition by Score\n- **0-1**: Outpatient management; low mortality risk (~1-3%)\n- **2**: Consider short inpatient stay or closely supervised outpatient care; mortality ~9%\n- **3-5**: Inpatient admission required; scores of 4-5 warrant ICU evaluation; mortality 15-40%\n\n## Common Pathogens", "metadata": {"source": "pneumonia_cap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395713", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_cap.md", "chunk_index": 0, "total_chunks": 4}}, {"content": "### Typical Organisms\n- *Streptococcus pneumoniae* (most common overall)\n- *Haemophilus influenzae* (especially COPD patients)\n- *Moraxella catarrhalis*\n- *Staphylococcus aureus* (post-influenza, IV drug use)\n\n### Atypical Organisms\n- *Mycoplasma pneumoniae* (younger adults, gradual onset)\n- *Chlamydophila pneumoniae*\n- *Legionella pneumophila* (contaminated water exposure; check urine antigen)\n\n## Empiric Antibiotic Therapy\n\n### Outpatient (No Comorbidities)\n- Amoxicillin 1g PO TID **or**\n- Doxycycline 100 mg PO BID\n- Duration: 5 days minimum (extend if not clinically stable by day 3)\n\n### Outpatient (With Comorbidities: COPD, DM, CKD, heart failure, alcoholism)\n- Amoxicillin-clavulanate 875/125 mg PO BID **plus** a macrolide (azithromycin 500 mg day 1 then 250 mg days 2-5) **or**\n- Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg PO daily or moxifloxacin 400 mg PO daily)", "metadata": {"source": "pneumonia_cap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395713", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_cap.md", "chunk_index": 1, "total_chunks": 4}}, {"content": "### Inpatient (Non-ICU)\n- Beta-lactam (ceftriaxone 1-2 g IV daily or ampicillin-sulbactam 3 g IV q6h) **plus** macrolide (azithromycin 500 mg IV/PO daily) **or**\n- Respiratory fluoroquinolone monotherapy IV\n\n### Inpatient (ICU)\n- Beta-lactam (ceftriaxone 2 g IV daily or ampicillin-sulbactam 3 g IV q6h) **plus** macrolide or fluoroquinolone\n- If *Pseudomonas* risk: piperacillin-tazobactam 4.5 g IV q6h or cefepime 2 g IV q8h **plus** fluoroquinolone\n- If MRSA risk (prior MRSA, cavitary infiltrate): add vancomycin 15-20 mg/kg IV q8-12h or linezolid 600 mg IV/PO q12h\n\n## Admission Criteria (Beyond CURB-65)\n- Hypoxemia: SpO2 < 94% on room air or PaO2 < 60 mmHg\n- Multilobar infiltrates on chest imaging\n- Hemodynamic instability or need for vasopressors\n- Inability to tolerate oral medications (persistent vomiting)\n- Significant comorbid decompensation\n- Social factors precluding safe outpatient management", "metadata": {"source": "pneumonia_cap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395713", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_cap.md", "chunk_index": 2, "total_chunks": 4}}, {"content": "## Treatment Duration and Follow-Up\n- Standard duration: 5 days if afebrile for >= 48 hours and clinically improving\n- Longer courses (7-10 days) for *Pseudomonas*, MRSA, lung abscess, or empyema\n- Follow-up chest radiograph at 6-8 weeks for smokers aged > 50 to exclude underlying malignancy\n- Procalcitonin may guide antibiotic discontinuation (stop if < 0.25 ng/mL and clinical improvement)\n\n## Prevention\n- Pneumococcal vaccination: PCV20 for all adults >= 65 and high-risk adults 19-64\n- Annual influenza vaccination\n- Smoking cessation counseling", "metadata": {"source": "pneumonia_cap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395713", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_cap.md", "chunk_index": 3, "total_chunks": 4}}, {"content": "# Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)\n\n## Definitions\n- **HAP**: Pneumonia occurring >= 48 hours after hospital admission, not incubating at time of admission\n- **VAP**: Pneumonia developing > 48 hours after endotracheal intubation and mechanical ventilation\n- **Ventilator-associated tracheobronchitis (VAT)**: Purulent secretions with positive cultures but no new infiltrate; may progress to VAP\n\n## Risk Factors\n- Mechanical ventilation > 48 hours (strongest risk factor for VAP)\n- Prior IV antibiotic exposure within 90 days\n- Hospitalization >= 5 days before pneumonia onset\n- Acute respiratory distress syndrome (ARDS)\n- Immunosuppression (steroids, chemotherapy, transplant)\n- Structural lung disease (bronchiectasis, COPD)\n- Known colonization with multidrug-resistant (MDR) organisms\n- Aspiration risk (reduced consciousness, dysphagia, supine positioning)", "metadata": {"source": "pneumonia_hap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395806", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_hap.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "## Common Pathogens\n- **Gram-negative bacilli**: *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli*, *Acinetobacter baumannii*, *Enterobacter* spp.\n- **Gram-positive**: MRSA (*Staphylococcus aureus*, methicillin-resistant)\n- **Anaerobes**: Consider in aspiration events\n- Late-onset (>= 5 days) and prior antibiotic exposure increase likelihood of MDR organisms\n\n## Diagnostic Evaluation\n- Obtain lower respiratory tract cultures (endotracheal aspirate or BAL) **before** initiating antibiotics\n- Blood cultures x2 from separate sites\n- Chest radiograph or CT showing new or progressive infiltrate\n- Clinical criteria: new or worsening fever, leukocytosis or leukopenia, purulent secretions, declining oxygenation\n- Procalcitonin can help guide duration but should not delay treatment\n\n## Empiric Antibiotic Therapy", "metadata": {"source": "pneumonia_hap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395806", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_hap.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "### Standard Risk (No MDR Risk Factors)\n- Piperacillin-tazobactam 4.5 g IV q6h **or**\n- Cefepime 2 g IV q8h **or**\n- Meropenem 1 g IV q8h (reserve for beta-lactam allergy or local resistance patterns)\n\n### High MDR Risk (Prior antibiotics, >= 5 days hospitalized, local MRSA prevalence > 10-20%)\nUse **two** antipseudomonal agents from different classes **plus** MRSA coverage:\n- Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, or meropenem) **plus**\n- Antipseudomonal fluoroquinolone (ciprofloxacin 400 mg IV q8h) or aminoglycoside (tobramycin or amikacin, dose per pharmacokinetics) **plus**\n- MRSA coverage: vancomycin 15-20 mg/kg IV q8-12h (target trough AUC/MIC 400-600) **or** linezolid 600 mg IV q12h\n\n### MRSA Coverage Indications\n- Prior MRSA isolation or colonization\n- ICU with MRSA prevalence > 10-20%\n- Recent IV antibiotics within 90 days\n- High severity of illness or septic shock\n- Hemodialysis patients", "metadata": {"source": "pneumonia_hap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395806", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_hap.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "## De-escalation Strategy\n- **Review cultures at 48-72 hours** and narrow antibiotic spectrum based on susceptibility results\n- Discontinue MRSA coverage if cultures are MRSA-negative\n- Switch to single antipseudomonal agent if susceptibilities allow\n- Transition IV to PO when patient is hemodynamically stable, tolerating oral intake, and clinically improving\n- Stop aminoglycosides as soon as susceptibilities confirm beta-lactam activity\n\n## Treatment Duration\n- **HAP**: 7 days in most cases\n- **VAP**: 7 days; may extend to 10-14 days for *Pseudomonas*, *Acinetobacter*, or immunosuppressed patients\n- Serial procalcitonin trending can support earlier discontinuation\n- Avoid prolonged courses (> 14 days) unless empyema, lung abscess, or inadequate source control", "metadata": {"source": "pneumonia_hap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395806", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_hap.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "## Prevention Bundle (VAP Prevention)\n- Elevate head of bed 30-45 degrees\n- Daily sedation interruption and spontaneous breathing trials\n- Oral care with chlorhexidine (per institutional protocol)\n- DVT and stress ulcer prophylaxis\n- Avoid unnecessary reintubation\n- Minimize duration of mechanical ventilation", "metadata": {"source": "pneumonia_hap.md", "category": "pulmonology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395806", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pneumonia_hap.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Hypertensive Disorders of Pregnancy\n\n## Classification\n\n### Chronic Hypertension\n- BP >= 140/90 mmHg diagnosed before 20 weeks gestation or preexisting before pregnancy\n- Continue pre-pregnancy antihypertensives; switch from ACE inhibitors, ARBs, and direct renin inhibitors (teratogenic) to pregnancy-safe alternatives\n- **Preferred medications**: Labetalol, nifedipine extended-release, methyldopa\n- **Treatment threshold**: BP >= 140/90 mmHg (CHAP trial 2022 supports treatment at this threshold to reduce adverse outcomes)\n- **Target**: BP <140/90 mmHg\n\n### Gestational Hypertension\n- New-onset BP >= 140/90 mmHg after 20 weeks gestation WITHOUT proteinuria or other features of preeclampsia\n- Close monitoring required: 25-50% progress to preeclampsia\n- Antihypertensive treatment if sustained BP >= 140/90 mmHg\n- Delivery recommended at 37+0 weeks if well-controlled; earlier if severe features develop\n\n## Preeclampsia", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 0, "total_chunks": 8}}, {"content": "### Diagnostic Criteria (ACOG)\nBP >= 140/90 mmHg on two occasions at least 4 hours apart after 20 weeks gestation, PLUS one or more of:\n- **Proteinuria**: >= 300 mg/24-hour urine, protein/creatinine ratio >= 0.3, or dipstick >= 2+\n- **Thrombocytopenia**: Platelets <100,000/mcL\n- **Renal insufficiency**: Creatinine >1.1 mg/dL or doubling of baseline\n- **Liver involvement**: Transaminases >= 2x upper limit of normal\n- **Cerebral symptoms**: New-onset headache unresponsive to medication, visual disturbances (scotomata, blurred vision)\n- **Pulmonary edema**\n\n### Preeclampsia with Severe Features\n- BP >= 160/110 mmHg on two occasions at least 4 hours apart (or once if treated immediately)\n- Platelets <100,000/mcL\n- Liver transaminases >= 2x normal, severe persistent RUQ or epigastric pain\n- Creatinine >1.1 mg/dL or doubling\n- Pulmonary edema\n- New-onset headache or visual disturbances", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 1, "total_chunks": 8}}, {"content": "### Management of Preeclampsia WITHOUT Severe Features\n- Expectant management with close monitoring until 37+0 weeks\n- Twice-weekly BP monitoring, weekly labs (CBC, CMP, LDH)\n- Fetal surveillance: NST and amniotic fluid index twice weekly\n- Antenatal corticosteroids (betamethasone 12 mg IM x 2 doses, 24 hours apart) if <37 weeks and delivery anticipated\n- Delivery at 37+0 weeks\n\n### Management of Preeclampsia WITH Severe Features\n- **<34 weeks**: Expectant management may be considered at a tertiary center with ability for daily maternal/fetal surveillance; deliver for uncontrollable BP, worsening labs, eclampsia, placental abruption, or non-reassuring fetal status\n- **34+0 to 36+6 weeks**: Delivery recommended after stabilization\n- **>= 37 weeks**: Delivery after stabilization\n\n### Acute Blood Pressure Management\nTreat BP >= 160/110 mmHg urgently (within 30-60 minutes) to prevent stroke:", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 2, "total_chunks": 8}}, {"content": "**First-Line Options**:\n- **Labetalol**: 20 mg IV over 2 minutes; if no response in 10 minutes, give 40 mg IV; then 80 mg IV; maximum 300 mg total\n- **Hydralazine**: 5-10 mg IV over 2 minutes; repeat every 20-40 minutes; maximum 30 mg total\n- **Nifedipine IR**: 10-20 mg PO; repeat every 20-30 minutes; maximum 50 mg total\n\n**Second-Line**:\n- Nicardipine IV infusion 5 mg/hour, titrate by 2.5 mg/hour every 5-15 minutes (max 15 mg/hour)\n- If refractory to above, consider sodium nitroprusside (last resort, fetal cyanide toxicity risk)\n\n## Eclampsia\n\n### Definition\nNew-onset seizures in a patient with preeclampsia (or postpartum), not attributable to other causes.\n\n### Magnesium Sulfate Protocol\n**First-line treatment AND prophylaxis for seizures in severe preeclampsia**:\n\n- **Loading dose**: 4-6 g IV over 15-20 minutes\n- **Maintenance dose**: 1-2 g/hour continuous IV infusion\n- Continue for 24-48 hours postpartum (or after last seizure)", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 3, "total_chunks": 8}}, {"content": "**Monitoring During Magnesium Therapy**:\n- Serum magnesium levels every 4-6 hours (therapeutic range: 4.8-8.4 mg/dL)\n- Patellar reflexes (loss at ~10 mg/dL)\n- Respiratory rate (depression at ~12 mg/dL); maintain >12 breaths/min\n- Urine output >= 0.5 mL/kg/hour\n- Continuous pulse oximetry\n\n**Magnesium Toxicity Reversal**:\n- **Calcium gluconate**: 1 g (10 mL of 10%) IV over 3-5 minutes for respiratory depression or cardiac arrest\n\n**Recurrent Seizures on Magnesium**:\n- Additional 2g MgSO4 IV bolus over 5 minutes\n- If refractory: Lorazepam 2-4 mg IV or diazepam 5-10 mg IV\n- Intubation if airway compromise", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 4, "total_chunks": 8}}, {"content": "### Immediate Seizure Management\n- Protect from injury; lateral decubitus position to prevent aspiration\n- Secure airway; supplemental oxygen\n- Seizures typically self-limited (60-90 seconds)\n- DO NOT delay magnesium administration\n- Continuous fetal monitoring (fetal bradycardia common during seizure; usually resolves within 10-15 minutes)\n- Plan for delivery once mother is stabilized (eclampsia is NOT an indication for immediate cesarean if mother and fetus stable)\n\n## HELLP Syndrome\n\n### Definition\nHemolysis, Elevated Liver enzymes, Low Platelets. Variant of severe preeclampsia.\n\n### Diagnostic Criteria (Mississippi Classification)\n- **Hemolysis**: LDH >= 600 IU/L, schistocytes on peripheral smear, indirect bilirubin elevated, low haptoglobin\n- **Elevated liver enzymes**: AST or ALT >= 70 IU/L (or >= 2x upper limit of normal)\n- **Low platelets**: Class 1 (<50,000), Class 2 (50,000-100,000), Class 3 (100,000-150,000)", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 5, "total_chunks": 8}}, {"content": "### Management\n- Delivery is definitive treatment; recommended at any gestational age for complete HELLP syndrome\n- If <34 weeks: Administer betamethasone for fetal lung maturity; attempt to delay delivery 24-48 hours if maternal condition permits\n- Magnesium sulfate for seizure prophylaxis\n- Aggressive BP management\n- Transfuse platelets if <20,000 for vaginal delivery or <50,000 for cesarean delivery\n- Dexamethasone 10 mg IV every 12 hours may be used for platelet improvement (evidence limited)\n- Monitor for complications: DIC, placental abruption, hepatic rupture, acute kidney injury, pulmonary edema", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 6, "total_chunks": 8}}, {"content": "### Postpartum\n- Labs typically worsen before improving (nadir 24-48 hours postpartum)\n- Continue magnesium for 24-48 hours postpartum\n- Monitor labs every 6-12 hours until trending toward normalization\n- Most cases resolve within 72 hours to 7 days postpartum\n- Long-term: Increased lifetime cardiovascular risk; counsel on annual BP monitoring, lipid screening, and cardiovascular risk reduction", "metadata": {"source": "pregnancy_hypertension.md", "category": "cardiology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395862", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/pregnancy_hypertension.md", "chunk_index": 7, "total_chunks": 8}}, {"content": "# Status Epilepticus Management\n\n## Definition\n- **Status epilepticus (SE)**: Continuous seizure activity lasting >= 5 minutes, or two or more discrete seizures without full recovery of consciousness between them\n- **Refractory SE (RSE)**: SE persisting despite adequate doses of an initial benzodiazepine and one second-line antiseizure medication\n- **Super-refractory SE (SRSE)**: SE continuing >= 24 hours after onset of anesthetic therapy, including cases that recur on attempted withdrawal of anesthetics", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 0, "total_chunks": 8}}, {"content": "## Initial Stabilization (Time 0-5 Minutes)\n- ABCs: secure airway, administer supplemental oxygen, suction as needed\n- Obtain IV access (two large-bore IVs); if IV access fails, proceed with IM or intranasal routes\n- Point-of-care glucose: treat hypoglycemia immediately with dextrose 50% (50 mL IV)\n- Thiamine 100 mg IV before dextrose if alcohol use disorder or malnutrition suspected\n- Continuous pulse oximetry and cardiac monitoring\n- Place patient in lateral decubitus position if not intubated\n\n## First-Line: Benzodiazepines (Time 5-20 Minutes)\nAdminister immediately upon SE recognition. Goal: terminate seizure within 5 minutes of drug administration.\n\n### IV Access Available\n- **Lorazepam** 0.1 mg/kg IV (max 4 mg per dose); may repeat once in 5-10 minutes\n- **Diazepam** 0.15 mg/kg IV (max 10 mg per dose); may repeat once", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 1, "total_chunks": 8}}, {"content": "### No IV Access\n- **Midazolam** 10 mg IM (for weight >= 40 kg) via autoinjector or standard syringe into deltoid or lateral thigh\n- **Midazolam** 0.2 mg/kg intranasal (max 10 mg) using mucosal atomization device\n- **Diazepam** 0.2 mg/kg rectal (max 20 mg)\n\n**Note**: Midazolam IM is preferred over IV lorazepam in the prehospital setting (RAMPART trial).\n\n## Second-Line: Urgent Control (Time 20-40 Minutes)\nAdminister if seizures persist after adequate benzodiazepine dosing. Choose **one** of the following:\n\n### Levetiracetam (Keppra)\n- **Dose**: 60 mg/kg IV (max 4500 mg) infused over 10-15 minutes\n- **Advantages**: No significant drug interactions, no cardiac monitoring required, safe in hepatic impairment, no hypotension\n- **Disadvantages**: May be less effective than fosphenytoin/valproate per ESETT trial (trend, not significant)", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 2, "total_chunks": 8}}, {"content": "### Fosphenytoin\n- **Dose**: 20 mg PE/kg IV (max rate 150 mg PE/min) infused over 10-15 minutes\n- **Advantages**: Long clinical experience; therapeutic drug monitoring available\n- **Disadvantages**: Hypotension, cardiac arrhythmias (requires cardiac monitoring), contraindicated in second/third-degree heart block; avoid in porphyria\n- Monitor ECG continuously during infusion; reduce rate if QTc prolongation or hypotension occurs\n\n### Valproate Sodium\n- **Dose**: 40 mg/kg IV (max 3000 mg) infused over 10 minutes\n- **Advantages**: Broad-spectrum efficacy, minimal sedation, generally well-tolerated hemodynamically\n- **Disadvantages**: Hepatotoxicity risk (avoid in liver disease), pancreatitis, thrombocytopenia, teratogenic (avoid in pregnancy), hyperammonemia\n- Check ammonia level if altered consciousness persists", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 3, "total_chunks": 8}}, {"content": "**ESETT Trial**: Levetiracetam, fosphenytoin, and valproate showed equivalent efficacy as second-line agents (~45-50% success rate each). Choice should be individualized based on comorbidities and contraindications.\n\n## Refractory Status Epilepticus (Time > 40 Minutes)\nIf seizures persist after first-line and one adequate second-line agent:\n\n### Immediate Actions\n- Intubation for airway protection\n- Arterial line and central venous access\n- Continuous EEG monitoring (mandatory)\n- ICU admission", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 4, "total_chunks": 8}}, {"content": "### Anesthetic Infusions (Choose One)\n- **Midazolam**: Load 0.2 mg/kg IV bolus, then 0.1-2 mg/kg/hr infusion\n- **Propofol**: Load 2 mg/kg IV bolus (may repeat), then 1-5 mg/kg/hr infusion; monitor for propofol infusion syndrome (PRIS) with CK, triglycerides, lactate\n- **Ketamine**: Load 1-2 mg/kg IV bolus, then 1-5 mg/kg/hr infusion; NMDA antagonist may be additive to GABAergic agents\n- **Pentobarbital**: Load 5 mg/kg IV at 50 mg/min, then 1-5 mg/kg/hr; titrate to burst suppression on continuous EEG\n\n### EEG Targets\n- Seizure suppression or burst suppression pattern\n- Maintain anesthetic for 24-48 hours, then taper over 24 hours\n- If seizures recur on taper, resume anesthetic and re-attempt taper after another 24 hours", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 5, "total_chunks": 8}}, {"content": "## Workup for Underlying Etiology\n- Comprehensive metabolic panel (sodium, calcium, magnesium, glucose, renal/hepatic function)\n- Antiseizure medication levels (if on home medications)\n- Toxicology screen (urine drug screen, serum ethanol)\n- Lumbar puncture if infection or autoimmune encephalitis suspected (after CT)\n- MRI brain with and without contrast (when patient stabilized)\n- Autoimmune encephalitis panel (NMDA-R, LGI1, CASPR2 antibodies) if no clear etiology\n- Consider paraneoplastic workup in new-onset refractory SE of unknown etiology (NORSE)", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 6, "total_chunks": 8}}, {"content": "## Monitoring and Supportive Care\n- Continuous EEG for at least 24-48 hours after clinical seizure cessation (nonconvulsive SE occurs in up to 48% of patients after convulsive SE)\n- Serial neurologic assessments\n- Temperature management: aggressively treat hyperthermia (goal < 38C)\n- Avoid and correct metabolic derangements (hyponatremia, hypocalcemia, hypomagnesemia)\n- Rhabdomyolysis screening: CK, renal function; aggressive IV hydration if elevated\n- DVT prophylaxis with pneumatic compression devices", "metadata": {"source": "seizure_status_epilepticus.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.395920", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/seizure_status_epilepticus.md", "chunk_index": 7, "total_chunks": 8}}, {"content": "# Sepsis and Septic Shock Management\n\n## Definitions (Sepsis-3 Criteria, 2016)\n- **Sepsis**: Life-threatening organ dysfunction caused by a dysregulated host response to infection, defined as an acute increase of >= 2 points in the SOFA score attributable to infection\n- **Septic shock**: Subset of sepsis with persistent hypotension requiring vasopressors to maintain MAP >= 65 mmHg **and** serum lactate > 2 mmol/L despite adequate fluid resuscitation\n\n## Quick SOFA (qSOFA) Screening\nAssess at the bedside without laboratory tests. Assign 1 point each:\n- Respiratory rate >= 22 breaths/min\n- Altered mental status (GCS < 15)\n- Systolic blood pressure <= 100 mmHg\n\n**qSOFA >= 2**: Prompts further evaluation for organ dysfunction; not a diagnostic criterion for sepsis but identifies patients at higher risk of poor outcomes. Full SOFA scoring should follow.", "metadata": {"source": "sepsis_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396027", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/sepsis_management.md", "chunk_index": 0, "total_chunks": 6}}, {"content": "## SOFA Score Components\nAssess 6 organ systems (0-4 points each, total 0-24):\n- **Respiration**: PaO2/FiO2 ratio\n- **Coagulation**: Platelet count\n- **Liver**: Bilirubin\n- **Cardiovascular**: MAP and vasopressor requirement\n- **CNS**: Glasgow Coma Scale\n- **Renal**: Creatinine and urine output\n\n## Hour-1 Bundle (Surviving Sepsis Campaign 2021)\nInitiate **all** elements within the first hour of sepsis recognition:\n\n### 1. Measure Lactate\n- If lactate > 2 mmol/L, remeasure within 2-4 hours to guide resuscitation\n- Target lactate normalization (< 2 mmol/L) or decrease by >= 20% every 2 hours\n\n### 2. Obtain Blood Cultures\n- Draw at least **2 sets** (aerobic + anaerobic) from separate venipuncture sites **before** antibiotics\n- Additional cultures from indwelling lines if present > 48 hours\n- Do **not** delay antibiotics for cultures if there is difficulty obtaining them", "metadata": {"source": "sepsis_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396027", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/sepsis_management.md", "chunk_index": 1, "total_chunks": 6}}, {"content": "### 3. Administer Broad-Spectrum Antibiotics\n- Administer within **1 hour** of sepsis recognition (each hour of delay increases mortality by ~4%)\n- Empiric coverage based on suspected source:\n  - **Pulmonary**: Ceftriaxone + azithromycin; if HAP/VAP risk: piperacillin-tazobactam or meropenem + vancomycin\n  - **Abdominal**: Piperacillin-tazobactam or meropenem (anaerobic + gram-negative coverage)\n  - **Urinary**: Ceftriaxone; if complicated/resistant risk: piperacillin-tazobactam or meropenem\n  - **Skin/soft tissue**: Vancomycin + piperacillin-tazobactam\n  - **Unknown source**: Meropenem or piperacillin-tazobactam + vancomycin\n- Add MRSA coverage (vancomycin or linezolid) if risk factors present\n- Add antifungal (micafungin, anidulafungin) if invasive candidiasis suspected (TPN, prior antibiotics, abdominal surgery, Candida colonization)", "metadata": {"source": "sepsis_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396027", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/sepsis_management.md", "chunk_index": 2, "total_chunks": 6}}, {"content": "### 4. Rapid IV Fluid Resuscitation\n- **30 mL/kg** of crystalloid (lactated Ringer's preferred over normal saline) within the first 3 hours for hypotension or lactate >= 4 mmol/L\n- Reassess volume status after each bolus (clinical exam, passive leg raise, point-of-care ultrasound IVC assessment, pulse pressure variation)\n- Avoid excessive fluid administration beyond initial resuscitation; excessive fluids worsen outcomes\n\n### 5. Vasopressors for Refractory Hypotension\n- Initiate if MAP remains < 65 mmHg during or after fluid resuscitation\n- Do not delay vasopressors while completing fluid boluses\n\n## Vasopressor Selection\n\n### First-Line\n- **Norepinephrine** 0.1-1 mcg/kg/min via central line (peripheral OK temporarily for short duration)\n- Target MAP >= 65 mmHg (higher targets 75-80 for chronic hypertension not clearly beneficial)", "metadata": {"source": "sepsis_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396027", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/sepsis_management.md", "chunk_index": 3, "total_chunks": 6}}, {"content": "### Second-Line (Add to Norepinephrine)\n- **Vasopressin** 0.03-0.04 units/min (fixed dose); add when norepinephrine > 0.25-0.5 mcg/kg/min\n- Catecholamine-sparing effect; particularly useful in patients with tachyarrhythmias\n\n### Third-Line\n- **Epinephrine** 0.1-0.5 mcg/kg/min if inadequate response to norepinephrine + vasopressin\n- **Phenylephrine**: Consider only in pure vasodilatory shock or significant tachyarrhythmias limiting norepinephrine\n\n### Inotropic Support\n- **Dobutamine** 2-20 mcg/kg/min if evidence of myocardial dysfunction (low cardiac output despite adequate filling pressures)\n\n## Source Control\n- Identify and address within **6-12 hours** when feasible\n- Drain abscesses (percutaneous or surgical)\n- Debride necrotic tissue (necrotizing fasciitis requires emergent surgical debridement)\n- Remove infected devices (central lines, urinary catheters, prosthetic material)\n- Operative repair of perforated viscus", "metadata": {"source": "sepsis_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396027", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/sepsis_management.md", "chunk_index": 4, "total_chunks": 6}}, {"content": "## Adjunctive Therapies\n- **Corticosteroids**: Hydrocortisone 50 mg IV q6h if shock refractory to adequate fluids and vasopressors (norepinephrine >= 0.25 mcg/kg/min for >= 4 hours); taper over 3-7 days\n- **Stress ulcer prophylaxis**: PPI or H2 blocker in mechanically ventilated patients\n- **Glucose control**: Target 144-180 mg/dL; avoid hypoglycemia\n- **VTE prophylaxis**: LMWH preferred unless contraindicated; use pneumatic compression if anticoagulation contraindicated\n\n## Reassessment and De-escalation\n- Reassess clinical status, lactate, and hemodynamics at 3 and 6 hours\n- Narrow antibiotics based on culture results at 48-72 hours\n- Procalcitonin-guided de-escalation: consider stopping antibiotics when procalcitonin < 0.5 ng/mL or decreased by >= 80% from peak\n- Typical antibiotic duration: 7-10 days; shorter courses acceptable for urinary source with adequate control", "metadata": {"source": "sepsis_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396027", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/sepsis_management.md", "chunk_index": 5, "total_chunks": 6}}, {"content": "# Hemorrhagic Stroke (Intracerebral Hemorrhage) Management\n\n## Definition\nSpontaneous (non-traumatic) bleeding into the brain parenchyma, often with extension into the ventricular system. Accounts for approximately 10-15% of all strokes with significantly higher mortality than ischemic stroke.\n\n## Common Etiologies\n- **Hypertension** (most common; deep structures: basal ganglia, thalamus, pons, cerebellum)\n- Cerebral amyloid angiopathy (lobar hemorrhages in elderly)\n- Anticoagulant or antiplatelet therapy\n- Vascular malformations (AVM, cavernous malformation)\n- Coagulopathy or thrombocytopenia\n- Hemorrhagic conversion of ischemic stroke\n- Illicit drug use (cocaine, amphetamines)\n- Cerebral venous sinus thrombosis\n\n## ICH Score (Prognostic Tool)\nAssign points to estimate 30-day mortality:", "metadata": {"source": "stroke_hemorrhagic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396081", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_hemorrhagic.md", "chunk_index": 0, "total_chunks": 6}}, {"content": "| Component | Criteria | Points |\n|-----------|----------|--------|\n| GCS | 3-4 | 2 |\n| GCS | 5-12 | 1 |\n| GCS | 13-15 | 0 |\n| ICH volume | >= 30 mL | 1 |\n| ICH volume | < 30 mL | 0 |\n| IVH present | Yes | 1 |\n| IVH present | No | 0 |\n| Infratentorial origin | Yes | 1 |\n| Infratentorial origin | No | 0 |\n| Age | >= 80 | 1 |\n| Age | < 80 | 0 |\n\n- **Score 0**: ~0% mortality\n- **Score 1**: ~13% mortality\n- **Score 2**: ~26% mortality\n- **Score 3**: ~72% mortality\n- **Score 4-5**: ~90-100% mortality\n\n**Note**: The ICH score should not be used in isolation to make withdrawal-of-care decisions; early aggressive care is recommended regardless of initial score.", "metadata": {"source": "stroke_hemorrhagic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396081", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_hemorrhagic.md", "chunk_index": 1, "total_chunks": 6}}, {"content": "## Acute Blood Pressure Management\n- **Target SBP < 140 mmHg** within 1 hour of presentation (per AHA/ASA 2022 guidelines and INTERACT2/ATACH-2 trials)\n- Avoid SBP < 110 mmHg (associated with AKI and worse outcomes)\n- **Preferred agents**:\n  - Nicardipine infusion: start 5 mg/hr, titrate by 2.5 mg/hr q5-15 min (max 15 mg/hr)\n  - Clevidipine infusion: start 1-2 mg/hr, titrate q90 seconds\n  - Labetalol 10-20 mg IV q10-20 min (bolus) or infusion 2-8 mg/min\n- Arterial line placement recommended for continuous BP monitoring\n- Maintain target for at least 24-72 hours\n\n## Reversal of Anticoagulation\n\n### Warfarin (Target INR < 1.3 within 4 hours)\n- **4-factor PCC (Kcentra)**: 25-50 units/kg IV based on INR (preferred over FFP)\n- **Vitamin K**: 10 mg IV over 10-20 minutes (for sustained reversal; slow onset)\n- FFP 10-15 mL/kg only if PCC unavailable", "metadata": {"source": "stroke_hemorrhagic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396081", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_hemorrhagic.md", "chunk_index": 2, "total_chunks": 6}}, {"content": "### Direct Oral Anticoagulants (DOACs)\n- **Dabigatran**: Idarucizumab (Praxbind) 5 g IV (two 2.5 g boluses); if unavailable, use activated PCC (FEIBA) 50 units/kg\n- **Rivaroxaban/Apixaban/Edoxaban**: Andexanet alfa (Andexxa) per dosing protocol; if unavailable, 4-factor PCC 50 units/kg\n- Consider activated charcoal if DOAC ingested within 2 hours\n\n### Heparin\n- Protamine sulfate: 1 mg per 100 units of heparin given in previous 2-3 hours (max 50 mg)\n\n### Antiplatelet Agents\n- Platelet transfusion is **not routinely recommended** (PATCH trial showed harm)\n- Consider desmopressin (DDAVP) 0.3 mcg/kg IV if aspirin-related ICH", "metadata": {"source": "stroke_hemorrhagic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396081", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_hemorrhagic.md", "chunk_index": 3, "total_chunks": 6}}, {"content": "## Surgical Indications\n- **Cerebellar hemorrhage > 3 cm** with neurologic deterioration, brainstem compression, or hydrocephalus: emergent surgical evacuation\n- **Lobar hemorrhage > 30 mL** within 1 cm of cortical surface: consider minimally invasive surgery (MISTIE III) or craniotomy in deteriorating patients\n- **Intraventricular hemorrhage with hydrocephalus**: External ventricular drain (EVD) with or without intraventricular tPA (CLEAR III trial)\n- Deep basal ganglia hemorrhage: surgery generally not beneficial\n- Decompressive craniectomy may be considered for large hemorrhages with refractory elevated ICP", "metadata": {"source": "stroke_hemorrhagic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396081", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_hemorrhagic.md", "chunk_index": 4, "total_chunks": 6}}, {"content": "## Monitoring and Supportive Care\n- ICU admission with neurochecks q1h for first 24 hours\n- Repeat CT head at 6 hours or with any neurologic change (hematoma expansion occurs in ~30%)\n- Maintain normoglycemia (glucose 140-180 mg/dL)\n- Maintain normothermia (treat fever aggressively; target temp < 37.5C)\n- DVT prophylaxis: pneumatic compression devices immediately; consider LMWH at 24-48 hours if hemorrhage stable\n- Seizure management: treat clinical seizures; routine prophylactic antiepileptics not recommended unless lobar ICH\n- Continuous EEG monitoring if decreased consciousness unexplained by hemorrhage size", "metadata": {"source": "stroke_hemorrhagic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396081", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_hemorrhagic.md", "chunk_index": 5, "total_chunks": 6}}, {"content": "# Acute Ischemic Stroke Management\n\n## Overview\nIschemic stroke results from arterial occlusion causing cerebral ischemia. Rapid evaluation and treatment are critical. Time-sensitive interventions include IV thrombolysis and endovascular thrombectomy.\n\n## NIH Stroke Scale (NIHSS)\nThe NIHSS is a 15-item neurologic assessment scored 0-42:\n- **0**: No stroke symptoms\n- **1-4**: Minor stroke\n- **5-15**: Moderate stroke\n- **16-20**: Moderate to severe stroke\n- **21-42**: Severe stroke\n\n### NIHSS Components\nLevel of consciousness, gaze, visual fields, facial palsy, motor arm (L/R), motor leg (L/R), limb ataxia, sensory, best language, dysarthria, extinction/inattention.", "metadata": {"source": "stroke_ischemic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396191", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_ischemic.md", "chunk_index": 0, "total_chunks": 6}}, {"content": "## Acute Assessment (Door-to-Needle Target: < 60 minutes)\n- ABCs and vital signs; continuous cardiac monitoring\n- Point-of-care glucose (exclude hypoglycemia as stroke mimic)\n- Non-contrast CT head: exclude hemorrhage (must precede tPA)\n- CT angiography (CTA) of head and neck: identify large vessel occlusion (LVO)\n- CT perfusion: assess salvageable penumbra (especially for extended window cases)\n- Labs: CBC, BMP, coagulation studies, troponin, type and screen\n\n## IV Thrombolysis (Alteplase / Tenecteplase)", "metadata": {"source": "stroke_ischemic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396191", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_ischemic.md", "chunk_index": 1, "total_chunks": 6}}, {"content": "### Alteplase (tPA) - Within 4.5 Hours of Symptom Onset\n- **Dose**: 0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 minute, remainder infused over 60 minutes\n- **Key Inclusion**: Measurable neurologic deficit, CT without hemorrhage, symptom onset clearly defined\n- **Key Exclusions**:\n  - Active internal bleeding or known bleeding diathesis\n  - Platelet count < 100,000/mcL\n  - INR > 1.7 or PT > 15 seconds\n  - Therapeutic LMWH within 24 hours\n  - Blood glucose < 50 mg/dL\n  - Major surgery or serious trauma within 14 days\n  - History of intracranial hemorrhage\n  - **3-4.5 hour window additional exclusions**: Age > 80, NIHSS > 25, oral anticoagulant use, history of both DM and prior ischemic stroke\n\n### Tenecteplase (Emerging Alternative)\n- 0.25 mg/kg IV bolus (max 25 mg); single bolus administration offers logistical advantages\n- Noninferior to alteplase, particularly for LVO patients proceeding to thrombectomy", "metadata": {"source": "stroke_ischemic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396191", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_ischemic.md", "chunk_index": 2, "total_chunks": 6}}, {"content": "## Endovascular Thrombectomy - Within 24 Hours for LVO\n- **Indications**: Confirmed LVO (ICA, M1, proximal M2, basilar artery) on CTA\n- **Standard window (0-6 hours)**: NIHSS >= 6, pre-stroke mRS 0-1, ASPECTS >= 6\n- **Extended window (6-24 hours)**: Must demonstrate favorable perfusion imaging (mismatch between infarct core and ischemic penumbra per DAWN or DEFUSE-3 criteria)\n- Thrombectomy should not delay IV tPA; administer tPA first if eligible, then proceed to angiography suite\n- Target reperfusion: TICI 2b/3 (successful reperfusion of >= 50% of affected territory)\n\n## Blood Pressure Management\n\n### Pre-Thrombolysis\n- Treat only if BP > 185/110 mmHg (to qualify for tPA)\n- Agents: labetalol 10-20 mg IV, nicardipine infusion 5-15 mg/hr, clevidipine\n\n### Post-Thrombolysis (First 24 Hours)\n- Maintain BP < 180/105 mmHg for 24 hours after tPA administration\n- Frequent monitoring: q15 min for 2 hours, then q30 min for 6 hours, then q1h", "metadata": {"source": "stroke_ischemic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396191", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_ischemic.md", "chunk_index": 3, "total_chunks": 6}}, {"content": "### No Thrombolysis Given\n- Permissive hypertension up to 220/120 mmHg unless end-organ damage, aortic dissection, or hypertensive emergency\n- Gradually lower BP by 15% in first 24 hours if treatment indicated", "metadata": {"source": "stroke_ischemic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396191", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_ischemic.md", "chunk_index": 4, "total_chunks": 6}}, {"content": "## Secondary Prevention\n- **Antiplatelet therapy**: Aspirin 325 mg within 24-48 hours (delay 24 hours if tPA given); dual antiplatelet (aspirin + clopidogrel) for 21 days in minor stroke (NIHSS <= 3) or high-risk TIA\n- **Statin therapy**: High-intensity statin (atorvastatin 80 mg or rosuvastatin 20 mg) regardless of LDL\n- **Atrial fibrillation**: Initiate anticoagulation (typically DOAC) at 4-14 days post-stroke depending on infarct size (1-3-6-12 day rule based on severity)\n- **Carotid stenosis**: Carotid endarterectomy or stenting for symptomatic stenosis >= 50% (NASCET criteria)\n- **Blood pressure control**: Target < 130/80 mmHg after acute phase; initiate antihypertensives before discharge\n- **Lifestyle**: Smoking cessation, exercise, Mediterranean-style diet, diabetes optimization (HbA1c < 7%)", "metadata": {"source": "stroke_ischemic.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396191", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/stroke_ischemic.md", "chunk_index": 5, "total_chunks": 6}}, {"content": "# Suicide Risk Assessment\n\n## Columbia Suicide Severity Rating Scale (C-SSRS)\n\nThe C-SSRS is a standardized, evidence-based tool for assessing suicidal ideation and behavior.\n\n### Screening Questions\n1. **Wish to be dead**: \"Have you wished you were dead or wished you could go to sleep and not wake up?\"\n2. **Active suicidal ideation**: \"Have you actually had any thoughts of killing yourself?\"\n3. **Ideation with method**: \"Have you been thinking about how you might do this?\"\n4. **Intent without plan**: \"Have you had these thoughts and had some intention of acting on them?\"\n5. **Intent with plan**: \"Have you started to work out or worked out the details of how to kill yourself?\"\n\nA \"yes\" to questions 3-5 warrants immediate psychiatric evaluation.\n\n## Risk Factors", "metadata": {"source": "suicide_risk_assessment.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396292", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/suicide_risk_assessment.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "### Static Risk Factors\n- Prior suicide attempt (single strongest predictor)\n- Family history of suicide\n- History of childhood abuse or trauma\n- Male sex (higher completion rate)\n- Age >65 or 15-24 years\n- Chronic medical illness or chronic pain\n\n### Dynamic Risk Factors\n- Current psychiatric diagnosis (depression, bipolar, schizophrenia, borderline PD)\n- Recent psychiatric hospitalization (within 90 days of discharge)\n- Active substance use disorder\n- Acute psychosocial stressors (job loss, divorce, bereavement, legal problems)\n- Access to lethal means (especially firearms)\n- Social isolation and hopelessness\n- Recent self-harm or increasing ideation intensity\n\n## Protective Factors\n- Strong social support and connectedness\n- Responsibility to children or family\n- Religious or spiritual beliefs against suicide\n- Active engagement in mental health treatment\n- Problem-solving and coping skills\n- Reasons for living (future-oriented thinking)\n\n## Safety Planning (Stanley-Brown Model)", "metadata": {"source": "suicide_risk_assessment.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396292", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/suicide_risk_assessment.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "A collaborative, written safety plan should include six steps:\n\n1. **Warning signs**: Identify personal triggers and early warning thoughts/feelings\n2. **Internal coping strategies**: Activities the patient can do alone to distract (exercise, music, breathing)\n3. **Social contacts for distraction**: Friends or family who can help redirect attention\n4. **People to contact during crisis**: Trusted individuals the patient can tell about suicidal feelings\n5. **Professional resources**: Therapist, psychiatrist, 988 Suicide and Crisis Lifeline, local crisis services, emergency department\n6. **Lethal means restriction**: Steps to reduce access to methods\n\n## Lethal Means Restriction", "metadata": {"source": "suicide_risk_assessment.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396292", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/suicide_risk_assessment.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "- **Firearms**: Counsel on temporary removal from home; offer storage with trusted individual, law enforcement, or gun shop. Firearms account for >50% of suicide deaths.\n- **Medications**: Limit quantities prescribed; recommend locking up or removing stockpiled medications\n- **Other means**: Assess and address access to sharp objects, ligatures, heights, or vehicles\n\n## When to Hospitalize\n\n### Criteria for Inpatient Psychiatric Admission\n- Active suicidal ideation with plan and intent\n- Recent serious suicide attempt requiring medical treatment\n- Inability to contract for safety or cooperate with outpatient plan\n- Command auditory hallucinations to harm self\n- Severe agitation or psychosis with suicidal ideation\n- Lack of adequate outpatient support or follow-up\n- Active intoxication with suicidal statements and inability to assess once sober", "metadata": {"source": "suicide_risk_assessment.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396292", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/suicide_risk_assessment.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "### Outpatient Management May Be Appropriate When\n- Passive ideation without plan or intent\n- Strong protective factors and social support\n- Patient is cooperative and engaged in safety planning\n- Reliable follow-up within 24-72 hours can be arranged\n- Lethal means have been secured\n\n## Documentation Requirements\n- Document risk assessment findings using structured format\n- Record risk level (low, moderate, high, imminent)\n- Note clinical rationale for disposition decision\n- Document safety plan discussion and means restriction counseling\n- Record follow-up plan and communication with outpatient providers", "metadata": {"source": "suicide_risk_assessment.md", "category": "psychiatry", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396292", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/suicide_risk_assessment.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Traumatic Brain Injury (TBI) Management\n\n## Definition\nTraumatic brain injury is an alteration in brain function or pathology caused by an external mechanical force. Severity is classified by the Glasgow Coma Scale (GCS) score at presentation.\n\n## Glasgow Coma Scale (GCS)\n\n### Eye Opening (E: 1-4)\n- 4: Spontaneous\n- 3: To voice/command\n- 2: To pain\n- 1: None\n\n### Verbal Response (V: 1-5)\n- 5: Oriented\n- 4: Confused\n- 3: Inappropriate words\n- 2: Incomprehensible sounds\n- 1: None\n\n### Motor Response (M: 1-6)\n- 6: Obeys commands\n- 5: Localizes pain\n- 4: Withdrawal (flexion)\n- 3: Abnormal flexion (decorticate)\n- 2: Extension (decerebrate)\n- 1: None\n\n**Total GCS range: 3-15**\n\n## TBI Classification by Severity\n\n### Mild TBI (GCS 13-15)\n- Includes concussion\n- LOC < 30 minutes, post-traumatic amnesia < 24 hours\n- Most patients recover fully; counsel on post-concussive syndrome\n- Discharge with reliable observer and head injury return precautions", "metadata": {"source": "tbi_management.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396350", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/tbi_management.md", "chunk_index": 0, "total_chunks": 5}}, {"content": "### Moderate TBI (GCS 9-12)\n- LOC 30 minutes to 24 hours, PTA 1-7 days\n- ICU admission with frequent neurochecks\n- Repeat neuroimaging at 6-8 hours or with clinical change\n\n### Severe TBI (GCS 3-8)\n- LOC > 24 hours, PTA > 7 days\n- Requires intubation for airway protection (GCS <= 8 = intubate)\n- ICU management with ICP monitoring\n- Neurosurgical consultation mandatory\n\n## Imaging Indications\n\n### CT Head Without Contrast (First-Line)\nApply the **Canadian CT Head Rule** (for mild TBI, GCS 13-15):\n- **High risk (need CT)**: GCS < 15 at 2 hours post-injury, suspected open/depressed skull fracture, signs of basal skull fracture, >= 2 episodes of vomiting, age >= 65\n- **Medium risk**: Retrograde amnesia > 30 minutes, dangerous mechanism (pedestrian struck, fall > 3 feet or 5 stairs, ejection from vehicle)\n\n### CT Angiography\n- Indicated when cervical spine fracture involves transverse foramen, Le Fort II/III fractures, or focal neurologic deficit suggesting vascular injury", "metadata": {"source": "tbi_management.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396350", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/tbi_management.md", "chunk_index": 1, "total_chunks": 5}}, {"content": "### MRI Brain\n- More sensitive for diffuse axonal injury, posterior fossa lesions, and subacute blood products\n- Obtain when CT does not explain neurologic deficits\n\n## Intracranial Pressure (ICP) Management\n\n### Indications for ICP Monitoring\n- Severe TBI (GCS 3-8) with abnormal CT (hematoma, contusion, edema, compressed cisterns)\n- Severe TBI with normal CT **if** age > 40, motor posturing, or SBP < 90 mmHg\n- Target ICP < 22 mmHg and cerebral perfusion pressure (CPP) 60-70 mmHg\n\n### Tiered ICP Management\n\n**Tier 1 (Initial Measures)**\n- Head of bed elevation 30 degrees, midline head positioning\n- Adequate sedation and analgesia (propofol, fentanyl)\n- Avoid hyperthermia (target normothermia)\n- Avoid hypotension (SBP > 100 mmHg if age 50-69; SBP > 110 if age 15-49 or >= 70)\n- Maintain PaCO2 35-40 mmHg (avoid routine hyperventilation)\n- CSF drainage via EVD if in place", "metadata": {"source": "tbi_management.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396350", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/tbi_management.md", "chunk_index": 2, "total_chunks": 5}}, {"content": "**Tier 2 (Escalation)**\n- Hyperosmolar therapy:\n  - Mannitol 0.25-1 g/kg IV bolus (hold if serum osmolality > 320 mOsm/L or osmolar gap > 20)\n  - Hypertonic saline (23.4% NaCl 30 mL IV via central line, or 3% NaCl infusion targeting Na 145-155 mEq/L)\n- Brief hyperventilation to PaCO2 30-35 mmHg (short-term rescue only)\n\n**Tier 3 (Refractory Elevated ICP)**\n- Decompressive craniectomy (DECRA/RESCUEicp trials: reduces ICP, may improve survival but with variable functional outcome)\n- Pentobarbital coma: load 5-10 mg/kg IV, infusion 1-4 mg/kg/hr titrated to burst suppression on continuous EEG\n- Therapeutic hypothermia (32-35C) is controversial; not routinely recommended per BTF guidelines", "metadata": {"source": "tbi_management.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396350", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/tbi_management.md", "chunk_index": 3, "total_chunks": 5}}, {"content": "## Seizure Prophylaxis\n- **Early post-traumatic seizures** (within 7 days) occur in 10-15% of severe TBI\n- Levetiracetam 500-1000 mg IV/PO q12h **or** phenytoin (load 20 mg/kg IV, then 100 mg IV/PO q8h) for **7 days**\n- Discontinue at 7 days unless clinical seizures occur (prophylaxis beyond 7 days does not prevent late epilepsy)\n- Continuous EEG monitoring recommended in severe TBI patients with unexplained decreased consciousness\n\n## Additional Supportive Care\n- Maintain euvolemia; avoid hypotonic fluids (use normal saline as primary crystalloid)\n- Glucose control: target 80-180 mg/dL; avoid hypoglycemia\n- DVT prophylaxis: pneumatic compression immediately; LMWH at 24-72 hours if hemorrhage stable on repeat imaging\n- Nutritional support: initiate enteral feeding within 24-72 hours\n- Pituitary dysfunction screening (cortisol, TSH) in moderate-severe TBI", "metadata": {"source": "tbi_management.md", "category": "neurology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396350", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/tbi_management.md", "chunk_index": 4, "total_chunks": 5}}, {"content": "# Thyroid Disorders\n\n## Hypothyroidism\n\n### Diagnosis\n- **Primary hypothyroidism**: Elevated TSH with low free T4\n- **Subclinical hypothyroidism**: Elevated TSH (4.5-10 mIU/L) with normal free T4\n- Common causes: Hashimoto thyroiditis (most common), post-radioactive iodine, post-thyroidectomy, medications (lithium, amiodarone), iodine deficiency\n\n### Levothyroxine (LT4) Dosing\n\n**Initial Dosing**:\n- Young, healthy adults: 1.6 mcg/kg/day (full replacement dose)\n- Elderly or coronary artery disease: Start 12.5-25 mcg/day; increase by 12.5-25 mcg every 4-6 weeks\n- Severe/prolonged hypothyroidism: Start low and titrate slowly\n\n**Administration**:\n- Take on empty stomach, 30-60 minutes before breakfast or at bedtime 3+ hours after last meal\n- Separate from calcium, iron, PPIs, and cholestyramine by at least 4 hours\n- Consistent timing improves TSH stability", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 0, "total_chunks": 7}}, {"content": "### TSH Targets\n- **General adult population**: 0.5-2.5 mIU/L (lower half of reference range)\n- **Elderly (>70 years)**: 1.0-5.0 mIU/L (higher target acceptable; overtreatment increases atrial fibrillation, osteoporosis, and fracture risk)\n- **Pregnancy**: Trimester-specific targets; first trimester <2.5 mIU/L, second/third trimester <3.0 mIU/L\n- **Thyroid cancer (DTC) suppression therapy**: 0.1-0.5 mIU/L for intermediate risk; <0.1 mIU/L for high risk\n\n### Monitoring\n- Recheck TSH 6-8 weeks after dose initiation or adjustment\n- Once stable, monitor TSH every 6-12 months\n- Dose adjustments may be needed with weight change, pregnancy, aging, or interacting medications", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 1, "total_chunks": 7}}, {"content": "### Subclinical Hypothyroidism\n- **TSH >10 mIU/L**: Treat with levothyroxine (high progression rate to overt hypothyroidism)\n- **TSH 4.5-10 mIU/L**: Consider treatment if symptomatic, positive TPO antibodies, dyslipidemia, or pregnancy/planning pregnancy\n- **Elderly with TSH 4.5-10**: Generally observe without treatment unless symptomatic (TRUST trial showed no benefit)\n\n## Hyperthyroidism\n\n### Diagnosis\n- Suppressed TSH with elevated free T4 and/or free T3\n- Common causes: Graves disease (most common), toxic multinodular goiter, toxic adenoma, thyroiditis (subacute, postpartum), exogenous thyroid hormone\n\n### Treatment Options\n\n**Methimazole (MMI)**:\n- First-line antithyroid drug for most patients\n- Starting dose: 10-30 mg/day depending on severity; maintenance 5-10 mg/day\n- Monitor CBC and LFTs at baseline and if symptoms develop\n- Adverse effects: Agranulocytosis (0.2-0.5%), hepatotoxicity, rash, arthralgia\n- Contraindicated in first trimester of pregnancy (teratogenic)", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 2, "total_chunks": 7}}, {"content": "**Propylthiouracil (PTU)**:\n- Reserved for first trimester of pregnancy and thyroid storm\n- Dose: 100-200 mg three times daily; maintenance 50-100 mg TID\n- Higher hepatotoxicity risk (including liver failure); more frequent dosing\n- Preferred in first trimester (lower teratogenic risk than MMI)\n\n**Radioactive Iodine (RAI) Ablation**:\n- Definitive treatment for Graves disease and toxic nodular disease\n- Contraindicated in pregnancy, breastfeeding, and moderate-to-severe Graves ophthalmopathy\n- Most patients become hypothyroid within 6-12 months and require lifelong LT4\n- Discontinue methimazole 3-5 days before RAI\n\n**Thyroidectomy**:\n- Indicated for large goiter with compressive symptoms, suspected malignancy, moderate-to-severe ophthalmopathy, or patient preference\n- Risks: Hypoparathyroidism, recurrent laryngeal nerve injury", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 3, "total_chunks": 7}}, {"content": "**Beta-Blockers**:\n- Propranolol 20-40 mg TID or atenolol 25-50 mg daily for symptomatic relief (tachycardia, tremor, anxiety)\n- Use as adjunct until euthyroid state achieved\n\n## Thyroid Storm\n\n### Diagnosis (Burch-Wartofsky Score)\nClinical diagnosis based on: Temperature >38.5C, tachycardia >130, atrial fibrillation, CNS dysfunction (agitation, delirium, seizure, coma), GI symptoms (nausea, vomiting, diarrhea, jaundice), heart failure. Score >=45: Highly suggestive of thyroid storm.", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 4, "total_chunks": 7}}, {"content": "### Management (Treat Simultaneously)\n1. **PTU** 500-1000 mg loading dose, then 250 mg every 4 hours (blocks synthesis AND peripheral conversion)\n2. **Iodine solution** (SSKI 5 drops q6h or Lugol solution 10 drops q8h) -- give at least 1 hour AFTER PTU to prevent iodine utilization\n3. **Hydrocortisone** 100 mg IV every 8 hours (blocks T4 to T3 conversion, treats relative adrenal insufficiency)\n4. **Propranolol** 60-80 mg PO every 4-6 hours (or esmolol IV if unable to take PO)\n5. **Cholestyramine** 4g QID (binds thyroid hormone in enterohepatic circulation)\n6. **Supportive care**: Cooling measures for hyperthermia (avoid aspirin -- displaces T4 from binding proteins), IV fluids, glucose, ICU monitoring\n7. **Plasmapheresis**: Consider for refractory cases", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 5, "total_chunks": 7}}, {"content": "## Subclinical Hyperthyroidism\n- TSH <0.1 mIU/L with normal free T4/T3: Consider treatment if age >65, cardiac risk factors, osteoporosis, or postmenopausal\n- TSH 0.1-0.4 mIU/L with normal free T4/T3: Generally observe with repeat testing in 3-6 months", "metadata": {"source": "thyroid_disorders.md", "category": "endocrinology", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396404", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/thyroid_disorders.md", "chunk_index": 6, "total_chunks": 7}}, {"content": "# Urinary Tract Infection (UTI) Management\n\n## Classification\n- **Uncomplicated cystitis**: Lower UTI in non-pregnant women without structural abnormalities\n- **Complicated UTI**: UTI with structural/functional abnormality, male sex, pregnancy, immunosuppression, indwelling catheter\n- **Pyelonephritis**: Upper UTI involving renal parenchyma\n- **Catheter-associated UTI (CAUTI)**: Symptoms + culture \u22651000 CFU/mL with catheter in place within 48 hours\n\n## Diagnosis\n- Symptoms: Dysuria, frequency, urgency, suprapubic pain (cystitis); fever, flank pain, CVA tenderness (pyelonephritis)\n- Urinalysis: Pyuria (>10 WBC/HPF), positive leukocyte esterase, nitrites (Gram-negative bacteria)\n- Culture: \u2265100,000 CFU/mL (symptomatic: \u22651000 CFU/mL may be significant)", "metadata": {"source": "uti_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396534", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/uti_management.md", "chunk_index": 0, "total_chunks": 3}}, {"content": "## Uncomplicated Cystitis \u2014 First-Line Treatment\n- **Nitrofurantoin** 100mg BID \u00d7 5 days (avoid if CrCl <30)\n- **TMP-SMX** 160/800mg BID \u00d7 3 days (if local resistance <20%)\n- **Fosfomycin** 3g single dose (less effective than above)\n- **Avoid** fluoroquinolones for uncomplicated cystitis (reserve for complicated infections)\n\n## Pyelonephritis\n### Outpatient (mild, no nausea/vomiting)\n- **Ciprofloxacin** 500mg BID \u00d7 7 days, or **Levofloxacin** 750mg daily \u00d7 5 days\n- **TMP-SMX** 160/800mg BID \u00d7 14 days (if susceptible)\n- Consider single dose IM ceftriaxone 1g before starting oral therapy\n\n### Inpatient (severe, sepsis, unable to tolerate PO)\n- **Ceftriaxone** 1g IV daily, or **Ciprofloxacin** 400mg IV BID\n- **Piperacillin-tazobactam** or **Meropenem** if ESBL suspected\n- Switch to PO when afebrile \u226548 hours and tolerating PO", "metadata": {"source": "uti_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396534", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/uti_management.md", "chunk_index": 1, "total_chunks": 3}}, {"content": "## Complicated UTI\n- Obtain culture before starting empiric therapy\n- Broader spectrum: Fluoroquinolone, ceftriaxone, or piperacillin-tazobactam\n- Duration: 7-14 days depending on severity and response\n- Address underlying cause (obstruction, catheter removal/exchange)\n\n## Special Populations\n- **Pregnancy**: Treat asymptomatic bacteriuria; safe antibiotics: amoxicillin, cephalexin, nitrofurantoin (avoid near term)\n- **Men**: Always consider complicated; evaluate for prostatitis; duration typically 7-14 days\n- **Recurrent UTI** (\u22653/year): Consider prophylaxis \u2014 low-dose nitrofurantoin, post-coital prophylaxis, vaginal estrogen (postmenopausal)", "metadata": {"source": "uti_management.md", "category": "infectious_disease", "type": "guideline", "last_updated": "2026-02-11T13:55:41.396534", "file_path": "/Users/nk/Downloads/clinical-decision-support/data/medical_guidelines/uti_management.md", "chunk_index": 2, "total_chunks": 3}}]